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Chinese Hamster Ovary (CHO) cells are the mammalian cell lines of choice for 
the production of approved recombinant biologics including recombinant monoclonal 
antibodies (mAb). Due to emerging biosimilars market, together with constant 
development of innovator recombinant biologics, new production cell lines would 
have to be created, and hence the use of engineered CHO cell lines with improved 
production capability can be explored. Together with the increasing demands for 
recombinant biologics, there is an on-going need create CHO cells with improved 
production yield. 
Based on the apoptosis transcript profiling of fed-batch CHO cultures, cell line 
engineering targets for creating robust CHO cells were identified. Among them, heat 
shock protein 27 (HSP27) was found to be down regulated toward the late-
exponential and stationary phase of the CHO fed-batch culture. HSP27 is found to be 
highly expressed in human and mouse pathological tissues and cells where they are 
reported to possess anti-cytotoxic functions. This led to the hypothesis that 
overexpression of HSP27 in CHO cells can increase the production of recombinant 
biologics by extending the culture duration. We have thus demonstrated in a previous 
study that overexpression of cgri-HSP27 in CHO cells producing recombinant human 
interferon-gamma (IFNɣ) fed-batch bioreactor cultures extended culture viability and 
resulted in higher yield of recombinant human IFNɣ.  
Due to the increasing importance of recombinant mAbs as new innovator drugs 
and biosimilars, we were motivated to assess the application of cgri-HSP27 
overexpression in CHO cells producing recombinant mAb fed-batch bioreactor 
cultures. The cgri-HSP27 engineered CHO cells producing recombinant mAb were 
created and they showed improvement in both peak viable cell density and extension 
of culture duration, resulting in an increased recombinant mAb titer, in fed-batch 
bioreactor system. Additionally, N-glycan distribution profiles of the recombinant 
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mAb produced were not compromised. Concurrently, a study of cgri-HSP27 potential 
molecular roles in CHO fed-batch bioreactor cultures was carried out. Cgri-HSP27 
was found to likely improve CHO cells fed-batch bioreactor cultures by delaying 
activation of caspases. Interaction with Akt, pro-Caspase-3 and Daxx involved in the 
apoptosis signaling pathways may likely suppressed the onset of apoptosis. 
Subsequently, targets that cgri-HSP27 can potentially interact with to improve culture 
performance in fed-batch bioreactor system were identified and a cgri-HSP27 
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CHAPTER 1 Introduction 
 
1.1 Background 
CHO cells are the mammalian cell lines of choice for the production of 
approved recombinant biologics including recombinant mAbs. Due to the increasing 
demands of recombinant biologics, there is a constant need to improve the production 
yield. With the emerging biosimilars market, new production cell lines would have to 
be created, and hence the use of engineered CHO cell lines with improved production 
capability can be explored.  
As fed-batch bioreactor cultures are one of the most commonly used mode of 
bioreactor operations in recombinant biologics product, transcript profiling of fed-
batch CHO culture was previously performed to identify cell line engineering targets 
for rational cellular engineering of CHO cells. Among them, HSP27 was found to be 
down regulated toward the late-exponential and stationary phase of the fed-batch 
CHO bioreactor culture. HSP27 are found to be highly expressed in human and 
mouse pathological tissues and cells where they are reported to have anti-cytotoxic 
functions. This led to the hypothesis that overexpression of HSP27 in CHO cells can 
increase the production of recombinant biologics by extending the culture duration. 
We have thus shown in a previous study that overexpression of cgri-HSP27 in CHO 
cells producing recombinant human IFNɣ extended culture duration and resulted in 
higher yield of recombinant human IFNɣ in fed-batch bioreactor cultures.  
In the past decade, recombinant mAbs represent almost 30% of all the 
regulatory approved recombinant biologics and the top three best recombinant mAbs 
are produced in CHO cells. Due to the increasing importance of recombinant mAbs 
as new innovator drugs and in the development of mAb biosimilars, there is 
motivation to evaluate the application of cgri-HSP27 overexpression in CHO cells 
producing recombinant mAb. Additionally, since the recombinant human IFNɣ 
producing cell line in the previous study was derived from a CHO DuxB11 host cell 
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line, a recombinant mAb-producing cell derived from CHO DG44 host cell line was 
chosen for this study. As such, this study will demonstrate the applicability of cgri-
HSP27 overexpression strategy in improving production titers of two different classes 
of therapeutic biologics (recombinant interferon and recombinant mAb) and in 
production cell lines derived from two different CHO host cell lines (CHO DuxB11 
and CHO DG44) in fed-batch bioreactor cultures.  
Recent studies on HSP27 in human and mouse pathological tissues and cells 
have demonstrated that besides functioning as a molecular chaperone, it has a 
multitude of other cellular functions including anti-apoptosis and enhancing cell 
proliferation by interacting with cellular regulatory proteins. However, there is 
limited understanding of the functions of cgri-HSP27 in CHO fed-batch bioreactor 
cultures, hence, study of cgri-HSP27 molecular roles in improving CHO fed-batch 
bioreactor cultures was explored. 
 
1.2 Thesis Objectives 
One of the goals of the thesis is to extend the application of cgri-HSP27 
overexpression strategy to create robust CHO production cell lines in a recombinant 
mAb producing CHO cells in fed-batch bioreactor cultures. The other goal is to add 
on the current limited knowledge of the roles of cgri-HSP27 in CHO cells, which can 
provide further insights for use in future cell line engineering of CHO cells.  
The scope of the thesis involved: 
(1) Examining the effects of cgri-HSP27 overexpression in improving recombinant 
mAb titer in fed-batch bioreactor cultures by overexpressing cgri-HSP27 in a 
mAb-producing CHO cell line, 
(2) Validating interacting targets of cgri-HSP27 in CHO fed-batch bioreactor 
cultures based on reported studies of HSP27 and its anti-apoptosis functions in 
human and mouse pathological tissues and cell lines, and 
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(3) Identifying potential interacting targets of cgri-HSP27 in CHO fed-batch 
bioreactor cultures that are involved in improving recombinant mAb titer using 
omics technologies. 
 
1.3 Thesis Organization 
There are eight chapters in this thesis. Chapter 1 provides a brief introduction 
and sets the objectives and scope of the dissertation. Chapter 2 reviews the literature 
on the production of biologics using CHO cell lines in fed-batch bioreactor systems, 
use of cellular engineering targets identified via transcriptome studies to improve 
biologics titers in CHO cell cultures as well as the cellular functions, including anti-
apoptotic function, of HSP27 in human, mouse and CHO cells. A detailed description 
of the materials and methods applied in the thesis is covered in Chapter 3. In Chapter 
4, the effects of cgri-HSP27 overexpression in CHO cells producing recombinant 
mAb cultured in batch shake flasks are reported. In Chapter 5, the effects of cgri-
HSP27 overexpression in CHO cells producing recombinant mAb cultured in fed-
batch bioreactors together with the glycosylation profile of the produced recombinant 
mAb are described. In Chapter 6, the results from the validation of cgri-HSP27 
interacting targets in CHO cells against those previously described in human and 
mouse pathological tissues and cells are reported. Chapter 7 describes the use of 
transcriptome profiling and metabolic profiling to identify other potential cgri-HSP27 
targets in CHO cells. The overall proposed molecular roles of cgri-HSP27 in CHO 
cells that may lead to improve recombinant mAb titers via improved cell growth and 
extended culture duration and the insights gained in further improving the robustness 
of cgri-HSP27 engineered CHO-mAb cells are also discussed in Chapter 7. Chapter 8 
summarizes the important conclusions resulting from this study and provides 




CHAPTER 2 Literature Review 
 
2.1. Recombinant Biologics Production Using CHO Cells  
First approved recombinant biologic produced in CHO cells is Activase, a 
Tissue-type Plasminogen Activator, in 1987. Since then, CHO cells have become the 
predominant mammalian production cell lines of choice for the production of many 
different classes of US Food Drug Administration (FDA) approved recombinant 
biologics (Table 2.1).  
 
Table 2.1 Different classes of FDA approved recombinant biologics produced in CHO 
cells                                                                                                                                             
(extracted from Walsh, G., Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32, 
992-1000). Recombinant biologics under each class is not exhaustive. 
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This is because CHO cells: (i) can be easily adapted for cultivation in large-
scale single-cell suspension, using serum-free chemically defined and protein-free 
media, (ii) can achieved high viable cell density in stirred tank suspension bioreactors, 
(iii) have good proven safety track records from the long history of regulatory 
approved recombinant biologics produced in CHO cells, (iv) able to perform human-
like post-translational modifications, such as proper protein folding and protein 
glycosylation, which can affect half-life, efficacy and stability of the recombinant 
biologics, and (v) can be easily manipulated genetically for the production of 
different recombinant biologics and for improved production capabilities [1-5]. There 
are five main CHO parental host cell lines used for the production of recombinant 
biologics: CHO DG44, CHO DuxB1l, CHO K1, CHO S, and CHO K1 SV. The first 
two CHO parental host cell lines are the most popular because they are dihydrofolate 
reductase negative (dhfr-), which offers opportunities for amplifying the gene copy 
encoding for the recombinant biologic and as such increases the chances of attaining 
high producing cells [2, 6].   
Over the past five years, more than half of the top 10 best-selling recombinant 
biologics were produced in CHO cells and they included recombinant mAbs. The 
demands for these recombinant mAbs are likely to increase due to their expanding 
approved indications over the years, generating billions in revenue.  Over the last 4 
years, there are 54 FDA newly approved biologics in the market and 17 of these 
recombinant biologics are recombinant mAbs [7]. Furthermore, due to the patent 
expiry of many original blockbuster recombinant biologics including recombinant 
mAbs in the recent and upcoming years, there is an increasing number of biosimilars 
emerging in the market. Remsima™ (Celltrion Healthcare, Hungary) and Inflectra™ 
(Hospira, UK), both infliximab biosimilars used mainly for the treatment of 
rheumatoid arthritis, are the first two mAbs biosimilars approved in 2013, in Europe 
[8, 9]. Together with other biosimilars, they are currently filing for approval with 
FDA. For the development and large scale manufacturing of new innovator 
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recombinant biologics and biosimilars, new production cell lines will have to be 
created as the production cell lines used for the production of innovator recombinant 
biologics and current blockbusters recombinant biologics are often propriety 
information [10, 11]. This presents opportunities to explore the use of parental CHO 
cell lines that have been engineered to be more robust. 
 
2.1.1 Fed-batch Bioreactor Cultures for Production of Recombinant Biologics 
Using CHO Cells  
For the large scale production of recombinant biologics, CHO cells are cultured 
in bioreactors under controlled environment where process conditions such as 
temperature, pH, dissolved oxygen concentration and stirring speed are operated and 
maintained at optimal levels that promotes cell growth and recombinant protein 
production [12-16]. The bioreactors can be operated in three culture modes: batch, 
fed-batch and perfusion. The batch culture mode is the simplest and easiest to operate: 
CHO cells are inoculated into the bioreactor together with fresh culture media and 
cultured for typically 5 days before harvest. However, final recombinant protein 
yields are fairly low as cells start to die once nutrients become limited. On the other 
hand, perfusion culture mode is complex: cells are retained in the bioreactor with 
fresh media added while waste metabolites together with the recombinant proteins are 
removed continuously. It is used for recombinant proteins that are easily degraded 
during culture. However, it has a high risk of contamination, uses large volumes of 
media and typical process can last over 20 days to months [12-16]. 
Fed-batch bioreactor system is the most common manufacturing mode used for 
production of recombinant biologics by CHO cells as it is simple to operate and high 
recombinant protein yields can be achieved in a relatively short time; on average, a 
fed-batch culture last 14 days. The cultures are fed concentrated media nutrients at 
regular intervals to extend culture duration and increase productivity, alleviating the 
problem of pre-mature cell death in a batch bioreactor system caused by nutrients 
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depletion [12-21]. Several approaches, including optimizing feed media nutrients 
components to enhance cell growth [22, 23] and optimizing process conditions to 
extend production phase [24, 25] have been developed to improve the CHO fed-batch 
culture process. 
Nevertheless, deprivation of culture viability and onset of programmed cell 
death, a predominant fashion of cell death in mammalian cell cultures in bioreactors, 
still occurs. This leads to a shorter process culture time, lower recombinant biologics 
yields and degradation of recombinant biologics [5, 26]. 
 
2.1.2 Apoptosis in CHO Bioreactor Cultures  
Apoptosis, an active and genetically controllable form of cell death, can be 
mediated either by the extrinsic pathway involving the death receptors, intrinsic 
pathway involving the mitochondria or endoplasmic reticulum pathway to activate 
the caspase-cascade signaling of events and non-caspase-independent cell death [27-
32]. Extrinsic pathway is mediated by binding of extracellular death ligands to the 
death receptors on the cell surface membrane. Upon binding, the death receptors will 
be activated, causing death-inducing signal complexes to be recruited and activated 
apoptosis via Caspase-8 and Caspase-3. Intrinsic pathway is mediated by the release 
of pro-apoptotic proteins such as Cytochrome c, SMAC/DIABLO and AIF from the 
mitochondria when the membrane integrity is compromised during stress [27-32]. 
Pro-apoptotic Bcl family of proteins (Bid, Bax, Bim and Bad) activated by stress 
signals can also cause the mitochondria membrane to be dysfunctional. Upon released, 
Cytochrome c forms the apoptosome complex with Apaf-1 and pro-Caspase 9, which 
activates Caspase-9 followed by Caspase-3 to execute the final stage of apoptosis. 
Endoplasmic reticulum pathway is mediated by stress responses such as improper 
folding in the endoplasmic reticulum and activates Caspase-12 to activate apoptosis. 
All three pathways can cross link to activate the caspase cascade. Additionally, the 
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extrinsic pathway is also able to promote caspase-independent apoptosis via the JNK 
signaling pathway [31, 32]. 
Transcription profiling of CHO cells producing recombinant human interferon 
gamma (IFNɣ) cultured in fed-batch bioreactors has been performed. Figure 2.1 
shows the sequential differential expression in the apoptosis genes from the 
exponential growth, stationary growth to the death phase of CHO fed-batch 
bioreactor cultures. The profiles correlates with the onset of apoptosis and the 
decreased in culture viability. Several pro-apoptosis genes were up-regulated during 
the CHO fed-batch bioreactor cultures, such as Bax and Fadd. On the other hand, 
several pro-survival genes such as HSP27 and HSP70 were down-regulated. 
Additionally, the apoptosis transcription profiling study also reveals apoptotic genes 
that have not been known previously to be involved in the apoptosis signaling of 
CHO fed-batch bioreactor cultures. In summary, this profiling revealed that apoptotic 
genes were up-regulated in the exponential and stationary growth phases of the fed-
batch bioreactor cultures when nutrients were not limiting, and that apoptosis 
mediated by the death receptors and mitochondria were more prevalent than by ER-
stress [33]. Apoptosis in fed-batch bioreactor cultures can be induced by several 
factors such as (i) accumulation of toxic metabolites, (ii) elevation of culture 
osmolality, (iii) withdrawal and decreased production of growth factors and (iv) 
increased accumulation and secretion of growth inhibiting factors and death ligands 
[20, 27, 34]. Hence, it provided a rational strategy to prevent onset of apoptosis and 





Figure 2.1 Apoptosis transcriptome profiling of CHO fed-batch bioreactor cultures 
(Source: Wong, D. C. F., Lee, Y. Y., BTI in-house Scientific Advisory Board meeting 
presentation. 2006.) Transcriptome profiling was done over 3 sequential growth phases; 
exponential, stationary and death. Red indicates up-regulation of gene expression and green 
indicates down-regulation of gene expression as shown in the colour bar chart on the bottom 
right corner. Genes represented in the microarray are indicated by solid square. Genes not 
represented in the microarray are indicated by dotted square. 
 
2.2 Anti-apoptosis CHO Cell Line Engineering to Increase Production Yields 
 The on-going aim for the production of recombinant biologics in CHO cells 
is to have maximum volumetric productivity; maximum yield of recombinant 
biologics in the shortest time, and one of the methods to achieve this aim to through 
CHO cell line engineering. With the study of apoptosis transcription profiles for CHO 
fed-batch bioreactor cultures, it was proposed that rational cellular engineering of 
CHO cells with early apoptotic genes can create CHO cells that are resistant to 
apoptosis with improved production of recombinant biologics in industrial relevant 
fed-batch bioreactor culture system. 
 Table 2.2 shows cellular engineering targets from the apoptosis transcript 
profiles being employed in CHO cell line engineering, and validated in industrial 
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relevant fed-batch bioreactor culture mode [35-38]. The rational anti-apoptosis 
cellular engineering strategy has proven successful in extending culture duration, 
leading to higher recombinant biologics yield. Notably, the strategies were employed 
to CHO cells producing recombinant human IFNɣ. Given the gaining importance and 
increased use of CHO cells in the production of recombinant mAbs, it would be of 
great interest to evaluate the applicability of these targets in CHO cells producing 
recombinant mAb in a fed-batch bioreactor system. Additionally, it will also evaluate 
whether the cellular engineering targets are independent of recombinant protein 














2.3 HSP 27 
Heat shock protein 27 (HSP27), well known for its role as a molecular 
chaperone, belongs to the small heat shock protein family of 10, with protein size 
ranging from 15 to 30 kDa. It is ubiquitously expressed in all tissues, but not in all 
cell lines [39-41]. HSP27 expression is transiently up regulated in normal tissues and 
cell lines to promote cell survival when stress-stimulated or when exposed to sub-
lethal conditions. HSP27 main function is as a molecular chaperone, to keep the 
misfolded protein in a refolding competent state, and together with the help of other 
molecular chaperone, HSP70 and HSP90, folds the misfolded proteins [40]. However, 
due to the discovery of HSP27 constitutively high expression in pathological human 
and mouse tissues [41, 42], recent studies on HSP27 have shown that it has more 
cellular functions than just its molecular chaperone function as illustrated in Figure 
2.2. Although the cellular functions of HSP27 have been tied in with its interactions 
of different proteins [41-46], not all the cellular functions may occur concurrently, as 
it is determined by the tissue type, cell line, the type of stress induced and status of 
HSP27 [43-46]. 
 
Figure 2.2 Cellular functions of HSP27 
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 When cells undergo oxidative stress, high expression level of HSP27 has 
been shown to correlate with the high expression and activity of anti-oxidative 
proteins including reduced glutathione to promote cell survival [46-50]. However, the 
interacting proteins associated with this HSP27 cellular function have not been 
determined. HSP27 interaction with cytoskeleton proteins have resulted in the 
stability and maintenance of cytoskeleton integrity during stress. This interaction has 
conferred HSP27 the function of regulating cell adhesion, cell differentiation, cell 
metastasis, cell invasion, intracellular signal transduction and indirectly, regulate 
apoptosis [51-58]. Regulation of signal transduction by HSP27 was also related to its 
interaction with receptors, kinases, phosphatases and signaling proteins [59-65]. 
Transcription factors were also regulated via interaction with HSP27 where upon 
interaction, the transcription factors are either stabilized [64, 68, 70] or have their 
transcriptional regulation activities are directly regulated [62, 64, 71, 72]. Besides 
maintaining aggregated protein in its refolding competent state, HSP27 also interacts 
with cellular proteins to prevent the protein either from being degraded [70, 73, 74] or 
promote its degradation and/or ubiquitination [66, 69, 74-76], dependent on the 
interacting target. Interactions with HSP27 in the cells under specific stress 
conditions may likely determine the cell fate, cell behaviour and phenotype of the 
cells. The reported interactions of HSP27 as discussed are summarized in Table 2.3. 
An exhaustive list of reported and non-reported HSP27 interacting proteins was 
created by protein interactome databases mining and will be discussed in Chapter 7.  
Recently, HSP27 anti-apoptotic cellular function has also been applied to 
bioprocessing, where CHO cells producing recombinant interferon gamma (IFNɣ) 
were engineered to constitutively express high levels of the HSP27 cloned from CHO 
cells (cgri-HSP27). It resulted in improved cell growth, delay loss of culture viability 
and as such, much improved recombinant IFNɣ yield in fed-batch bioreactors [36]. 
However, cgri-HSP27’s interacting targets in the CHO cells under stress conditions 




Table 2.3 List of HSP27 cellular functions and its associated interacting proteins.  










Table 2.3 (continued) List of HSP27 cellular functions and its associated interacting proteins.  




2.3.1 HSP27 and Its Interaction with the Apoptosis Signaling Pathways  
 One of the well-studied cellular functions of HSP27, besides its role as a 
molecular chaperone, is its role as an anti-apoptotic protein, especially in human 
pathological tissues where hsap-HSP27 is constitutively expressed at high levels [42, 
43]. Its anti-apoptotic function has been associated with its ability to interact with a 
multitude of targets along the apoptosis signaling pathways, both death receptor and 
mitochondria mediated [78-84]. HSP27 has been reported to interact with apoptotic 
proteins involved in the death receptor and mitochondria mediated apoptosis 
signaling pathways in various human and mouse pathological tissues and cell lines 
[45, 72, 78, 80, 82-87]. These interactions resulted in increased resistance to 
apoptosis insults including exposure to cytotoxic drugs and chemicals [80, 81, 83]. 
Because of its anti-apoptotic functions in human pathological tissues, therapy based 
on anti-HSP27 human has gained interests [8-9]; HSP27 inhibitor, Apatorsen (OGX-
427, OncoGenex Healthcare, USA) [9] is currently in clinical trials. Use of HSP27 as 
biomarkers in several human pathological conditions are also being investigated [88-
90].  
Interestingly, transient high expression of HSP27 during stress in normal, non-
pathological cells were observed and promoted cell survival. However, in cells that 
were committed to apoptosis, transient high expression of HSP27 was not observed 
and cell death occurred. Cells with constitutive expression of HSP27 before 
committing to apoptosis, though, had proven to delay onset of programmed cell death 
and cell destruction. Hence it suggests that early constitutive expression of HSP27 is 
required for its anti-apoptotic cellular function [42-45]. 
 As shown in Table 2.3, there are several known HSP27 interacting proteins 
involved in conferring apoptosis resistance to the cells via the apoptosis signaling 
pathways. Interaction with Akt enhanced the activity of Akt to regulate pro-apoptotic 
proteins such as Bad, Bax, Pea-15 and Caspase-9 activation [71, 91-97]. PTEN, an 
inhibitor of Akt activation, was demonstrated to interact with HSP27 via a PTEN 
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complex in the cytosol [96] which promotes degradation of PTEN. The activity of 
Caspase-3, the executioner caspase-dependent cell death is inhibited with the binding 
of HSP27 to the inactive form, pro-Caspase-3 [72]. Upon binding, cleavage of pro-
Caspase-3 to active Caspase-3 is prevented to delay the final execution of apoptosis 
by active Caspase 3. Cytochrome C, a pro-apoptotic protein, becomes bound to 
HSP27 once it is released from mitochondria with dysfunctional membrane [87] and 
this binding prevents its interaction with Apaf-1 and pro-Caspase 9 to delay the 
activation of Caspase-9 and Caspase-3 thereafter [97]. Additionally, HSP27 
interactions with Daxx prevents Daxx from interacting with FADD and ASK1 at the 
Fas-receptor, and thus delays Daxx-mediated Fas-induced caspase independent cell 
death via JNK [86].  
Notably, HSP27 interaction with other non-apoptotic signaling pathways 
proteins may also contribute to the increased resistance to apoptosis. This includes 
and is not limited to: (i) increased resistance to oxidative stress by decreasing the 
intracellular reactive oxygen species and reactive nitrogen species [48, 49], (ii) 
maintaining the cytoskeletal integrity [52-55] which prevent translocation of tBid to 
the mitochondria by preventing cytoskeleton disruption during stress [82], (iii) 
prompting the degradation of cell cycle arrest proteins [74], and (iv) regulation of 
transcription factors that in turn regulate cell proliferation and cell survival proteins 
[67-70].  
 
2.3.2 HSP27 Protein Sequence  
 Beside the type of cells and kind of stress induction, HSP27 interaction with 
its interacting proteins is dependent on the state of the HSP27 protein [43-45, 98]. 
The different states are dependent on the stress signals that the cells are experiencing 
and are a reversible process by kinases and phosphatases [98]. Table 2.4 shows the 
state of hsap-HSP27 when interacting with its target proteins and the associated 
cellular functions. Hsap-HSP27 cellular function as a molecular chaperone is 
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conferred when hsap-HSP27 is presented as large oligomers [99], together with its 
thermo-protective function [41], and its ability to regulate reactive oxidative stress 
[49, 50]. On the other hand, phosphorylated small hsap-HSP27 and mmus-HSP27 
oligomers have been reported to bind to Daxx [86], regulating the death receptor-
mediated apoptosis pathway. Besides that, maintenance and stabilization of 
cytoskeleton and actin filaments [52, 54] and regulating degradation and 
ubiquitination [75, 77] of its target proteins are dependent on phosphorylation of 
hsap-HSP27. Hsap-HSP27 as small oligomers is required for the interaction with pro-
Caspase-3 to prevent its proteolytic cleavage to active Caspase-3. Some of hsap-
HSP27 cellular functions, including regulation of transcription factor activity, are 
conferred in varying states of hsap-HSP27 [70, 71].  
 
Table 2.4 Reported states of HSP27 when interacting with specific cell regulatory 
proteins and the associated cellular functions 
 
The WD/EPF motif at the N-terminal and the α-crystallin domain towards the 
C-terminal of hsap-HSP27 are required for the formation of oligomers [40, 98]. 
Serine at positions 15, 78 and 82 along the hsap-HSP27 protein sequence are required 
for its phosphorylation [53, 99]. Notably, for mmus-HSP27 only two phosphorylation 
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sites are present (Serine 15 and 86) but are sufficient for the phosphorylated mmus-
HSP27 to carry out its relevant cellular functions [84].   
 In this study, cgri-HSP27 was cloned from CHO K1 cells induced by heat 
shock. Its protein sequence [36] was compared to both hsap-HSP27 (Swiss-Prot: 
P04792) and mmus-HPS27 (Swiss-Prot: P14602) as most of the studies on HSP27 
cellular functions were carried out using tissues and cells from human and mouse. It 
was found that the protein sequence of cgri-HSP27 was 90% similar to that of hsap-
HSP27 but more similar to mmus-HSP27 at 96%. As certain domains in the protein 
sequence are essential for HSP27 to achieve its cellular functions, the WD/EPF motif, 
α-crystallin domain and phosphorylation sites of cgri-HSP27 were compared against 
those of hsap-HSP27 and mmus-HSP27 (Figure 2.3). The WD/EPF motif was 
conserved between the HSP27 from the three different mammalian species. On the 
other hand, the α-crystallin domain of cgri-HSP27 was 100% aligned to that of 
mmus-HSP27 but 96% aligned to hsap-HSP27. As for the phosphorylation sites, cgri-
HSP27 has two phosphorylation sites: Serine 15 and 86, similar to mmus-HSP27. 






Figure 2.3 Comparison of hsap-HSP27, cgri-HSP27 and mmus-HSP27 protein 
sequence. 



















CHAPTER 3 Materials & Methods 
 
3.1 Cell Line 
3.1.1 CHO-mAb 
CHO-mAb 2.11 subclone M250-9 is a CHO DG44-derived suspension cell line 
expressing a secreted recombinant humanized IgG monoclonal antibody against 
Rhesus D antigen [100]. CHO DG44 was cotransfected with a vector containing the 
heavy chain variable domain with neomycin selection marker and another vector 
containing the light chain variable domain with DHFR selection marker. In this thesis, 
the cell line will be referred to as CHO-mAb. 
3.1.2 Culture Maintenance 
CHO-mAb cells were maintained in a protein-free media mixture consisting of 
a 1:1 ratio of HyQ-PF-CHO (HyClone-GE Healthcare, Sweden) and CD CHO (Life 
Technologies, USA), supplemented with 6 mM glutamine (Sigma-Aldrich, USA), 
0.05% Pluronic F-68 (Life Technologies), 600 g/ml Geneticin (Life Technologies) 
and 250 nM methotrexate (Sigma-Aldrich). Cells were routinely subcultured every 3 
to 4 days in shake flasks with a seeding viable cell density of 3 x 105 cells/ml in a 
culture volume of 20 ml. Cell cultures were maintained in a 37oC humidified 
incubator with 8% CO2 atmosphere on a shaker at an orbital speed of 110 rpm with a 
shaking amplitude of 12.5 mm. 
3.2 Vector Construction of pIRES2 and pIRE2-27  
To generate the control null vector pIRES2 (Fig. 3.1), the truncated internal 
ribosome entry site (IRES) fragment from the mammalian expression vector, pIRES 
(Clontech Laboratories, USA), was replaced with that from the  mammalian 
expression vector, pIRES2-DsRedExpress (Clontech Laboratories), using restriction 
enzymes EcoR I and Xba I. The neomycin selection marker was then replaced with 
the hygromycin selection marker from vector pcDNA 3.1-hyg (Life Technologies) 
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using restriction enzymes, Stu I and Bst BI. To generate vector pIRES2-27 (Fig. 3.1) 
for overexpression of cgri-HSP27, the coding region of cgri-HSP27 from pIRES-27 
[37] was digested using restriction enzymes, Nhe I and Xho I, and inserted upstream 
of pIRES2. To ensure efficient translation, a Kozak sequence, GCCGCC, was placed 
upstream of the cgri-HSP27 start codon.  
 
Figure 3.1 Vectors used of the overexpression of cgri-HSP27 in CHO-mAb cells.                                            
(A) pIRES 2 is the null vector and (B) pIRES2.27 is the cgri-HSP27 overexpression vector. 
 
3.3 Creation of Stable Cell Lines 
3.3.1 Generation of Stable HSP27 Overexpressing cells 
CHO-mAb cells were stably transfected with vectors pIRES2 and pIRES2-27 
to obtain stable p2.Blank CHO-mAb and p2.27 CHO-mAb cells respectively. Briefly, 
transfection was performed using Lipofectamine 2000 reagent (Life Technologies) 
according to manufacturer’s instructions using 1:3 ratio of vector (g) to transfection 
reagent (l) and 1.2 x 106 CHO-mAb cells, in 6-well culture plates under static 
condition and were expanded into shake flasks upon confluence. Pools of stable 
transfectants were obtained after 14 days of culture under 300 g/ml hygromycin 
(Clontech Laboratories) selection pressure and maintained thereafter under a reduced 
selection pressure of 100 g/ml hygromycin (Clontech Laboratories) for banking, 
characterization and single cell cloning. These cell pools were then characterized in 
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batch shake flasks. A viable seeding cell density  of 3 x 105 cells/ml with a starting 
culture volume of 60 ml were used. Daily sampling was carried out for the 
determination of viable cell density, culture viability, extracellular biochemical 
concentrations and recombinant mAb titer. Additionally, analysis of cgri-HSP27 gene 
and protein expression levels was carried out on Day 3 of culture. 
 
3.3.2 Single Cell Cloning 
Concurrently, single clones were obtained from the respective pools of stable 
transfectants by limiting dilution in a 96-well plate. Wells that contained one cell 
were maintained by replacing half of the media with fresh media twice weekly. 
Surviving clones, upon reaching confluence, were expanded into shake flasks for 
banking and characterization. 
 
3.3.3 Selection of Single Cell Clones for Fed-batch Bioreactor Evaluation 
Single cell clones underwent an initial selection which involved culturing the 
cells in batch shake flasks with a viable seeding cell density of 3 x 105 cells/ml and a 
starting culture volume of 30 ml. Determination of viable cell density, culture 
viability and cgri-HSP27 protein expression levels were carried out on Day 6 of 
culture. Thereafter,  the selected clones were thawed and recovered in passage before 
they were cultured in batch shake flasks to determine their growth and production 
profiles using a viable seeding cell density of 3 x 105 cells/ml and a starting culture 
volume of 130 ml. Determination of viable cell density, culture viability, extracellular 
biochemical concentrations and recombinant mAb titer were carried out daily. In 
addition, analysis of cgri-HSP27 gene expression levels was carried out on Day 3 of 






3.4 Fed-batch Bioreactors 
3.4.1 Fed-batch Bioreactor Culture Operation 
Fed-batch bioreactor systems of 1.5 L working volume were conducted in a 2L 
double-walled, round-bottom glass vessel (B. Braun, Melsungen, Germany) with a 
heated water jacket. The bioreactor was inoculated with a viable seeding cell density 
of 2.7 to 3.8 x 105 cells/ml at a starting working culture of 1.5L. Bubble-less aeration 
was achieved through the use of a gas-permeable silicon membrane tubing basket (B. 
Braun, Melsungen, Germany) and the dissolved oxygen concentration (DO) were 
maintained at 50% air saturation using an Air/Nitrogen mix during the early phase of 
culture or Oxygen/Air mix during the late phase of culture at a set flow rate of 
1L/min. pH in the culture was maintained at 7.15 using either intermittent carbon 
dioxide addition to the gas mix or addition of 7.8% (w/v) sodium bicarbonate (Sigma-
Aldrich) solution. Agitation rate was set at 120 rpm using a three-blade segmented 
impeller. 
3.4.2 Feeding Strategy 
Feed-forward control strategy was employed to achieve discrete control of 
glutamine and glucose concentrations by feeding the projected amount of glutamine 
and glucose that will be consumed by the cells until the next forecasted sampling time. 
Set points of 0.04 g/L glutamine and 0.5 g/L glucose were used based on pre-
determined glutamine and glucose specific consumption rates during the exponential 
growth phase. Glutamine and glucose concentrations in the culture were monitored 
offline daily at 20-24 h intervals before feedings. Two separate feeds were used: a 
180 g/L glucose feed (Sigma-Aldrich), and a glucose-free, protein-free feed 
formulated based on a fortified 10X DMEM/F12 (Sigma-Aldrich) supplemented with 
10 g/L of soybean protein hydrolysate (Kerry, USA) and 7.3 g/L of glutamine 
(Sigma-Aldrich). The glutamine-containing feed were fed into the culture at 1.5 h 
intervals, while the glucose feed were fed into the culture daily at 20-24 h intervals.  
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3.5 Determination of Extracellular Biochemical Concentrations 
Concentrations of extracellular biochemical: glucose, glutamine, lactate and 
ammonium were determined offline by analysing the culture supernatant using the 
YSI 7100 biochemical analyser (Yellow Spring Instruments, USA) , according to 
manufacturer’s instructions.  
3.6 Determination of Viable Cell Density and Culture Viability 
3.6.1 Trypan Blue Exclusion Viability Assay 
Viable cell concentration was determined by manual cell counting using an 
Improved Neubauer haemocytometer (Weber, England) counting chamber and 
culture viability was estimated based on the trypan blue exclusion method. The trypan 
blue exclusion method is based on the evidence that the live cell possess intact cell 
membrane that exclude trypan blue, whereas dead cells do not. Hence, when mixed 
with trypan blue, viable cell will be clear while dead cells are stained.  
3.6.2 Calculation of Integrated Viable Cell Density 
Integrated viable cell density (IVCD) was calculated using the formula: IVCD 
= 0.5(t2 - t1) (x1 + x2),  where t is the culture time (h) and x is the viable cell density 
(cells/ml). 
3.7 Determination of Recombinant mAb Titer 
3.7.1 Determining mAb Titer Using Nephelometry Method 
Recombinant mAb titers were determined using an IMMAGE 800 
immunochemistry system (Beckman Coulter, USA) based on rate nephelometry 
method, according to manufacturer’s instructions. 
 
3.7.2 Calculation of Specific Recombinant mAb Production Rates 
Specific production rate (QP) was calculated using the formula: QP  = (Ct2 - 
Ct1)/(IVCDt1 + IVCDt2),  where C is the concentration of mAb (mg/ml), t is the 
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culture time (h) and IVCD is the intergrated viable cell concentration (cells-h/ml). 
Exponential specific production rate was calculated during the exponential growth 
phase of culture. Stationary specific production rate was calculated after the 
exponential growth phase of culture till harvest at approximately 70 to 80% culture 
viability. The average specific production rate was calculated from the start of culture 
till harvest.  
3.8 Determination of Caspase 2, 3, 8 and 9 Activities 
2 x 106 cells were collected at 24 h intervals during fed-batch bioreactor culture 
until viability dropped to about 80%. Fluorimetric assay using BD ApoAlertTM 
caspase profiling kit (Clontech Laboratories) to detect activities of caspase 2, 3, 8 and 
9 in the cells was performed as per manufacturer’s instructions. Briefly, cells were 
resuspended in 50 μl of ice-cold 1X cell lysis buffer and incubated on ice for 10 min. 
The cell lysate was then centrifuged at 18,078 g (14,000 rpm) for 5 min at 4oC to 
remove cell debris. The cell lysate was transferred to a new microcentrifuge tube and 
kept on ice. 50 μl of 2X reaction buffer/DTT mix was added to each well of the 
provided 96 well plate and covered with an adhesive cover to avoid evaporation. The 
plate was pre-incubated in a 37oC incubator for 5 min. Each well was pre-coated with 
a peptide substrate unique to its respective caspase  and was covalently linked to the 
fluorogenic dye, 7-amino-4-methyl coumarin (AMC). Samples that contain the 
corresponding activated caspase will cleave the dye  from the substrate, resulting in 
an emitted fluorescence wavelength of 465 nm. An increase in the fluorescence 
activity can be directly correlated to an increase in the activity of the respective 
caspase in the sample. 50 μl of debris-free cell lysate was then added to each well of 
the pre-incubated plate and further incubated for 2 h in the 37oC incubator. The 
fluorescence intensities were read using a fluorescence spectrometer, SPECTRAFluor 
PLUS (Tecan, Switzerland), at an excitation wavelength of 360 nm and an emission 
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wavelength of 465 nm. Raw fluorescence readings were subtracted from the 
background and normalized against the start of fed-batch bioreactor culture. 
3.9 Determination of Total  HSP27CHO and pIRES2-27 Gene Expression  
3.9.1 Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) 
1 x 107 cells were collected on Day 3 of batch shake flask cultures and total 
RNA was extracted using Trizol reagent (Life Technologies) as per manufacturer’s 
instructions. Total RNA extracted was quantified using GeneQuant Pro RNA/DNA 
Calculator (GE Healthcare), followed by reverse transcription using 1 g of total 
RNA and the Improm-II Reverse Transcription System (Promega, USA) as per 
manufacturer’s instructions. The resulting first strand cDNA was used in equal 
amount for qRT-PCR carried out using ABI PRISM 7000 Sequence Detection 
System (Life Technologies) with SYBR Green PCR Master Mix (Life Technologies). 
The gene specific primer pair used for verification of cgri-HSP27 consisted of 
forward primer 5’ CAC TGG CAA GCA CGA AGA AAG 3’ and reverse primer 5’ 
GCC TCG AAA GTA ACC GGA ATG 3’. Vector specific primers were used for 
verification of pIRES2-27 vector straddled between the 3’ end of cgri-HSP27 and the 
vector backbone. This consisted of forward primer 5’ CCA GAA GCT GGG AAG 
TCT GA 3’ and reverse primer 5’ GGT ACC GTC GAC TGC AGA AT 3’. Duplicate 
runs were conducted for each sample and normalised against cgri--actin expression 
(U20114). The gene specific primers used for cgri--actin consisted of forward 
primer 5’ AGC TGA GAG GGA AAT TGT GCG 3’ and reverse primer 5’ GCA 
ACG GAA CCG CTC ATT 3’. Fold change in gene expression was calculated using 
the delta-delta threshold cycle method [101] where relative expression, Log2 ratio = 





3.9.2 Semi-quantitative Reverse-transcriptase Polymerase Chain Reaction (RT-
PCR) 
1 x 107 cells were collected on Day 3 of batch shake flask cultures and total 
RNA was extracted using RNeasy mini kit (Qiagen, Netherlands) as per 
manufacturer’s instructions. Total RNA extracted was quantified using NanoDrop 
2000 UV-VIS spectrophotometer (Thermo Scientific, USA), followed by RT-PCR 
using OneStep RT-PCR kit (Qiagen) as per manufacturer’s instruction with 1 g of 
total RNA. Gene amplification of cgri-HSP27 and pIRES2-27 vector was carried out 
using gene specific primers and normalized against cgri--actin as described in 
Section 3.9.1. The RT-PCR exponential phase was determined at 26 cycles for semi-
quantitative comparison of cgri-HSP27 gene expression. The amplified RT-PCR 
products were then subjected to electrophoresis for visualization on a 1.5% agarose 
gel containing 0.05 g/ml of ethidium bromide, followed by UV analysis using the 
InGenius3 system (Syngene, UK).  
3.10 Determination of cgri-HSP27 Expression at Protein Level  
1 x 107 cells were collected, washed once with ice-cold 1X phosphate buffered 
saline solution (Life Technologies) and lysed in radio-immunoprecipitation assay 
(RIPA) buffer (Pierce-Thermo Scientific, USA) supplemented with 1X Complete 
protease inhibitor cocktail (Roche, Switzerland) for 40 min on ice with intermittent 
vortexing. The complex mixture was centrifuged at 18,078 g (14,000 rpm) for 20 min 
at 4oC to obtain the total cellular proteins in suspension and quantified using BCA 
Protein Assay kit as per manufacturer’s instructions (Pierce-Thermo Scientific). 
Based on the quantified protein concentration, equal amounts of total cell lysate were 
treated with 1X lithium dodecyl sulfate (LDS) sample buffer (Life Technologies), 
denatured for 5 min at 95oC, separated on 10% Bis-Tris gel (Life Technologies) and 
transferred onto iBlot (nitrocellulose membranes (Life Technologies). The membrane 
was then probed for cgri-HSP27 and cgri--actin using rabbit anti-HSP27 (#06-517, 
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Merck Millipore, Germany) and mouse anti- actin (ab8226, Abcam, England) 
respectively. The primary antibodies were detected using horse-radish peroxide (HRP) 
conjugated anti-rabbit (ab6721, Abcam) and HRP conjugated anti-mouse HRP 
(ab6728, Abcam) respectively, visualized using enhanced chemiluminescent (ECL) 
substrate (GE Healthcare) for HRP and captured on ImageQuant LAS 500 imager 
system (GE Healthcare). The antibodies were verified and shown to work for CHO 
cellular proteins prior to use. 
3.11 Co-Immunoprecipitation Analysis 
p2.27 CHO-mAb clone 12 was cultured in batch shake flask and 1 x 107 cells 
were collected on Day 3 to Day 6 of culture. The cells were washed twice with ice-
cold 1X phosphate buffered saline solution (Life Technologies) and lysed by 
mechanical pipetting in lysis buffer containing 50 mM Tris-HCl pH 7.5 (Sigma-
Aldrich), 150 mM NaCl (Sigma-Aldrich), 1% Nonidet P40 (Sigma-Aldrich), 0.5% 
sodium deoxycholate (Sigma-Aldrich), 1X Complete protease inhibitor cocktail 
(Roche) and 1X PhosSTOP phosphatase inhibitor cocktail (Roche). The mixture 
was then centrifuged at 15,587 g (13,000 rpm) for 10 min at 4oC to collect the total 
cellular proteins containing the protein-protein interaction complexes and quantified 
using the BCA Protein Assay kit as per manufacturer’s instructions (Pierce-Thermo 
Scientific). Protein samples were pre-cleared by incubating with 100 l of Protein G 
agarose bead suspension (Roche) for 3 h at 4oC with constant mixing. Pre-cleared 
protein samples were collected after centrifugation at 15,587 g (13,000 rpm) for 20 s 
before incubating overnight with mouse anti-HSP27 (sc13132, Santa Cruz, USA) or 
mouse IgG (sc2025, Santa Cruz) respectively in separate tubes at 4oC with constant 
mixing. 100 l of Protein G agarose bead suspension was then added, followed by 
further incubation for 3 h at 4oC with constant mixing. The complexes were washed 
twice with lysis buffer, followed by another two washes with buffer containing 50 
mM Tris-HCl pH 7.5, 500mM NaCl, 0.1% Nonidet P40 and 0.05% sodium 
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deoxycholate and once with buffer containing 10 mM Tris-HCl pH 7.5, 0.1% Nonidet 
P40 and 0.05% sodium deoxycholate. Protein complexes retained on beads were 
eluted by incubating with 1X LDS sample buffer (Life Technologies) for 5 min at 
room temperature, followed by incubation at 95oC for 5 min. Eluted proteins were 
separated from the Protein G agarose beads by centrifuging at 15,587 g (13,000 rpm) 
for 20 s. The eluted proteins and total cellular proteins were separated in 4-12% Bis-
Tris gel (Life Technologies) and transferred onto iBlot nitrocellulose membranes 
(Life Technologies). The membranes were then probed for Akt, cytochrome c, cgri-
HSP27 and pro-caspase 3 using rabbit anti-Akt (#9272, Cell Signalling Technology, 
USA), rabbit anti-cytochrome c (#4280, Cell Signalling Technology), rabbit anti-
HSP27 (#06-517, Merck Millipore) and rabbit anti-pro-caspase 3 (#9662, Cell 
Signalling Technology) respectively. The antibodies were diluted in blocking buffer 
(1X Tris Buffered Saline, 0.1% Tween20 and 3% BSA) except rabbit anti-
cytochrome c, which was diluted in Signal Enhancer HIKARI Solution A (Nacalai 
Tesque, USA). The primary antibodies were detected using HRP conjugated anti-
rabbit (ab6721, Abcam) diluted in blocking buffer, except for the detection of 
cytochrome c where Signal Enhancer HIKARI Solution B (Nacalai Tesque) was used 
for the dilution. ECL substrate (GE Healthcare) for HRP was used to visualize the 
blots and the images were captured on ImageQuant LAS 500 imager system (GE 
Healthcare). The antibodies were verified and shown to work for CHO cellular 
proteins prior to use. 
3.12 Transcriptome Analysis 
3.12.1 Total RNA Isolation and Probe Array Hybridization 
p2.Blank CHO-mAb clone 8 and p2.27 CHO-mAb clone 12 were cultured in 
triplicates for fed-batch bioreactors, and 1 x 107 cells were collected on Day 3 to Day 
5 of culture. Total RNA was extracted using Trizol reagent (Life Technologies) and 
purified using RNeasy mini kit (Qiagen) as per manufacturer’s instructions. 
43 
 
Integrity of purified total RNA was checked using Aligent 2100 Bioanalyzer (Aligent 
Technologies, USA) prior to generation of labeled probes for hybridization using 
GeneChip 3’ IVT Express Kit (Affymetrix, USA), as per manufacture’s instructions. 
Briefly, Poly-A RNA controls and T7-Oligo(dT) promoter primer were added to 50 
ng of purified total RNA for first strand cDNA synthesis, followed by RNase H-
mediated second-strand cDNA synthesis. The double-stranded cDNA was purified 
and served as the template for subsequent in vitro transcription (IVT) to synthesize 
biotin-labelled complementary RNA (cRNA) using T7 RNA polymerase and 
biotinylated nucleotide analog/ribonucleotide mix. The biotin-labelled cRNA was 
then purified, quantitated using NanoDrop 2000 UV-VIS spectrophotometer 
(Thermo Scientific), fragmented and hybridized to customized GeneChip CHO 
probe array (Affymetrix). After hybridization, the probe array was subjected to the 
automated washing and staining protocol on the GeneChip Fluidics Station 450 
(Affymetrix) before the final scan using the GeneChip Scanner 3000 (Affymetrix). 
GeneChip Operating Software (Affymetrix) was used to create images of the probe 
array, view images created and to compute the intensity for each cell on the probe 
array for pre-processing. 
 
3.12.2 Pre-processing of Probe Array Data 
Pre-processing of probe array raw intensity values was performed using the 
GeneSpring GX software (Aligent Technologies). Quality control checks on the 
efficiency of cDNA synthesis reaction, entire labelling process and efficiency of 
hybridization of the probe array were carried out before background correction was 
performed on the raw intensity values using the Robust Multi-array Average (RMA) 
normalization method. Probe cells with new intensity values below 100 were filtered 
out and the intensities of the remaining probe cells corresponding to the same gene 
were averaged and condensed to gene level. Fold-change was calculated for p2.27 
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CHO-mAb clone 12 samples in comparison to p2.Blank CHO-mAb clone 8 samples 
(Day 3 p2.27 vs Day 3 p2.Blank; Day 4 p2.27 vs Day 4 p2.Blank; Day 5 p2.27 vs 
Day 5 p2.Blank) and a 2-way ANOVA significance statistical test based on the 
Benjamini-Hochberg FDR analysis method was performed on genes with fold change 
of more than or equal to ± 1.5 on either Day 3, Day 4 or Day 5 of culture. Genes with 
P-values of less than 0.05 were shortlisted (p2.27 CHO-mAb Clone 12 vs p2.Blank 
CHO mAb clone 8) and used for pathway analysis using MetaCore™ (Thomas 
Reuters, New York, USA). 
 
3.12.3 Data Analysis 
MetaCore (Thomas Reuters) is a web-based suite for the functional analysis 
of experimental data. It is based on a manually curated database of canonical 
pathways, signaling pathways, metabolite pathways, molecular interactions such as 
protein-protein and protein-DNA interactions, and knowledge-based ontologies of 
genes and cellular processes. To identify the network of signaling pathways most 
enriched in the transcriptome profile, the “Analyse network (transcription factor) 
algorithm function” by MetaCore  (Thomas Reuters) was used. First, two separate 
lists of transcription factors and receptors were created from the input transcript list. 
Based on these two lists, the algorithm created a network unique to each transcription 
factor by connecting it to its relevant receptor via the shortest pathway. All networks 
with the same receptors were grouped and merged into the one network. For the 
identification of key regulators modulating the majority of differentially expressed 
genes, the “Transcription regulation function” was used. Sub-networks were 
generated centred on key regulators with direct target genes from the list of 
differentially expressed transcripts previously obtained from probe array data.  
For the identification of significant biological processes, “Functional 
annotation clustering function” from The Database for Annotation, Visualization and 
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Integrated Discovery (DAVID) version 6.7 [102] was used. DAVID is a web-based 
program that consists of a comprehensive set of functional annotation tools for 
classification of large gene list [102]. Each gene in the list was first annotated with a 
Gene Ontology (GO) process and grouped together in annotation clusters based on 
GO process with similar biological meaning as they share similar enriched gene 
function. The clusters of annotated biological processes were ranked based on the 
enrichment score, which is the geometric mean of all the P-values of each gene in the 
cluster. Higher enrichment scores indicate greater significance of the biological 
process. The P-values were calculated based on one-tail Fisher Exact method. 
3.13 Intracellular Metabolite Analysis 
3.13.1 Intracellular Metabolites Extraction 
1 x 107 cells were collected on Day 3 to Day 5 of p2.Blank CHO-mAb clone 8 
and p2.27 CHO-mAb clone 12 triplicates fed-batch bioreactor cultures, similar to 
samples for transcriptome analysis. The cells were quenched immediately after 
collection in five volumes of ice-cold 150 mM sodium chloride solution (Sigma-
Aldrich) and centrifuged at 1,123 g (3,500 rpm) for 3 min at 4oC. All liquids were 
aspirated and 400 μl  of ice-cold Methanol (Merck, USA) was added to the cell pellet.  
The cell pellet was resuspended by pipeting 20 times and transferred to a 2 ml 
microcentrifuge tube. 200 μl of ice-cold chloroform (J.T. Baker, USA) was added to 
the mixture, followed by 900 μl of ice-cold methanol and 3.8 mM tricine solution 
(Sigma-Aldrich) in 9:10 ratio  and 500 μl of ice-cold chloroform. The cell mixture 
was vortexed for 20 s after the addition of each solvent. The mixture was kept on ice 
for 3 min before centrifugation at 15,587 g (13,000 rpm) for 20 min at 4oC. 800 μl of 
the aqueous phase was collected in a new microcentrifuge tube. A second extraction 
was performed, where 700 μl of ice-cold methanol and 3.8 mM tricine solution 
(Sigma-Aldrich) in 9:10 ratio were added to the chloroform fraction and vortexed for 
20 s. The mixture was centrifuged at 15,587 g (13,000 rpm) for 10 min at  4oC. 1 ml 
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of the aqueous phase was combined with the first extract and kept at -80oC until 
measurement. Prior to measurement, the extracts were dried and concentrated four 
times by adding the appropriate volume of sample buffer (20% methanol in water). 
 
3.13.2 Detection of Intracellular Metabolites  
The extracts were analyzed in triplicates using an ultra performance liquid 
chromatography (UPLC) system (Acquity; Waters Corp., Milford, MA) coupled to a 
mass spectrometer (MS; LTQ-Orbitrap; Thermo Scientific, Bremen, Germany) as 
described in [103]. Briefly, a reversed phase (C18) UPLC column with polar end-
capping (Acquity UPLC HSS T3 column, 2.1_100 mm, 1.7 mm; Waters Corp.) was 
used with two solvents: ‘‘A’’ being water with 0.1% formic acid (Merck), and ‘‘B’’ 
being methanol (Optima grade, Fisher Scientific, Pittsburgh, PA) with 0.1% formic 
acid. The following UPLC program was used: the column was first equilibrated for 
0.5 min at 0.1% B. The gradient was then increased from 0.1% B to 50% B over 8 
min before being held at 98% B for 3 min. The column was washed for a further 3 
min with 98% acetonitrile (Optima grade, Fisher Scientific) with 0.1% formic acid 
and finally equilibrated with 0.1% B for 1.5 min. The solvent flow rate was set at 400 
l/min and a column temperature of 30oC was used. The eluent from the UPLC 
system was directed into the MS. Electrospray ionization (ESI) was conducted in both 
positive and negative modes in full scan with a mass range of 80 to 1,000 m/z at a 
resolution of 15,000. Sheath and auxiliary gas flow were set at 40.0 and 15.0 
(arbitrary units) respectively, with a capillary temperature of 400oC. The ESI source 
and capillary voltages were 4.5 kV and 40 V, respectively, for positive mode 
ionization, and 3.2 kV and- 15 V, respectively, for negative mode ionization. Mass 
calibration was performed using standard LTQ-Orbitrap calibration solution (Thermo 






3.13.3 Pre-processing of UPLC-MS Data 
The raw UPLC-MS data obtained was pre-processed and analyzed using an in-
house BTI software which incorporated the XCMS peak finding algorithm [104]. 
Detected mass peaks were assigned putative metabolite identities by matching the 
respective masses (< 10 ppm error) with the KEGG and Human Metabolome 
Database (HMDB). Where possible, the metabolite identities were confirmed by MS2 
spectral comparison with commercially available metabolite standards (all standards 
purchased from Sigma-Aldrich unless otherwise stated). The intensities of the 
detected mass peaks were then normalized using a pooled sample comprising equal 
aliquots of all samples in the batch run as the quality control (QC) sample. The QC 
sample was analysed at regular intervals during the batch UPLC-MS run.  
A two-tailed Student’s T-Test was performed for p2.27 CHO-mAb clone 12 
samples in comparison to p2.Blank CHO-mAb clone 8 samples ( Day 3 p2.27 vs Day 
3 p2.Blank; Day 4 p2.27 vs Day 4 p2.Blank; Day 5 p2.27 vs Day 5 p2.Blank) and 
metabolites with mass peak intensities having P-values of less than 0.05 were 
shortlisted. Metabolites with fold change more than or less than 1.5 (p2.27 CHO-mAb 
Clone 2 vs p2.Blank CHO mAb clone 8) were shortlisted and used for pathway 
analysis using MetaCore™ (Thomas Reuters). 
 
3.13.4 Data Analysis 
Pathway analysis of the differential regulated metabolites was carried out to 
identify the network of metabolic pathways most affected in p2.27 CHO-mAb clone 
12 versus p2.Blank CHO-mAb clone 8. The “Analyse network algorithm function” by 
MetaCore™ (Thomas Reuters) was applied to generate networks of metabolic 






3.14 N-glcosylstaion Analyses of Purified Recombinant Anti-Rhesus D mAb 
Recombinant anti-Rhesus D mAb produced by p2.Blank CHO-mAb clone 8 
and p2.27 CHO-mAb clone 12 in the triplicates fed-batch bioreactor cultues at culture 
viabilities of  between 80 to 90%. Samples were purified using a Tricorn 5/150 
Protein A column packed with MabSelect SuRe (GE Healthcare) with 1X PBS 
(Merck) as loading buffer, 0.1 M glycine (Merck ) at pH 2.7 as elution buffer and 1 
M sodium bicarbonate (Merck) at pH 8 as a neutralization buffer after sample elution.    
The N-linked glycan distribution of the purified recombinant mAb was then 
analyzed in triplicates using matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS) and categorized as described previously [105]. 
Briefly, 200 g of purified recombinant mAb was digested using 8 g of sequencing 
grade modified trypsin (Promega, USA) in a 50 mM ammonium bicarbonate buffer 
(Merck) at pH 8.2, for 4 h at 37oC. The digestion was stopped by heating at 95oC for 
15 min followed by overnight deglycoslyation using 70 U of PNGase F (Prozyme, 
USA) at 37oC. The released N-glycan were then purified using Hypersep Hyercarb 
cartridges (Thermo Scientific), permethylated and cleaned up using Sep-Pack C18 
cartridge (Waters Corp.) The N-glycans containing samples were reconstituted in 
sample buffer (80% methanol in water) and spotted on a target plate in a 1:1 ratio 
with 2,5 dihydroxybenzoic acid matrix (Waters Corp.) dissolved in sample buffer. 
5800 MALDI-TOF/TOF MS (AB Sciex, USA) operating in a positive reflectron 
mode with laser intensity of 50% was used to acquire the data. 4700 calibration 
standard kit, Calmix (AB Sciex) was used as the external calibrant for the MS mode.  
The distribution of N-glycans was divided into sialylated N-glycans with at 
least one sialic acid residue in terminal position, fucosylated complex N-glycans, 
high-mannose-type, G0 with no terminal galactose residue, G1 with one terminal 
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galactose residue and G2 with two galactose residue. A two-tailed Student’s T-Test 
significance statistical test of P-Value less than 0.05 for the difference in N-glycan 































Cgri-HSP27 transcript expression level was found to be down regulated during 
the late exponential-stationary growth phase of CHO fed-batch bioreactor cultures in 
an in-house transcriptome profiling study (Figure 2.1). Together with the reported 
anti-apoptosis functions of HSP27 in human and mouse cell lines, it led to the 
hypothesis that overexpression of cgri-HSP27 can improve recombinant protein 
production by extending the culture duration of CHO fed-batch bioreactor cultures. It 
was thus demonstrated in an earlier study that cgri-HSP27 overexpression in CHO 
cells extended culture duration and improved the production of recombinant human 
IFNɣ in fed-batch bioreactors [37]. Due to the increasing importance and demands of 
therapeutic mAbs in both innovator and biosimilar forms, it would be of great interest 
to investigate whether the advantages of the cgri-HSP27 overexpression strategy can 
be extended to a CHO production cell line producing recombinant mAb, cultured in 
fed-batch bioreactors.  
Cgri-HSP27 protein expression level of a CHO DG44 cell line producing a 
recombinant IgG mAb against Rhesus D antigen [100] (CHO-mAb) cultured in fed-
batch bioreactor, at mid-exponential, late-exponential and stationary growth phases, 
was first profiled. Subsequently, the cell line was transfected with the cgri-HSP27 
overexpressing vector and stable cell pools were obtained after 2 weeks of selection 
in batch shake flasks. After obtaining the stable transfected cell pools, it will be 
necessary to select for stable transfected single cell clones to perform evaluations in 
fed-batch bioreactors since heterogeneous cell pools may cause large variability in the 
fed-batch evaluation. For this purpose, single cell clones from the stably transfected 
cell pools were obtained using limiting dilution, expanded and cultured in batch shake 
flasks for selection. The work flow was as illustrated in Figure 4.1.  
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Prior to the evaluation of cgri-HSP27 overexpression in CHO-mAb fed-batch 
bioreactor cultures, the workflow involved culturing of stably transfected cell pools 
and single cell clones in shake flasks under batch conditions. As cgri-HSP27 
overexpression has not been shown to improve batch shake flask cultures before, 
hence the growth and mAb production characteristics of stably transfected cell pools 
cultured in batch shake flasks were conducted. Notably, nutrients limitation and 
uncontrolled culture environment in the batch shake flask culture may result in cell 
death by a different mechanism from fed-batch bioreactor cultures [33]. Additionally, 
stable transfected cell pools are frequently employed for the rapid production of 
sufficient recombinant proteins as pre-clinical materials used in drug candidate 
screening as well as later stages of pharmacology, formulation and stability studies 
[106-109]. Batch shake flask culture systems are often preferred for convenience and 
process simplicity [106-109]. To avoid the complications of clonal variability, stable 
transfected cell pools were used for the assessment under batch shake flask systems.  
The effects of cgri-HSP27 overexpression CHO-mAb cells cultured in batch 






Figure 4.1 Workflow summary for generation of cgri-HSP27 overexpression CHO cells 
producing recombinant mAb. 
 
Results and Discussion 
4.1 Evaluation of Stably Transfected CHO-mAb Cell Pools in Batch Shake 
Flasks  
Cgri-HSP27 protein expression profile of CHO-mAb fed-batch bioreactor 
cultures showed gradual reduction from mid-exponential growth phase towards late-
exponential and stationary growth phases (Figure 4.2). This corroborated with the 
Cgri-HSP27 transcriptome profile carried out previously and allowed for subsequent 
Cgri-HSP27 overexpression to be carried out. To investigate whether cgri-HSP27 
overexpression is also able to improve batch shake flask culture, stable transfected 
CHO-mAb cell pools were evaluated to avoid the complications of clonal effects: 
CHO-mAb 2.11 subclone M250-9 cells were transfected either with control null 
vector pIRES2 or cgri-HSP27 overexpressing vector pIRES2-27, for the generation 
of p2.Blank CHO-mAb cells and p2.27 CHO-mAb cells respectively. Stable 
transfected p2.Blank and p2.27 CHO-mAb cell pools were obtained after 14 days of 
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selection in hygromycin-supplemented culture media. Both pools of stable 
transfectants cultures were expanded for another 18 days and batch shake flask 
growth study were performed. The cells were cultured in shake flasks with a seeding 
viable cell density of 3 x 105 cells/ml in a starting culture volume of 60 ml for the 
evaluation study. 
 
Figure 4.2 cgri-HSP27 protein expression in CHO-mAb fed-batch bioreactor cultures 
Cgri-HSP27 protein expression during mid-exponential, late exponential and stationary 
growth phase in CHO-mAb fed-batch bioreactor cultures was analyzed using western blot. 




4.1.1 Growth Characteristics 
For the comparison of growth profiles, that of untransfected CHO-mAb cells 
was included as a reference, although the untransfected cells were maintained in 
culture without hygromycin antibiotic selection while the stable transfected cells were 
cultured in the presence of hygromycin. Figure 4.3 shows the growth profiles of the 
untransfected CHO-mAb cells and the two stably transfected CHO-mAb cell pools in 
batch shake flasks. Growth profile of p2.Blank CHO-mAb cell pool was similar to 
that of the untransfected CHO-mAb cells (Figure 4.3), indicating that the transfection 
process and selection pressure was not detrimental to cell growth.  
The p2.27 CHO-mAb cell pool reached a maximum viable cell density of 9.1 x 
106 cells/ml (Figure 4.3), 110% and 76% higher compared to untransfected CHO-
mAb and p2.Blank CHO-mAb cell pool respectively. The p2.27 CHO-mAb cell pool 
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also sustained for an additional day at culture viability above 80% (Figure 4.3). These 
improvements in growth and delay loss of culture viability led to a maximum 
cumulative IVCD of 9.7 x 108 cells.h/ml, 84% and 70% higher than that of 
untransfected CHO-mAb and p2.Blank CHO-mAb cell pool respectively. This is 
similar to observation in the previously engineered cgri-HSP27 CHO-IFNɣ cell pools 
cultivated in a different basal media: 48% and 26% higher compared to the 
untransfected CHO-IFN-ɣ and control null vector transfected CHO-IFNɣ cell pool 
respectively (Appendix 1). 
It is postulated that the inhibition of apoptosis by cgri-HSP27 may be a likely 
mechanism for the observed improvement in culture performance of p2.27 CHO-
mAb cells: while the p2.Blank CHO-mAb cell pool entered death phase due to 
culture stress after Day 5, cgri-HSP27 may have prevented the same from happening 
to the p2.27 CHO-mAb cell pool to allow the further proliferation of these cells. This 
experiment together with previous experiment thus demonstrated that cgri-HSP27 
overexpression can improve growth and prolong culture duration of cgri-HSP27 










Figure 4.3 Growth profiles of untransfected and stable transfected CHO-mAb cell pools 
in batch shake flasks                                                                                                                                                               
CHO-mAb cells were transfected either with pIRES2 vector to generate p2.Blank CHO-mAb 
cell pool or pIRES2.27 to generate p2.27 CHO-mAb cell pool and characterized in batch 
shake flasks. (A) Viable cell density, (B) culture viability and (C) cumulative IVCD were 
monitored and calculated daily (n=1; error bars denote standard deviation of duplicate 
technical replicates from a single culture). 
 
4.1.2 Recombinant mAb Production Characteristics 
When examining the recombinant mAb production characteristics, stably 
transfected p2.Blank CHO-mAb cell pool yielded a maximum recombinant mAb titer 
of 250 mg/L, 30% lower compared to untransfected CHO-mAb culture as shown in 
Figure 4.4. As their growth profiles were similar (Figure 4.3), leading to similar 
maximum cumulative IVCD of 5.5 ± 0.3 x 108 cells.h/ml, the reduced recombinant 
mAb titer in p2.Blank CHO-mAb cell pool culture was due to a lowered average 
specific productivity of 10 pg/cell.day compared to 16 pg/cell.day for the 
untransfected CHO-mAb cells. While it is likely that the lower specific productivity 
may be due to the presence of hygromycin antibiotics in the transfected cell pool, 
another possibility may be chromosomal rearrangements post-transfection in  the 
stably transfected cell pools, since CHO cells are prone to spontaneous mutations 
when stressed under selection pressure [110-112]. 
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The recombinant mAb titer of stably transfected p2.27 CHO-mAb pool was 
338 mg/L, 38% higher than the titer obtained from the stably transfected p2.Blank 
CHO-mAb pool and similar to that of the untransfected CHO-mAb. Since the p2.27 
CHO-mAb pool had a 70% higher maximum IVCD than the p2.Blank and 
untransfected cell pools (Figure 4.3), the average specific productivity of the p2.27 
CHO-mAb pool was 8 pg/cells-day, 20% and 50% lower than that of the p2.Blank 
CHO-mAb and untransfected CHO-mAb cell pools. 
In addition to the presence of hygromycin antibiotics and possible 
chromosomal rearrangements post-transfection, the p2.27 CHO-mAb cell pools were 
also overexpressing cgri-HSP27, an extra metabolic load which may contribute to the 
lower specific productivity of the cells [110-112]. The p2.27 CHO-mAb cells may 
also have allocated more resources to cell growth, compromising specific protein 
productivity since nutrients are limiting in the batch cultures. The conclusion is 
therefore that although cgri-HSP27 overexpression can improve cell growth and 
delay loss of culture viability of batch shake flask cultures, it is not an effective 
strategy for improving recombinant mAb titer of stably transfected cell pools batch 
shake flask cultures.  
However, it should be noted that HSP27 transcript and protein expression 
levels were initially observed to be down-regulated and reduced towards the end of 
CHO fed-batch bioreactor cultures, leading to the hypothesis that HSP27 
overexpression can improve CHO fed-batch bioreactor cultures. Subsequent 
overexpression of HSP27 in CHO cells producing recombinant interferon-gamma 
showed improvement in fed-batch bioreactors. Therefore, one of the end goals and 
aims of this thesis was to evaluate the effects of cgri-HSP27 overexpression in 





Figure 4.4 Recombinant mAb titer and productivity from untransfected and stable 
transfected CHO-mAb cell pools batch shake flask cultures                                                                                              
CHO-mAb cells were stably transfected either with pIRES2 vector to generate p2.Blank 
CHO-mAb cell pool or pIRES2.27 to generate p2.27 CHO-mAb cell pool and characterized in 
batch shake flasks. Concentrations of recombinant mAb were monitored daily. Presented in 
this figure is one time-point concentration of recombinant mAb at harvest (n=1; error bars 
denote standard deviation of duplicate technical replicates from a single culture). 
 
4.1.3 cgri-HSP27 Gene and Protein Expression Level 
To verify that cgri-HSP27 was overexpressed in stably transfected p2.27 CHO-
mAb cell pool, qRT-PCR and western blot analyses were performed during early 
exponential growth phase of both the stably transfected cell pools. As seen in Table 
4.1, stable transfected p2.27 CHO-mAb cell pool showed overexpression of total 
cgri-HSP27 mRNA and transfected pIRES2-27 vector when compared to stably 
transfected p2.Blank CHO-mAb cell pool, normalized to untransfected CHO-mAb 
cells. Furthermore, a thicker protein band of approximately 27 kDa, corresponding to 
cgri-HSP27 protein, was observed for stably transfected p2.27 CHO-mAb cell pool as 
compared to stably transfected p2.Blank CHO-mAb cell pool (Figure 4.5), 





Table 4.1 cgri-HSP27 gene expression in stably transfected CHO-man cell pools  
CHO-mAb cells were stably transfected with either pIRES2 vector to generate p2.Blank 
CHO-mAb cell pool or pIRES2.27 vector to generate p2.27 CHO-mAb cell pool. cgri-HSP27 
gene expression during early exponential growth phase in batch shake flask cultures was 
analyzed using qRT-PCR with specific primers for cgri-HSP27 and pIRES2.27 vectors, and 





Figure 4.5 cgri-HSP27 protein expression in stably transfected CHO-man cell pools  
CHO-mAb cells were stably transfected with either pIRES2 vector to generate p2.Blank 
CHO-mAb cell pool or pIRES2.27 vector to generate p2.27 CHO-mAb cell pool. Cgri-
HSP27 protein expression during early exponential growth phase in batch shake flask cultures 
was analyzed using western blot. The same blot was also probed for cgri--actin to 
demonstrate equal protein loading for all samples (n=1). 
 
Figure 4.6 shows the cgri-HSP27 protein expression level at the start and the 
late exponential-stationary growth phases of p2.Blank and p2.27 CHO-mAb cell 
pools batch shake flask growth study. cgri-HSP27 protein expression level decreased 
on Day 6 of p2.Blank CHO-mAb cell pool culture, whereas in p2.27 CHO-mAb cell 
pool culture, cgri-HSP27 protein expression level remained high even up to Day 8. 
This demonstrates that constitutive high expression of cgri-HSP27 can improve cell 





Figure 4.6 Cgri-HSP27 protein expression of stable transfect CHO-mAb cell pools batch 
shake flask cultures CHO-mAb cells were stably transfected either with pIRES2 vector to 
generate p2.Blank CHO-mAb cell pool or pIRES2.27 to generate p2.27 CHO-mAb cell pool 
and characterized in batch shake flasks. Cgri-HSP27 protein expression was analyzed at the 
start of the culture and at the late exponential-stationary growth phase using western blot. The 
same blot was also probed for cgri--actin to demonstrate equal protein loading for all 
samples (n=1). 
 
4.1.4 Extracellular Biochemical Concentrations 
Glucose and glutamine are two essential key nutrients that support the growth 
of CHO cells. Depletion of these nutrients can lead to decline cell growth and onset 
of apoptosis. Looking at the extracellular concentrations of these nutrients in Figure 
4.7, glutamine was depleted on Day 6 for p2.Blank and p2.27 CHO mAb pools, while 
glucose was not depleted even on Day 9 for all cultures. Glutamine was not depleted 
in the untransfected CHO-mAb cells, suggesting that its glutamine consumption rate 
is lower than that of the transfected cell pools. Its glucose consumption profile was 
also different from the p2.Blank CHO-mAb cell pool despite the similar growth 
profiles. These suggest that the untransfected CHO-mAb cells were behaving in a 
metabolically different manner when compared to the transfected CHO-mAb cell 
pools, corroborating with the previous postulations that the antibiotic selection 
pressure and possible post-transfection chromosomal rearrangement had affected the 






Figure 4.7 Extracellular biochemical concentrations of untransfected and stable 
transfected CHO-mAb cell pools shake flask batch cultures                                            
CHO-mAb cells were stably transfected either with pIRES2 vector to generate p2.Blank 
CHO-mAb cell pools or pIRES2.27 to generate p2.27 CHO-mAb cell pools and characterized 
in shake flask batch cultures. Concentrations of extracellular (A) glucose, (B) glutamine, (C) 
lactate, (D) ammonium and (E) glutamate were monitored daily (n=1; error bars denote 
standard deviation of duplicate technical replicates from a single culture).  
 
Comparing the glutamine and growth profiles, glutamine depletion corroborate 
with the decrease in viable cell density of both untransfected CHO-mAb cells and 
p2.Blank CHO-mAb cell pool after Day 5 (Figure 4.3). On the other hand, viable cell 
density of p2.27 CHO-mAb cell pool continued to increase till Day 8 despite 
glutamine depletion. Looking at the extracellular glutamate profiles (Figure 4.7), 
consumption of glutamate was observed in p.27 CHO-mAb cells pool on Day 4 till 
Day 7. The dropped in viable cell density and culture viability was observed one day 
after (Figure 4.3). This suggests that p2.27 CHO-mAb cell pool may be utilizing 
glutamate to compensate for the depleted glutamine: intracellular glutamate 
dehydrogenase converts glutamate to α-ketoglutarate as part of the intracellular 
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glutaminolysis-TCA pathway and intracellular glutamine synthetase converts 
glutamate to glutamine as part of the intracellular glutaminolysis cycle (Figure 4.8). 
This may have supplied the cells with extra energy source and amino acids for the 
sustained cell proliferation observed in p2.27 CHO-mAb cell pool. Notably, 
consumption of glutamate was not observed in both untransfected CHO-mAb and 
p2.Blank CHO-mAb cell pool (Figure 4.7), suggesting that cgri-HSP27 may have 
modulated the intracellular glutaminolysis cycle. 
Figure 4.8 Simplified glutaminolysis pathway and TCA cycle in animal cells.                   
(Adapted from Stumvoll, M., Perriello, G., Meyer, C., Gerich, J., Role of glutamine in human 
carbohydrate metabolism in kidney and other tissues. Kidney Int.1999, 55, 778-792).  
 
Cellular metabolism of glucose and glutamine generates lactate and 
ammonium, known to inhibit cell growth at minimum inhibitory levels of 20 mM and 
2-5 mM respectively [113]. Extracellular concentrations of lactate in all cultures 
(Figure 4.7) did not reach the minimum growth inhibitory concentration of 20 mM. 
Lactate accumulated to the highest concentration of 0.7 mM in the untransfected 
CHO-mAb culture on Day 6 while p2.Blank and p2.27 CHO-mAb cell pool cultures 
had maximal lactate concentration of 0.4 mM on Day 6 followed by a decrease in 
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concentrations from Day 7. As with the extracellular ammonium concentration, it did 
not reach the minimum growth inhibitory concentration of 2mM in all cultures. 
Untransfected CHO-mAb culture had the highest accumulated concentration of 
ammonium at 0.5 mM at harvest, whereas p2.Blank and p2.27 CHO-mAb cell pools 
had similar profile; maximal accumulated concentration of 0.3 mM on Day 6. The 
concentration profiles of both lactate and ammonium suggest that accumulation of 
both toxic metabolites may not be the cause of growth inhibition and cell death in the 
shake flask batch cultures. Similar to glucose, glutamine and glutamate profiles, the 
lactate and ammonia profiles of the untransfected CHO-man cells were notably 
different from those of the transfected CHO-man cell pools, suggesting that the 
transfected cell pools were inherently different from the untransfected cells, as 
previously postulated.  
 
4.2 Selection of p2.27 CHO-mAb Single Cell Clones in Batch Shake Flasks for 
Fed-batch Bioreactor 
Stable transfected cell pools are generally heterogeneous populations due to 
random gene integration and varying gene copy numbers [112, 114-117]. Clones 
derived from such populations may vary widely in expression of the engineered gene, 
cgri-HSP27 in this case, causing variations in growth and recombinant protein 
production characteristics. Furthermore, regulatory authorities require approved 
production cell lines intended for utilization in the manufacturing of biologics to 
derive from a single cell clone [118-120], to prevent inconsistencies to the 
manufacturing process and final end product quality. The objective of this section 
was to select single cell clones based on cgri-HSP27 protein expression level along 
with the growth and culture viability for further evaluation in fed-batch bioreactor 
cultures, where the differential cgri-HSP27 expression level was first detected and 
successive extension of the culture duration and recombinant human IFNɣ yield were 
observed [36].   
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Stably transfected p2.Blank and p2.27 CHO-mAb cell pools were single cell 
cloned using limiting dilution in a 96-well suspension culture plate. 15 p2.Blank 
CHO-mAb clones and 23 p2.27 CHO-mAb clones survived the single cell cloning 
process and were expanded from a single cell in the 96-well plate to shake flasks in 
84 days. The clones were banked and seeded in shake flask with a viable cell density 
of 3 x 105 cells/ml and a culture volume of 30 ml for the single culture time-point 
analysis concurrently. The single culture time-point analysis was carried out as a 
quick screening for selecting single cell clones to be cultured in fed-batch bioreactors. 
Cells were harvested on Day 6 of culture and their viable cell density and culture 
viability determined (Figure 4.9). Day 6 of culture was selected as the difference in 
HSP27 protein expression between the two stably transfected pools was previously 
noticed on Day 6 of the shake flask batch culture (Figure 4.3). The difference in 
viable cell density and culture viability was also evident on Day 6. Additionally, 
culture time-points beyond Day 6 was not considered because at low culture 
viabilities, cellular proteins may get degraded and this may affect the visual 
quantification of HSP27 on the western blots. To compare the cgri-HSP27 protein 
expression between the clones, all p2.27 CHO-mAb clones and p2.Blank CHO-mAb 
clone 1, 6, 8, 13 and 15 that had the average and highest viable cell density amongst 
the p2.Blank clones were selected for western blotting (Figure 4.10).  
Selected p2.Blank CHO-mAb clones showed similar cgri-HSP27 protein 
expression level when compared to each other, as evidenced by the similar thickness 
of the ~27 kDa protein bands in Figure 4.10. Hence, cgri-HSP27 protein expression 
level of all the p2.27 CHO-mAb clones were next detected and compared against 
those from p2.Blank CHO-mAb clone 8 (representative of the average viable cell 
density) and clone 15 (representative of the highest viable cell density). Cgri-HSP27 
protein expression level varied among the p2.27 CHO-mAb clones. Out of the 23 
clones, eight of the clones displayed thicker protein bands of ~27 kDa (Figure 4.10) 
when compared to the cgri-HSP27 protein bands from p2.Blank CHO-mAb clones 8 
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and 15. This variation demonstrated the heterogeneous clonal population and 
variability among the clones, since intra-clonal variability has been reported to 
deviate between 50-70% among clones [112, 114-117].  Interestingly, these eight 
p2.27 CHO-mAb clones had viable cell densities representative of the average viable 
cell density amongst the p2.27 CHO-mAb single cell clones (Figure 4.9) and they 
were higher than that of p2.Blank CHO-mAb clone 8 (average growth). However, 
when compared to p2.Blank CHO-mAb clones 15 (highest growth), seven of the 
p2.27 CHO-mAb clones had lower viable cell densities except for p2.27 CHO-mAb 
clone 8. This indicates that the effect of cgri-HSP27 varies from clone to clone in 
shake flask batch culture.  
 
 
Figure 4.9 Growth profiles of p2.Blank and p2.27 single cell clones in single time point 
analysis                                    
Surviving p2.Blank and p2.27 CHO-mAb single cell clones were cultured in batch shake 
flasks. Viable cell density (represented by white and black bars) and culture viability 
(represented by open triangles and closed circles) were monitored on Day 6 of culture (n=1; 
error bars denote standard deviation of duplicate technical replicates from a single culture). 
Blue arrows indicate selected p2.Blank CHO-mAb clones for western blotting. Grey arrows 
indicate p2.27 CHO-mAb clones with high cgri-HSP27 protein expression. Open grey arrow 
indicates p2.27 CHO-mAb clone with highest viable cell density. 
 
As single culture time-point analysis, used as a quick screening process, may 
be subjected to variations cause by small viable cell seeding density differences and 
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recombinant mAb titer was not previously evaluated, daily growth and mAb 
production profile of the p2.27 CHO-mAb clones with HSP27 overexpression, p2.27 
CHO-mAb clone 12 with the highest viable cell density, as well as the three selected 
p2.Blank CHO-mAb clones (8, 13 and 15) were determined. The selected clones were 
first thawed and harvested during exponential phase (Day 3) in the eighth passage to 
verify gene expression of transfected pIRES2-27 by RT-PCR. All nine p2.27 CHO-
mAb clones, but not the p2.Blank CHO-mAb clones showed expression of the 
pIRES2-27 vector (Figure 4.11), demonstrating that they still contained the 
transfected pIRES2-27 vector. The clones were then seeded in shake flask batch 
culture with a seeding viable cell density of 3 x 105 cells/ml and a starting culture 
volume of 130 ml. Viable cell density, culture viability and recombinant mAb titer 
were monitored daily.  
 
 
Figure 4.10 Cgri-HSP27 protein expression of p2.Blank and p2.27 CHO-mAb single cell 
clones in single time point analysis     
Surviving p2.Blank and p2.27 CHO-mAb single cell clones were cultured in batch shake 
flasks. (A) Cgri-HSP27 protein expression of selected p2.Blank CHO-mAb clones were 
analyzed on Day 6 using western blot. (B) Cgri-HSP27 protein expression of p2.27 CHO-
mAb clones were analyzed and compared against selected p2.Blank CHO-mAb clones. The 
same blots were also probed for cgri--actin to demonstrate equal protein loading for all 






Figure 4.11 pIRES2-27 vector gene expression in selected p2.Blank and p2.27 CHO-mAb 
single cell clones in shake flask batch cultures                                                            
Selected p2.Blank and p2.27 CHO-mAb single cell clones were cultured in shake flask batch 
cultures. pIRES2.27 vector gene expression was verified using RT-PCR on Day 3 of culture 
(n=1). 
 
Growth and recombinant mAb production characteristics of the clones in shake 
flask batch cultures were summarized in Table 4.2. Comparing across the clones, 
p2.27 CHO-mAb clones achieved a maximum viable cell density of 1.1 ± 0.2 x 107 
cells/ml, 13% higher compared to the p2.Blank CHO-mAb clones. However, no 
extension in culture duration was observed in the p2.27 CHO-mAb clones and this 
resulted in a slight improvement of 11% in maximum cumulative IVCD compared to 
p2.Blank CHO-mAb clones. This smaller improvement led to a similar average 
recombinant mAb titer of 378 ± 41 mg/L by p2.27 CHO-mAb clones versus 359 ± 71 
mg/L by p2.Blank CHO-mAb clones. These improvements were not significant 
(Student T-Test, P-value > 0.05).  
The similar mAb titer was likely to the non-improvement in specific 
productivity of the cells. Hence it is a phenomenon observed in both cell pools and 
clones batch shake flask cultures and it could be due to the different stress and culture 
conditions. Fed-batch bioreactor systems are different from batch shake flask systems 
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in terms of culture environment control, nutrients availability and depletion, and 
stress experienced by the cells [33].   
Hence, further evaluation in fed-batch bioreactor culture systems needed to 
be carried out. Additionally, preliminary observation of cgri-HSP27 differential 
transcript expression level, cgri-HSP27 protein reduction and the successive 
extension of the culture duration and recombinant human IFNɣ yield observed [36] 
gave indications on the effect of HSP27 overexpression in CHO-mAb fed-batch 
bioreactor cultures.  
Table 4.2 Growth and recombinant mAb production characteristics of selected p2.Blank 
and p2.27 CHO-mAb single cell clones in shake flask batch cultures 
Selected p2.Blank and p2.27 CHO-mAb single cell clones were cultured in shake flask batch 
cultures. Viable cell density, culture viability and recombinant mAb titer were monitored daily 
(n=1). Clones selected for evaluation in fed-batch bioreactor indicated by an asterisk. 
 
 
Six clones were chosen from the shake flask batch culture for further 
evaluation in fed-batch bioreactors. All three p2.Blank CHO-mAb clones (8, 13 and 
15) were selected for comparisons as control clones in the fed-batch bioreactor 
evaluation. As the shake flask batch cultures showed that the maximum recombinant 
mAb titers of the p2.27 CHO-mAb clones were comparable within ± 41 mg/L of each 
other (Table 4.2), p2.27 CHO-mAb clones 5, 7 and 12 that slightly outperformed the 
others were selected. Notably, p2.Blank CHO-mAb clone 13 had maximum 
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cumulative IVCD and maximum recombinant mAb titer similar to the three selected 
p2.27 CHO-mAb clones (Table 4.2). 
 
Conclusions 
We have successfully engineered stable cgri-HSP27 engineered CHO-mAb 
single cell clones for fed-batch bioreactor culture evaluation which will be discussed 
in Chapter 5.  
As shake flask batch culture growth and recombinant mAb production data 
were obtained during the development process, we evaluated whether cgri-HSP27 
overexpression is also able to improve shake flaks batch cultures. The cgri-HSP27 
engineered CHO-mAb cell pool had lower specific productivity of 8 pg/cell.day but 
higher maximum viable cell density of 9.1 x 106 cells/ml and delayed loss of culture 
viability by one day as compared to untransfected CHO-mAb and p2.Blank CHO-
mAb cell pools. 
15 p2.Blank CHO-mAb clones and 23 p2.27 CHO-mAb clones next 
evaluated in single culture time-point (Day 6) analysis. Eight of the p2.27 CHO-mAb 
clones had higher HSP27 protein expression compared to the p2.Blank CHO-mAb 
clones and 45% higher viable cell density than the p2.Blank CHO-mAb clones on 
average. However, when a smaller subset of nine p2.27 CHO-mAb clones were 
selected for a second evaluation in shake flask batch culture, the maximum viable cell 
density, specific productivity and recombinant mAb titer were not significantly 
different. These observations suggest that cgri-HSP27 overexpression did not 











Fed-batch bioreactor system is one of the most commonly employed cell 
culture mode for the manufacturing of biologic drugs from CHO cells as it can 
support high cell density cultures, that are crucial for achieving high recombinant 
protein titers, by having optimal controlled culture conditions such as temperature, 
stirring speed, pH and dissolved oxygen. Premature cell death due to nutrient 
limitation is eliminated as intermittent feeding of nutrients is implemented in fed-
batch bioreactor system. Evaluation in scaled-down fed-batch bioreactor systems can 
also be used to predict cell line behavior in large scale manufacturing operating in 
similar culturing system. As the cgri-HSP27 transcript expression level was found to 
be down regulated during the late exponential-stationary growth phase of CHO fed-
batch bioreactor cultures (Figure 2.1) and subsequent cgri-HSP27 overexpression 
extended culture duration and improved the production of recombinant human IFNɣ 
in fed-batch bioreactor systems [36], the application of the cgri-HSP27 
overexpression strategy to a recombinant mAb-producing cell derived from CHO 
DG44 host cell line in fed-batch bioreactor cultures was evaluated. Since 
heterogeneous cell pools may cause large variations in the fed-batch evaluation, it 
will be necessary to select for stable transfected single cell clones to perform the fed-
batch bioreactor cultures evaluations. In the previous chapter, three p2.27 CHO-mAb 
clones (5, 7 and 12) were selected for evaluation in fed-batch bioreactor against 
p2.Blank CHO-mAb clone 8, 13 and 15. Notably, p2.Blank CHO-mAb clone 13 had 
maximum cumulative IVCD and maximum recombinant mAb titer similar to the 





This chapter will present the results of cgri-HSP27 overexpression strategy in 
improving growth and recombinant mAb titer of a CHO DG44 cell line producing a 
recombinant IgG mAb against Rhesus D antigen [100] in fed-batch bioreactors. 
Quality of the recombinant mAb produced will also be discussed in terms of 
glycosylation profile because changes in glycosylation can affect the efficacy of 
recombinant mAbs. 
 
Results and Discussion 
5.1 Evaluation of Stable Transfected p2.27 CHO-mAb Clones in Fed-batch 
Bioreactors  
The cells were inoculated into the 2 L bioreactor with a seeding viable cell 
density of 3 x 105 cells/ml in a starting culture volume of 1.5 L. Process control 
parameters and feeding strategy developed in-house for generic CHO cell lines were 
employed for all fed-batch bioreactor cultures, as described in Chapter 3 under 
section 3.4. Off-line monitoring of viable cell density, culture viability, recombinant 
mAb titers and extracellular biochemical concentrations were carried out daily. 
 
5.1.1 Growth characteristics 
Growth profiles of the fed-batch bioreactor cultures were shown in Figure 5.1 
and Table 5.1 compares the growth indicators of the transfected cell pools in batch 
shake flasks and the selected clones in fed-batch bioreactors. When compared to the 
growth characteristics of the stable transfected cell pools in batch shake flasks (Table 
5.1), all the clones managed to achieve better growth in fed-batch bioreactors: 
p2.Blank CHO-mAb clones achieved 71% improvement and p2.27 CHO-mAb clones 
achieved 113% improvement in maximum viable cell densities over their respective 
cell pools. These improvements are potentially due to the difference in culture modes: 
batch shake flasks versus fed-batch bioreactors which are known to improve 
maximum viable cell densities of CHO cell cultures. Despite achieving higher 
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maximum viable cell densities in fed-batch bioreactors for all clones, a huge 
improvement in p2.27 CHO-mAb clones fed-batch bioreactor culture performances 
over p2.Blank CHO-mAb clones fed-batch bioreactor cultures were still observed 
(Figure 5.1) and is most likely due to the overexpression of cgri-HSP27. 
Comparing the clones cultured in fed-batch bioreactors, p2.27 CHO-mAb fed-
batch bioreactor cultures achieved an average maximum viable cell density of 2.0 ± 
0.2 x 107 cells/ml, 120% higher compared to p2.Blank CHO-mAb fed-batch 
bioreactor cultures (Figure 5.1). The p2.27 CHO-mAb fed-batch bioreactor cultures 
also sustained for an additional, on average, 2 days at culture viability above 80% 
(Figure 5.1), as compared to p2.Blank CHO-mAb cultures. These improvements in 
maximum viable cell density and extended culture duration led to a 160% higher 
average maximum cumulative IVCD of 2.0 ± 0.5 x 109 cells-h/ml for p2.27 CHO-
mAb cultures compared to p2.Blank CHO-mAb cultures (Figure 5.1). Notably, 
although p2.Blank CHO-mAb clone 13 had maximum cumulative IVCD similar to 
the three p2.27 CHO-mAb clones under batch shake flask conditions, under fed-batch 
bioreactor culture conditions, p2.27 CHO-mAb clones had 165% higher max IVCD 
on average compared to p2.Blank CHO-mAb clone 13. This demonstrates that cgri-
HSP27 overexpression greatly improves maximum IVCD of CHO-mAb fed-batch 
bioreactor cultures. 
These improvements observed in p2.27 CHO-mAb fed-batch bioreactor 
cultures over p2.Blank CHO-mAb fed-batch bioreactor cultures are most likely not an 
artefact of the process controls as all bioreactor process control parameters including 
temperature, stirring speed, pH and dissolved oxygen were maintained within optimal 
range throughout the duration of the fed-batch bioreactor runs (data not shown). 
Neither is it an artefact of the feeding strategy as p2.Blank CHO-mAb fed-batch 
bioreactor cultures was not depleted of key nutrients: glucose and glutamine, from the 





Figure 5.1 Growth profiles of p2.Blank and p2.27 CHO-mAb clones fed-batch bioreactor 
cultures 
(A) Viable cell density and (B) culture viability and (C) cumulative IVCD were monitored 
and calculated daily (n=1; error bars denote standard deviation of duplicate technical 
replicates from a single culture). 
 
Table 5.1 Growth characteristics of p2.Blank and p2.27 CHO-mAb clones fed-batch 
bioreactor cultures and their respective transfected cell pools batch shake flask cultures 
 
  The constitutive high expression of cgri-HSP27 protein in p2.27 CHO-mAb 
fed-batch bioreactor cultures remained high even till the culture viabilities dropped 
below 50%, as shown in Figure 5.2. The likely mechanism for the observed growth 
improvements could be: apoptosis inhibition by cgri-HSP27 may allow p2.27 CHO-
mAb cells to continue proliferating after p2.Blank CHO-mAb cells entered death 
phase due to culture stress on Day 5 (Figure 5.1). On the other hand, cgri-HSP27 
protein expression level decreased on Day 4 of p2.Blank CHO-mAb fed-batch 
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bioreactor cultures and then increased again on Day 6. However, as the p2.Blank 
CHO-mAb cells have entered the death phase on Day 5, this increased in cgri-HSP27 
protein expression level on Day 6 could have been transiently induced by cellular 
stress in the death phase, but it did not prevent further drop in viable cell density and 
loss of cell viability (Figure 5.1). 
 
Figure 5.2 Cgri-HSP27 protein expression level of p2.Blank and p2.27 CHO-mAb clones 
fed-batch bioreactor cultures  
Cgri-HSP27 protein expression was analyzed at the start of the culture and at the late 
exponential-stationary growth phase using western blot. The same blot was also probed for 
cgri--actin to demonstrate equal protein loading for all samples (n=1).  
 
5.1.2 Recombinant mAb Production Characteristics 
To evaluate the effect of cgri-HSP27 overexpression on recombinant mAb 
productivity, mAb titer profiles were determined. Figure 5.3 shows the recombinant 
mAb titer profile in the clones fed-batch bioreactor cultures and Table 5.1 compares 
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the production characteristics of transfected cell pools in batch shake flask culture 
and clones fed-batch bioreactor cultures. Improvements in recombinant mAb titers for 
p2.Blank CHO-mAb and p2.27 CHO-mAb fed-batch bioreactor cultures were 71% 
and 239% higher compared to their respective transfected cell pools (Table 5.2). This 
correlates with the higher improvements in maximum cumulative IVCD of 35% and 
104% in the clones fed-batch bioreactor cultures as compared to their respective 
transfected cell pools batch shake flask cultures (Table 5.1). 
The p2.27 CHO-mAb fed-batch bioreactor cultures yielded an average 
maximum recombinant mAb titer of 1146 ± 451 mg/L, 160% higher compared to 
p2.Blank CHO-mAb fed-batch bioreactor cultures (Figure 5.3). Notably, p2.Blank 
CHO-mAb clone 13 had maximum recombinant mAb titer similar to the three 
selected p2.27 CHO-mAb clones (Table 4.1) in batch shake flasks. This was also 
observed in the stable transfected cell pools batch shake flask cultures study. It was 
demonstrated that overexpression of HSP27 does not improve batch shake flask 
cultures of CHO-mAb cells. However, in the fed-batch bioreactor cultures, p2.27 
CHO-mAb clones had 211% higher maximum recombinant mAb titer compared to 
p2.Blank CHO-mAb clone 13. This demonstrates that cgri-HSP27 overexpression 
greatly improves the recombinant mAb titer of CHO-mAb fed-batch bioreactor 
culture. This could be due to the different stress and culture conditions. Fed-batch 
bioreactor systems are different by batch shake flasks systems in terms of culture 
environment control, nutrients availability and depletion, and stress experienced by 






Figure 5.3 Recombinant mAb titer profile of p2.Blank and p2.27 CHO-mAb clones fed-
batch bioreactor cultures 
Recombinant mAb titers were monitored offline daily (n=1; error bars denote standard 
deviation of duplicate technical replicates from a single culture).  
 
Table 5.2 Recombinant mAb production characteristics of p2.Blank and p2.27 CHO-
mAb clones fed-batch bioreactor cultures and their respective transfected cell pools 
batch shake flask cultures 
 
 
The improvement in mAb titer (Table 5.2), was directly correlated to the 160% 
improvement in average IVCD (Table 5.1), indicating that cgri-HSP27 improves 
recombinant mAb titer mainly by improving cell growth and extending culture 
viability. Comparing back to the transfected cell pools batch shake flask cultures, 
p2.27 CHO-mAb cell pools displayed a 20% lower average specific productivity, but 
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managed to improve recombinant mAb titer by 38% due to the 70% improvement in 
maximum cumulative IVCD (Figure 4.3). However, in the fed-batch bioreactors, the 
average specific productivity was not affected and hence the improvement in 
recombinant mAb titers is directly correlated to the improvements in the cumulative 
IVCD.  This strongly affirms that cgri-HSP27 overexpression improves recombinant 
mAb titer by improving cell growth and extends the culture duration in fed-batch 
bioreactor cultures. 
In terms of final volumetric productivity (Table 5.2), p2.27 CHO-mAb cells 
had an average volumetric productivity of 120 ± 27 mg/L/day, 91% higher as 
compared to p2.Blank CHO-mAb clones. When relating this to recombinant biologics 
production, an efficient process requires the culture to yield a high recombinant mAb 
titer in the shortest production time. This implies that with the use of the p2.27 CHO-
mAb clones, the fed-batch bioreactor production time needed approximately 8 days to 
achieve ~ 1g/L, as compared to 16 days with the use of p2.Blank CHO-mAb clones. 
 
5.1.3 Extracellular Biochemical Concentrations 
As can be seen in Figure 5.4, residual glucose and glutamine were being 
maintained at above the set points of 0.04 g/L and 0.5 g/L respectively, indicating that 
the fed-batch bioreactor cultures were not depleted of these two key nutrients from 
the start of the culture till harvest. It further supports that the improvements in p2.27 
CHO-mAb fed-batch bioreactor cultures as compared to p2.Blank CHO-mAb fed-





Figure 5.4 Extracellular biochemical concentrations of p2.Blank and p2.27 CHO-mAb 
clones fed-batch bioreactors                                                                                                                     
Concentrations of extracellular (A) glucose, (B) glutamine, (C) lactate and (D) ammonium 
were monitored offline daily (n=1; error bars denote standard deviation of duplicate technical 
replicates from a single culture).  
 
Lactate concentrations in all the fed-batch bioreactor cultures reached 
minimum growth inhibitory concentrations of 20 mM on Day 4. In p2.Blank CHO-
mAb cultures, the viable cell densities continued to increase for an extra day before 
viable cell densities started to drop. On the other hand, the viable cell densities of 
p2.27 CHO-mAb cultures continued to increase for an additional 2-3 more days with 
increasing lactate accumulation. It suggests that cgri-HSP27 may affect CHO-mAb 
cells sensitivity to growth inhibition by lactate when cultured in fed-batch bioreactors. 
Notably, consumption of lactate was observed in both transfected cell pools batch 
shake flask cultures (Figure 4.7). However, only p2.27 CHO-mAb clone 12 fed-batch 
bioreactor cultures displayed consumption of lactate after Day 5. This indicates the 
inherent mutability of CHO cells during culture [110-112] and clonal variability [112, 
114-117]. The lower level of lactate in the fed-batch bioreactor cultures may have 
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allowed p2.27 CHO-mAb clone 12 to proliferate for another 3 days and led to a 
slower decline in culture viability (Figure 5.1).  
Ammonium concentrations in both set of fed-batch bioreactor cultures 
exceeded the minimum growth inhibitory level of 2-5 mM on Day 3 (Figure 5.4). 
However, the drop in viable cell densities of p2.Blank CHO-mAb cultures (Figure 5.1) 
was only observed 2 days later when ammonium accumulated to an average 
maximum level of 25 ± 12 mM on Day 5. For p2.27 CHO-mAb cultures, the drop in 
viable cell density was observed 3-4 days later when ammonium accumulated to 16 ± 
8 mM and maintained at similar concentrations of 11 ± 7 mM till harvest. The 
observations indicate that the cell growth of all transfected CHO-man clones fed-
batch bioreactor cultures were likely not involved by the levels of ammonium present 
in the culture supernatant. Notably, a spike in the ammonium concentration was 
observed on Day 5 of all p2.Blank CHO-mAb cultures and p2.27 CHO-mAb clone 7 
cultures, which corroborated with the overfeeding of glutamine at the same culture 
time (Figure 5.4). The overfeeding of glutamine was most likely due to the feed-
forward strategy where the pre-determined glutamine specific consumption rate 
during the exponential growth phase was used throughout fed-batch bioreactor runs.  
 
5.2 Validation of Stable Transfected p2.27 CHO-mAb Culture Performance in 
Fed-batch Bioreactor 
To validate whether the cgri-HSP27 engineered CHO-mAb cells are suitable as 
production cell lines for the manufacturing of recombinant biologics, reproducibility 
in terms of cell growth, high volumetric productivity and recombinant mAb with a 
consistent and uncompromised glycan profile were investigated in fed-batch 
bioreactor systems, commonly used for production of recombinant mAb biologics. 
Best performing p2.27 CHO-mAb clone 12 from earlier fed-batch bioreactor 
evaluation study was selected and compared against a randomly selected p2.Blank 
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CHO-mAb clone 8. The cells were seeded into a 2-L bioreactor at a seeding density 
of 3 x 105 cells/ml with a starting culture volume of 1.5 L. Fed-batch bioreactor 
process controls and feeding strategy used was as described in Chapter 3, section 3.4, 
similar to the earlier fed-batch bioreactor evaluation study. Triplicates fed-batch 
bioreactors were ran for each clone. 
Figure 5.5 shows the growth profiles of the fed-batch bioreactor cultures while 
Table 5.3 shows the recombinant mAb production characteristics of the fed-batch 
bioreactor cultures. p2.27 CHO-mAb clone 12 fed-batch bioreactor cultures achieved 
a maximum viable cell density of 2.0 ± 0.2 x 107 cells/ml, 184% higher when 
compared to p2.Blank CHO-mAb clone 8 cultures (Figure 5.5). The p2.27 CHO-mAb 
fed-batch bioreactor cultures also experienced the drop in culture viability to 80%, 
after 2 days (Figure 5.5). These improvements in growth and extension of culture 
duration were reflected in the maximum cumulative IVCD of 2.4 ± 0.3 x 109 
cells.h/ml achieved by p2.27 CHO-mAb clone 12, 240% higher than what was 
achieved by p2.Blank CHO-mAb clone 8. Additionally, the differences in maximum 
viable cell densities between p2.27 CHO-mAb triplicates fed-batch bioreactor 






Figure 5.5 Growth characteristics and recombinant mAb titer of p2.Blank CHO-mAb 
clone 8 and p2.27 CHO-mAb clone 12 fed-batch bioreactor cultures 
(A) Viable cell density, (B) culture viability, (C) cumulative IVCD and (D) recombinant mAb 
titer were monitored offline and calculated daily (n=1; error bars denote standard deviation of 
3 biological replicates). 
 
In terms of the recombinant mAb production (Table 5.3), the improvement in 
maximum cumulative IVCD led to a 350% increase in recombinant mAb titer: 1823 ± 
95 mg/L by p2.27 CHO-mAb clone 12 cultures versus 328 ± 87 mg/L by p2.Blank 
CHO-mAb clone 8 cultures. Notably, the specific productivity of p2.27 CHO-mAb 
clone 12 fed-batch bioreactor cultures remained stable throughout the culture till 
harvest. It had a 29% higher specific productivity at exponential growth phase and a 
50% higher average specific productivity as compared to p2.Blank CHO-mAb clone 
8 fed-batch bioreactor cultures. The p2.27 CHO-mAb clone 12 cultures also achieved 
a final volumetric productivity of 183 ± 9 mg/L/day, 289% higher than p2.Blank 
CHO-mAb clone 8 cultures. Additionally, the difference in the high volumetric 
productivities of p2.27 CHO-mAb triplicates fed-batch bioreactor cultures were less 
than 10%. The fed-batch bioreactor cult ure performance of p2.27 CHO-mAb clone 
12 was also comparable to that of the earlier fed-batch bioreactor cultures (Figure 5.1 
and 5.3); indicating consistency of improved fed-batch bioreactor culture 
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performance in cgri-HSP27 engineered CHO-mAb cells and culture reproducibility 
of this cell line. This suggests that p2.27 CHO-mAb clone 12 is a suitable production 
cell line for the manufacturing of recombinant mAb biologics. These cultures were 
used for study of cgri-HSP27 molecular roles in CHO-mAb cells in the subsequent 
chapters. 
 
Table 5.3 Recombinant mAb production characteristics of p2.Blank CHO-mAb clone 8 
and p2.27 CHO-mAb clone 12 triplicates fed-batch bioreactor cultures 
 
 
5.3 N-glycan Profiles of Recombinant mAb Produced by Stable Transfected 
p2.27 CHO-mAb in Fed-batch Bioreactor 
Glycans profiling and glycan distribution of any approved biologics, including 
recombinant mAb is required by regulatory bodies to demonstrate its safety, purify 
and potency [121, 122]. That is because glycosylation has been known to directly 
impact the safety and efficacy, such as half-life, antibody-dependent cell-mediated 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of recombinant 
mAbs when functioning in vivo [123-125]. CHO cells have been used for the 
production of most approved biologics included recombinant mAb because it 
processes human-like post-translation modification capabilities especially 
glycosylation to produce therapeutic glyco-proteins. Given the importance of the 
glycan distribution of recombinant mAb, it would be of importance to see if cgri-
HSP27 overexpression has any impact on the glycosylation signaling pathways in 
CHO-mAb cells when cultured in fed-batch bioreactor and result in the production of 
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recombinant mAb with different glycan profile. Additionally, this study can be used 
to evaluate the suitability of cgri-HSP27 strategy in producing higher titers of 
recombinant mAb without affecting the quality of recombinant map produced by 
CHO-mAb cells. 
To examine the effect of cgri-HSP27 on the glycosylation signaling pathway of 
CHO-mAb cells during fed-batch bioreactor cultures, N-glycan distribution of the 
recombinant mAb produced by cgri-HSP27 engineered CHO-mAb cells were 
compared against that of null vector engineered CHO-mAb cells. N-glycans 
distribution was analysed as recombinant mAb produced by mammalian cells are 
typically N-linked complex biantennary structures with little sialylation and has many 
galactosylation with fucose [125, 126]. Culture spent media containing the 
recombinant mAb were harvested from the triplicates fed-batch bioreactor cultures of 
p2.Blank clone 8 and p2.27 clone 12 CHO-mAb cells (Figure 5.5), purified and 
analysed using MALDI-TOF-MS. The culture spent media were harvested when the 
culture viabilities were above 80% to prevent any degradation of the recombinant 
mAb by the cellular proteases released from the non-viable cells [125, 126]. As 
glycosylation can be affected by culture conditions such as pH, DO, temperature, 
ammonium concentration and culture viability [126], Table 5.4 shows the culture 
conditions at the point of harvest for glycosylation profiling. All culture conditions 
remained stable and similar, except for the concentrations of ammonium and 










Table 5.4 Fed-batch bioreactor culture conditions at the point of sampling for 
glycosylation profiling  
 
N-glycan distribution of recombinant mAb produced by both set of cultures 
were distributed into six categories [105]: (i) sialylated with at least one sialic acid 
residue in the terminal position, (ii) fucosylated complex N-glycans, (iii) high 
mannose-type, (iv) G0 without bearing terminal galactose residue, (v) G1 bearing one 
terminal galactose residue and (vi) G2 bearing two terminal galactose which is 
typically what was observed for humanized recombinant mAb IgG produced by CHO 
cells [124]. When compared to null vector engineered CHO-mAb fed-batch 
bioreactor cultures, there was no significant difference (P-value < 0.05) in the N-
glycans distribution of the recombinant mAb produced by cgri-HSP27 engineered 
CHO-mAb cells (Figure 5.6). This suggests that overexpression of cgri-HSP27 does 
not affect the glycosylation signaling pathways of CHO-mAb cells under fed-batch 
bioreactor culture conditions. It also demonstrates the applicability of cgri-HSP27 
overexpression strategy in producing recombinant mAb in high titers without causing 




Figure 5.6 Percentage glycan distribution of purified recombinant mAb produced by 
p2.Blank CHO-mAb clone 8 and p2.27 CHO-mAb clone 12 fed-batch bioreactor cultures 
(Figure 5.X), based on analysis by MALDI-TOF MS.  
Glycan distribution is divided into categories: sialylated with at least one sialic acid residue in 
terminal position, fucosylated complex N-glycans, high-mannose-type, G0 with no terminal 
galactose residue, G1 with one terminal galactose residue and G2 with two galactose residue 
(n=3, error bars ± SD from the mean, each biological sample measure with technical triplicate, 
Student t-test with pValue < 0.05 was performed). 
 
Conclusions 
Application of cgri-HSP27 overexpression strategy in a CHO DG44 cell line 
producing recombinant mAb was evaluated in fed-batch bioreactor systems to 
demonstrate its generic applicability for production of biologics. The overexpression 
of cgri-HSP27 in CHO cells producing recombinant mAb increased maximum viable 
cell density by 119% and extended the culture duration by 2 days, as such the 
recombinant mAb titers was greatly improved by 161%. This demonstrates that cgri-
HSP27 overexpression can evidently increase recombinant mAb titers in fed-batch 
bioreactors cultures. The suitability of a representative cgri-HSP27 engineered CHO-
mAb cell line as a production cell line was affirmed in terms of displaying consistent 
growth profiles, consistently high volumetric productivity and without compromising 




CHAPTER 6 Molecular Roles of cgri-HSP27 in CHO-mAb cells  
 
Introduction 
Overexpression of cgri-HSP27 in CHO-mAb cells demonstrated increased 
recombinant mAb titers by increasing peak viable cell density and extending culture 
duration in fed-batch bioreactor cultures, as described earlier in Chapter 5. This is 
likely due to the inhibition of the apoptotic pathways because delayed Caspase-2, -3, -
8 and -9 activations in previous cgri-HSP27 engineered CHO cells producing 
recombinant human IFNɣ fed-batch bioreactor cultures were reported [36]. As there 
are no other reported mechanistic studies of how cgri-HSP27 improves culture 
performance of CHO fed-batch bioreactor cultures, it would be of interest to elucidate 
the molecular roles of cgri-HSP27 in inhibiting apoptosis in CHO-mAb fed-batch 
bioreactor cultures to complement the knowledge of HSP27 molecular roles. 
The strategy would be to verify the modulation of caspase activities in cgri-
HSP27 engineered CHO-mAb fed-batch bioreactor cultures as previously observed in 
cgri-HSP27 engineered CHO-IFNɣ fed-batch bioreactor cultures [37].  
Concomitantly, reported HSP27 interacting targets involved in the apoptosis 
signaling pathways that attributes to its anti-apoptosis function would be identified 
through literature survey and then isolated in cgri-HSP27 engineered CHO-mAb 
under fed-batch bioreactor stress conditions to validate if similar interacting targets 
were observed, giving insights into how the resistance to apoptosis in these 
engineered CHO-mAb cells is most likely attained. These interacting targets and the 
effects of interacting with HSP27 would have been extensively studied and validated 
in both human and mouse cell line studies. Hence the aim of isolating and identifying 
these anti-apoptotic interacting targets was to observe if these interactions translate to 
cgri-HSP27 in CHO-mAb cells, under fed-batch bioreactor culture conditions. 
Additionally, it provide insights into the improvements of cgri-HSP27 engineered 
CHO-mAb fed-batch bioreactor cultures. 
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This chapter presents the validation of established HSP27 molecular roles in 
regulating caspase activities and identification cgri-HSP27 interacting targets 
involved in apoptosis signaling pathways of cgri-HSP27 engineered CHO-mAb 
during fed-batch bioreactor cultures, as compared to HSP27 studies in human and 
mouse cells. 
 
Results and Discussion 
6.1 Effect of cgri-HSP27 on Caspase Activities in CHO-mAb Cells  
Apoptosis is a major form of regulated cell death known to occur in CHO fed-
batch bioreactor cultures [33, 34, 126, 127]. It triggers a cascade of effects mediated 
by caspases and leading to apoptotic cell death. Activities of Caspase -2, -3, -8 and -9 
in CHO [36], human and mouse cells [73, 81, 128, 129] were reported to be affected 
by constitutive high expression of HSP27, which led to extension of cell viability and 
is one of the known anti-apoptosis functions of HSP27. Caspase-8 is known to initiate 
death-receptor mediated apoptosis pathway, whereas Caspase-2 and Caspase-9 are 
known to initiate mitochondria-mediated apoptosis pathway. Both apoptosis pathway 
activates Caspase-3 to execute the apoptotic events such as DNA fragmentation and 
proteolysis of cellular proteins [27, 130], resulting in cell death. 
To investigate if similar effects on caspase activities was observed in cgri-
HSP27 engineered CHO-mAb cell, activities of Caspase-2, -3, -8 and -9 in cgri-
HSP27 engineered CHO-mAb fed-batch bioreactor cultures (p2.27 CHO-mAb clone 
12, Figure 5.5) were profiled and compared against null vector engineered CHO-mAb 
fed-batch bioreactor cultures (p2.Blank CHO-mAb clone 8, Figure 5.5). Triplicated 
biological fed-batch bioreactor cultures of both cell lines were sampled once daily at 
24 intervals from start of culture till before the culture viabilities dropped below 80%. 
The caspase activities were quantified using a fluorescence intensity-based caspase 
profiling kit where the increase in fluorescence intensity is correlated to increase in 
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caspase activity, and the fluorescence intensity was normalized to the start of the 
respective fed-batch bioreactor cultures.  
The sharp increase in Caspase-2, -8 and -9 activities was observed on Day 6 of 
cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures (Figure 6.1), a day 
later compared to null vector engineered CHO-mAb fed-batch bioreactor cultures, 
based on the 24 h daily sampling time interval used. The sharp increase in Caspase-3 
activity was observed on Day 5 of cgri-HSP27 engineered CHO-mAb fed-batch 
bioreactor cultures, 2 days later when compared to null vector engineered CHO-mAb 
fed-batch bioreactor cultures.  
 
 
Figure 6.1 Caspase activities of null vector engineered and HSP27 engineered CHO-mAb 
fed-batch bioreactor cultures 
Activity profiles of (A) Caspase 2, (B) Caspase 3, (C) Caspase 8 and (D) Caspase 9 were 
monitored daily at 24 h intervals before culture viabilities dropped to 80% (n=3; error bars 
denote standard deviation of 3 biological replicates). 
 
The sharp increase in caspase activations corroborated with the drop in culture 
viabilities of null vector engineered CHO-mAb fed-batch bioreactor cultures on Day 
6 and cgri-HSP27 engineered CHO-mAb fed-batch bioreactors on Day 8 (Figure 5.5). 
These observations were similar to those previously reported in cgri-HSP27 
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engineered CHO-IFNɣ cells fed-batch bioreactors [36]. This suggests that cgri-
HSP27 is able to modulate caspase activities initiated by both the death receptor-
mediated and mitochondria-mediated apoptosis signaling pathways in CHO-mAb 
fed-batch bioreactor cultures. These delays are likely contributing to the longer 
culture duration and resultant higher recombinant mAb titer observed in cgri-HSP27 
engineered CHO-mAb fed-batch bioreactor cultures. 
 
6.2 Isolation and Identification of Validated HSP27 Interacting Targets in CHO-
mAb Cells  
Well studied HSP27 interacting targets involved in the apoptosis signaling 
pathway are: (i) Akt, which functions as a pro-survival and pro-proliferation cellular 
protein upon phosphorylation [60, 70, 85, 93, 113, 131]; (ii) pro-Caspase-3, which 
upon proteolytic cleavage becomes active Caspase-3 [72, 97, 128]; (iii) Cytochrome c, 
a pro-apoptotic protein when released from the mitochondria activates Caspase-9 
upon binding with pro-Caspase-9 and APAF-1 to form the apoptosome complex [72, 
87, 97, 129] and (iv) Daxx, which forms a complex with the Fas receptor and ASK1 
leading to JNK-mediated caspase-independent cell death [86].  
As an extension in culture duration and delays in caspase activities were both 
observed in cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures, it was 
postulated that the reported interactions of HSP27 with its targets in the apoptosis 
signaling pathways of human and mouse cells may be occurring in CHO-mAb fed-
batch bioreactor cultures. Henceforward, isolation and identification of the above-
mentioned four reported HSP27 interaction targets in CHO-mAb cells were carried 
out. cgri-HSP27 engineered CHO-mAb cells were used for this investigation as 
endogenous expression of cgri-HSP27 in null vector engineered CHO-mAb cells are 
stress-inducible, hence interaction with its targets may be transient, making isolation 
of cgri-HSP27-interacting targets complex experimentally tricky. Cells were 
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collected during the mid to late exponential growth phase (Day 3-6) of cgri-HSP27 
engineered CHO-mAb cultures and cgri-HSP27 interacting targets were isolated 
using co-immunoprecipitation (Co-IP) with Protein G beads and anti-HSP27 antibody, 
followed by identification using western blot assays. Anti-mouse IgG was used as a 
negative control for isotype and species specificity against the anti-HSP27 antibody 
used. 
Cgri-HSP27 was pulled down with anti-HSP27 antibody, but not with mouse 
IgG antibody, as depicted on the western blot assays of the eluted complexes (Figure 
6.2). This demonstrates that the Co-IP method used can pull down cgri-HSP27 
specifically in CHO-mAb cells. Akt, pro-Caspase-3 and Daxx were also pulled down 
using anti-HSP27 antibody, but not with mouse IgG antibody (Figure 6.2) in cgri-
HSP27 engineered CHO-mAb cells. These observations suggest that cgri-HSP27 is 
able to interact with Akt, pro-Caspase-3 and Daxx in CHO-mAb cells, potentially 
affecting the apoptosis signaling pathways and caspases activities, contributing to the 
observed delayed caspase activities and improved fed-batch bioreactor cultures 
performance of cgri-HSP27 engineered CHO-mAb cells.  
Cytochrome c, however, was not pulled down using both anti-HSP27 antibody 
and mouse IgG antibody, although the protein was detectable in the total cellular 
protein lysate of cgri-HSP27 engineered CHO-mAb cultures (Figure 6.2). This was 
despite the long exposure time of 2 min 30 s for the blot with Co-IP elute complexes 
versus 10 s for the blot with total cellular protein lysates in combination with the use 
of a signal enhancer buffer to enhance the antigen-antibody binding signal. While 
hsap-HSP27 has been shown to interact with hsap-Cytochrome c in human cells [87, 
97], cgri-HSP27 used in this study [36] and cgri-Cytochrome c (Swiss-Prot: G3H2K2) 
protein sequences differ from those of human (Swiss-Prot: P04792 and Swiss-Prot: 
P99999 respectively) by 14%. These variations may have resulted in the different 
HSP27-Cytochrome c interaction observed in human and CHO cells. Additionally, 
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the proteins that hsap-HSP27 interacted with at the time of stress is partly dependent 
on the size and phosphorylation status of hsap-HSP27 present in the cells during 
stress [40, 43, 44]. Hsap-HSP27 was presented as small unphosphorylated oligomers 
when interacting with Akt [70] and pro-Caspase-3 [128]. Both hsap-HSP27 and 
mmus-HSP27 were presented as small phosphosylated oligomers when interacting 
with Daxx [86]. However, the state of hsap-HSP27 when interacting with 
Cytochrome c is not conclusive [72, 87, 97]. Hence, it is possible that cgri-HSP27 
was presented as both unphosphorylated and phosphorylated small oligomers during 
points of sampling for the Co-IP experiment, and that interaction with Cytochrome c 
may require cgri-HSP27 to be presented as large oligomers. 
 
Figure 6.2 Co-IP of cgri-HSP27 engineered CHO-mAb cells                                            
Co-IP was carried out with Protein G beads and pulled down using anti-HSP27 antibody and 
mouse IgG antibody as negative control. Total cellular lysates used for co-IP and eluted co-IP 
complex were immunoblotted with anti-HSP27, anti-Akt, anti-pro-Caspase-3,anti-Cytochrome 
c and  anti-Daxx antibodies. Figure shown is representative of biological replicates (n=3). 
 
Based on the Co-IP results and the reported effects of HSP27 interactions to 
these identified isolated targets, it was proposed that: firstly, cgri-HSP27 interaction 
with Akt in CHO-mAb cells may have enhanced the activity of Akt, which in turn 
increase regulation of  signals and proteins regulating cell proliferation and cell 
survival of CHO-mAb cells. Akt have also been reported to reduce the activity of 
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Caspase-8 indirectly via its direct regulation of death-effector domain, Pea-15 [95] 
and reduce the activity of Caspase-9 directly [93, 94]. This seems to corroborate with 
the delayed spike in both Caspase-8 and -9 activities observed in cgri-HSP27 
engineered CHO-mAb fed-batch bioreactor cultures (Figure 6.1) as compared to null 
vector engineered CHO-mAb fed-batch bioreactor cultures. Secondly, the interaction 
of cgri-HSP27 with pro-Caspase-3 in CHO-mAb cells may have prevented its 
proteolytic cleavage into active Caspase-3 [128]. This seems to corroborate with the 
delayed increased in Caspase 3 activity as seen in Figure 6.1. The delayed increase in 
Caspase-3 activity of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor 
cultures may likely have resulted in delayed activation of Caspase-2 as Caspase-3 
was shown to activate pro-Caspase-2 to active Caspase-2 through its active 
proteolytic functions [27, 130]. Lastly, the interaction with Daxx in CHO-mAb cells 
may have prevented the binding of Ask1 to Daxx and the Fas-receptor, hence 
preventing the activation of the JNK signaling pathway, which leads to caspase-
independent cell death. This may be inferred by the observed delayed loss of viable 
cells (Figure 5.5) in cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures.  
Notably, even though the possible interaction of cgri-HSP27 with its targets 
involved in the apoptosis signaling pathways may lead to modulation of caspase 
activities and cellular apoptosis to delay cell death, the culture viability of cgri-
HSP27 engineered CHO-mAb fed-batch bioreactor cultures was observed to have 
dropped to below 80%  after Day 8 (Figure 5.5). This indicates that there may be 
other channels in the apoptosis signaling pathways that are not affected by cgri-
HSP27 and that there are other culture stress causing cell death in cgri-HSP27 
engineered CHO-mAb fed-batch bioreactor cultures. These may be interesting cell 
line engineering targets for further improving the culture performance and 





Overexpression of Cgri-HSP27 is able improve cell growth and extend the 
culture duration of CHO-mAb cells fed-batch bioreactor cultures by regulating the 
activities of Caspase-2, -3, -8 and -9. Additionally, overexpression of Cgri-HSP27 
may potentially modulate the apoptosis signaling pathways by interacting with Akt, 
pro-Caspase-3 and Daxx. This is based on the insights provided from the Co-IP 
studies and extensive studies done on the effects of HSP27-Akt, -pro-Caspase 3 and –
Daxx interactions. However, cgri-HSP27 in CHO-mAb cells did not interact with 
Cytochrome C, which plays a major role in inducing apoptotic cell death, contrary to 
what was reported in other cell line studies. It is postulated that the non-interaction 
with Cytochrome c may be due to the oligomer size of cgri-HSP27 present. These 
potential molecular roles of cgri-HSP27 in CHO-mAb in fed-batch bioreactor 
cultures (Figure 6.3) offers insights into further improving the robustness of the CHO 












Figure 6.3 Schematic illustration of cgri-HSP27 and its proposed effect on caspases and 
validated interacting targets in CHO-mAb cells apoptosis signaling pathways.                                            
Cgri-HSP27 delayed the activation of Caspase-2, -3, -8 and -9 in CHO-mAb cells. Cgri-
HSP27-Daxx interaction may inhibit caspase-independent cell death via JNK signaling 
pathway. Cgri-HSP27-Akt interaction may likely increase level of phosphorylated Akt and 
enhanced cell proliferation and survival. Cgri-HSP27-pro-Caspase-3 interaction may have 















CHAPTER 7 Multi omics to study potential molecular roles of cgri-HSP27 in 
CHO-mAb cells  
 
Introduction 
At present, it is demonstrated that cgri-HSP27 delays activities of Caspase-2, -
3, -8 and -9 in HSP27 engineered CHO-mAb fed-batch bioreactor cultures as 
compared to null vector engineered CHO-mAb fed-batch bioreactor cultures (Figure 
6.1). It is also demonstrated in the previous chapter that HSP27 in the engineered 
CHO-mAb cells interact with Akt, pro-Caspase-3 and Daxx, part of the apoptosis 
signaling pathways when cultured in fed-batch bioreactors (Figure 6.2). These 
mechanisms of cgri-HSP27 are postulated to contribute, in part, to the higher 
maximum viable cell density and longer culture duration of cgri-HSP27 engineered 
CHO-mAb fed-batch bioreactors (Figure 5.5). Besides these, HSP27 was also 
reported to interact with other targets involved in various cellular processes and 
functions in human and mouse pathological tissues and cells [43-45] (Table 2.3). The 
results of the interaction with its targets are associated with how HSP27 achieves its 
multitude of cellular functions (Figure 2.2). However, when looking at each 
individual interacting target, the interaction may be particularly for a particular cell 
line under a specific stress induced culture environment. This entails that the 
molecular roles of cgri-HSP27 in CHO-mAb cells contributing to the better fed-batch 
bioreactor culture performances may likely be either limited to or more exhaustive 
than what was reported earlier in the study (Figure 6.3).  
The aim of this chapter will be to identify other probable cgri-HSP27 
interacting targets and its molecular roles that improve cell growth and extend the 
culture duration of CHO-mAb cells when cultured in fed-batch bioreactors. The 
findings will help build an initial proposed cgri-HSP27 interactome in CHO-mAb 
cells under fed-batch bioreactor conditions and supplement the current limited 
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knowledge of cgri-HSP27 molecular roles in CHO cells. Additionally, insights into 
better rationale cell-engineering targets for further improving the robustness of cgri-
HSP27 engineered CHO-mAb cells will be gained. This will be performed with the 
help of omics technologies.  
Global identification of protein-protein interaction targets isolated from Co-IP 
studies is often carried out by proteomics analysis using Mass Spectrometry (MS) and 
follow-up by functional assays to reveal the aftermath of the interaction. When the 
protein-protein interaction results in the degradation or ubiquitination of the 
interacting protein, identification would prove difficult. Additionally, most protein-
protein interactions involved actin or cytoskeleton proteins, which may hinder the 
identification of other interacting proteins when using MS for identification and result 
in false negatives. When bait antibody was used for the Co-IP study, masking of 
interacting proteins peak in the MS may be possible, making identification 
challenging. Furthermore, transient interactions that resulted in regulation of 
signaling pathways and transcription activities may not be picked up by both Co-IP 
and MS identification. Hence, transcriptomics based on the transcriptome expression 
profile to indirectly identify potential cgri-HSP27 interacting targets were employed 
in this study. It is based on the assumption that upon cgri-HSP27 interaction with its 
targets, transcript levels downstream will be affect due to cellular regulation during 
cgri-HSP27-target interaction. Hence we were looking at the regulation of transcripts 
affected by HSP27 engineering in CHO-mAb cells during fed-batch bioreactor 
cultures. Additionally, cellular functions of cgri-HSP27 in CHO-mAb cells as an 
aftermath of cgri-HSP27 interactions can also be identified using the transcriptome 
profiling study and indirectly enable identification of potential cgri-HSP27 
interacting targets. 
First, an exhaustive list of probable cgri-HSP27 interacting targets in CHO 
cells was created by mining databases for HSP27-interactome based on human and 
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mouse cell line studies. This bioinformatics information served as a reference list 
against the potential cgri-HSP27 interacting targets that may be identified further 
down using other omics technologies based on CHO-mAb fed-batch bioreactor 
cultures transcriptome and metabolomics experimental data. Next, transcriptome 
expression profiling of cgri-HSP27 engineered versus null vector engineered CHO-
mAb fed-batch bioreactor cultures was carried out. Key regulators of the 
differentially regulated transcripts that regulate these cellular functions were 
identified and list as probable cgri-HSP27 interacting targets. Concomitantly, the 
comparative metabolomics study was carried out using cgri-HSP engineered and null 
vector engineered CHO-mAb fed-batch bioreactor cultures to define the intracellular 
metabolites involved in the metabolism pathways. Extraction of possible cgri-HSP27 
interacting targets was also carried out as it was previously suggested that the delay 
loss of culture viability may be linked to cgri-HSP27 modulation of metabolism 
pathways in fed-batch bioreactor cultures. Identified probable interacting proteins 
from these two studies would be compared against the reference list of probable cgri-
HSP27 interacting targets created to narrow down to ‘most’ probable interacting 
targets. 
The transcriptome profiling and metabolic studies carried out in this chapter 
were based on the experimental samples from cgri-HSP27 engineered CHO-mAb 
(p2.27 clone 12) and null vector engineered CHO-mAb (p2.Blank clone 8) fed-batch 
bioreactor cultures, as described in Chapter 5 (Figure 5.5). 
Results and Discussion 
7.1 Database Mining for Potential cgri-HSP27-interacting Targets in CHO-mAb 
Cells 
In order not to miss out on any potential cgri-HSP27 interacting targets, 
protein-protein interaction databases were mined to create an exhaustive list of 
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probable cgri-HSP27 interacting targets as shown in Table 7.1. The databases mined 
were Biological General Repository for Interaction Datasets (BioGrid) [132, 133], 
IntAct Molecular Interaction Database (IntACt) [134], Human Protein Reference 
Database (HPRD) [135] and Metacore™ (Thomas Reuters) as they contain one of the 
most numbers of interactions per database.  
All the entries in these databases are based on manual curations from both 
published single-experiments and high throughput screening experiments, using 
human and mouse cells, and may be stress-induced differently from the stress 
experienced in a CHO cells fed-batch bioreactor. Aftermath of HSP27 interactions 
with some of the interacting targets listed in Table 7.1 has been studied and the 
associated cellular functions were previously listed in Table 2.3. However, there are a 
handful of interacting targets with unknown outcome upon interactions with HSP27. 
This list of targets has been associated with varied cellular functions of HSP27 
including anti-apoptosis and enhanced cell growth and proliferation which 
corroborated with observed better fed-batch bioreactor cultures performances of cgri-
HSP27 engineered CHO-mAb cells: higher maximum viable cell density, longer 
culture time at high culture viability and as such, increased recombinant mAb titer. 
Hence this exhaustive list would serve as a reference list against the potential cgri-
HSP27 interacting targets in CHO-mAb fed-batch bioreactor cultures identified in the 








7.2 Transcriptome Profiling of cgri-HSP27 Engineered CHO-mAb Fed-batch 
Bioreactor Cultures 
To compare the transcriptome profile of cgri-HSP27 engineered CHO-mAb 
cells against the null vector engineered CHO-mAb cells, cells were harvested from 
both p2.Blank clone 8 and p2.27 clone 12 CHO-mAb triplicates fed-batch bioreactor 
cultures on Day 3, Day 4 and Day 5 (Figure 5.5).  
On Day 3 and 4, both set of cultures were at exponential growth phase where 
cell growth was optimal, viable cell densities on both days between the cultures were 
similar and culture viabilities were above 95%. Hence, the differences in transcript 
profiles on Day 3 and Day 4 would likely be due to cgri-HSP27 engineering and not 
be affected by differences in cell growth and clonal variation. On Day 5 of the fed-
batch bioreactor cultures, cgri-HSP27 engineered CHO-mAb cells continued to 
proliferate at an exponential growth rate while null vector engineered CHO-mAb 
cells had entered the stationary growth phase. The difference was reflected in the 
cumulative IVCD (Figure 5.5). The culture viabilities remained above 95% on Day 5. 
Notably, the activities of Caspase-2, -8 and -9 increased at Day 5 for the null vector 
engineered CHO-mAb fed-batch bioreactor cultures but not for cgri-HSP27 
engineered CHO-mAb fed-batch bioreactor cultures (Figure 6.1). This was earlier 
postulated to be contributed by cgri-HSP27 and its interactions with the targets from 
the apoptosis signaling pahtways, resulting in the improved cell growth and extended 
culture duration of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures. 
For Caspase-3, the increased in activity was earlier on Day 4 of null vector 
engineered CHO-mAb fed-batch bioreactor cultures and Day 6 for cgri-HSP27 
engineered CHO-mAb cells fed-batch bioreactor cultures. 
Henceforth, transcriptome expressing profiling of cgri-HSP27 engineered 
versus null vector engineered CHO-mAb fed-batch bioreactor cultures on Day 3, Day 
4 and Day 5 would help to illustrate the cellular functions of engineered cgri-HSP27 
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that contributed to the observed improved phenotype in fed-batch bioreactor cultures: 
where in cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures, activations 
of caspases were delayed and cells continued to grow. On the other hand, in null 
vector engineered CHO-mAb fed-batch bioreactor cultures, caspases were activated 
and cells entered the stationary growth phase. Biological gene functions and signaling 
pathways enrichments were next carried out to illustrate the cellular functions and 
signaling pathways representative of the comparative transcriptome profile. At the 
same time, key regulators of the represented cellular functions and pathways were 
identified, listed as probable interacting targets and compared against the created list 
of potential cgri-HSP27 interacting targets (Table 7.1) to generate a list of likely 
interacting targets in CHO-mAb fed-batch bioreactor cultures. 
Customized CHO GeneChip probe array (Affymetrix) containing 43,856 
probe sets matching to 26,828 gene sequences annotated from various CHO cell lines 
and CHO tissues were used for this study. After pre-processing and normalization of 
the transcripts raw intensity values, the fold-change of remaining 8,304 transcripts 
intensities from cgri-HSP27 engineered over null vector engineered CHO-mAb were 
then calculated. A total of 201 differentially regulated transcripts wth fold change 
more than or equal to ± 1.5 on either of the 3 days with a P-value of less than 0.05 (p 
< 0.05) was shortlisted for further analyses (Appendix 3). 
 
7.2.1 Biological Gene Functions Enriched in Transcriptome Profile  
To find out what gene functions are most represented in the list of differentially 
regulated transcripts of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor 
cultures (Appendix 3), biological gene functions enrichment analysis was carried out 
[91]. The differentially regulated transcripts were involved mainly in the following 
cellular functions: apoptosis, cell cycle and cell division, cell to cell signaling, 
chromosomal organization, intracellular signal transduction, lipid biosynthetic 
process, phosphorylation, proliferation, biogenesis and assembly of protein complex, 
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protein localization, proteolysis and regulation of transcription. These cellular 
functions supported the observations of higher viable cell numbers and longer culture 
duration of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures (Figure 
5.5). Notably, most of the cellular functions, except for chromosomal organization, 
lipid biosynthetic process, and protein localization, aligned with the cellular functions 
HSP27 were reported to be involved [43-45] (Figure 2.2). This infers that the effects 
of cgri-HSP27 interactions and associated cellular functions are reflected in the 
transcriptome profile of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor 
cultures. 
 
7.2.2 Signaling Pathways Enriched in Transcriptome Profile 
Next, the relationship between the differentially regulated transcripts 
(Supporting information, Table S7.1) were examined to reveal signaling pathways 
that were enriched and that may indicate the involvement of cgri-HSP27 interacting 
targets and its cellular functions in CHO-mAb cells under fed-batch bioreactor 
conditions. Unknown signaling pathways that may indicate involvement of cgri-
HSP27 may also be revealed.  
The list of 201 differentially regulated transcripts obtained from the probe 
array data (Appendix 3) were inputted into MetaCore™ (Thomas Reuters) and the 
‘Analyse network (transcription factor) algorithm function’ was used to generate a 
list of enriched signaling pathway networks. A list of 30 networks were generated 
(Appendix 4), ranked by the saturation of classical signaling pathways fragments in 
the each network, P-value and interpreted by the major Gene Onthology (GO) 
processes that the pathways in the networks were involved in. Overall, the networks 
involved the following main GO processes: regulation of apoptosis, biological and 
metabolic processes, regulation of extracellular matrix organization and cell surface 
receptor signaling pathways, responses to endogenous stimulus, growth factors, 
oxygen containing compounds and lipids, cell cycle and multicellular organismal 
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development. Looking at the top five networks generated; the P-values varied from 
2.90e-44 to 3.09e-220 and included 12-48% of the differentially regulated transcripts 
(Appendix 3). 
Network 1 (Figure 7.1) and Network 2 (Figure 7.2) had a similar number of 
classical pathways fragments, P-values, and involved 25 of the differentially 
regulated transcripts. They differed in some of the end receptors, but had the same 
GO processes and canonical pathways fragments. The GO process that describes 
these two networks were regulation of apoptotic process, response to endogenous 
stimulus and growth factors, and extracellular matrix organization. The main classical 
pathway fragments linked growth factors and cell-membrane adhesion proteins in the 
extracellular matrix, to growth factor receptors on the cell membrane surface, with 
pro- and anti-apoptotic genes (Apaf-1, Bax, Bad, Bcl-xl and Cytochrome c)  in the 
cyostol and ended up with Caspase-3 (Figure 7.1). PI3K-Akt-Caspase-9 pathway 
fragments were also present (Figure 7.2). These two networks of pathways suggest 
that Caspase-3 activation by extracellular stimulus is likely to occur in CHO-mAb 
cells during fed-batch bioreactor cultures, and that regulation of Caspase-9 by Akt is 
likely to be involved. The two classical pathways fragments involved in the networks 
supported the validated interaction of cgri-HSP27 with pro-Caspase 3 (Figure 6.2) 
and delayed in Caspase-3 activations (Figure 6.1) most likely contributed to the 
extended culture duration of cgri-HSP27 engineered CHO-mAb cells in fed-batch 
bioreactors (Figure 5.5). It also supported the validated interaction of cgri-HSP27 





Figure 7.1 Network 1.                                                                                                                   
Network of signaling pathways generated from the differential transcriptome profile of cgri-
HSP27 engineered versus null vector engineered CHO-mAb fed-batch bioreactor cultures. 
Seed nodes are indicated by a blue circle. Canonical pathways fragments indicated by 
highlighted lines. Source: MetaCore™ (Thomas Reuters) 
 
Figure 7.2 Network 2.                                                                                                                   
Network of signaling pathways generated from the differential transcriptome profile of cgri-
HSP27 engineered versus null vector engineered CHO-mAb fed-batch bioreactor cultures. 
Seed nodes are indicated by a blue circle. Canonical pathways fragments indicated by 
highlighted lines. Source: MetaCore™ (Thomas Reuters) 
 
Network 3 (Figure 7.3) was described by GO processes involved in positive 
regulation of cellular component movement and cell motility and extracellular matrix 
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organization. It involved mainly canonical pathway fragments that link cell adhesion 
proteins and protease inhibitors in the extracellular space to Akt in the cytosol. 
Classical pathways fragments involving TNF-α receptor, Caspase-8 and Akt were 
also present This network of signaling pathways suggest that the regulation of Akt by 
the extracellular matrix proteins may be one of the major pathways affected in cgri-
HSP27 engineered CHO-mAb fed-batch bioreactor cultures.  
Interestingly, TNF-α interaction with HSP27 has been reported. The interaction 
leads to the degradation of TNF-α mRNA [78] and this regulates its roles in the death 
receptor-mediated apoptosis signaling pathway: TNF-α, upon binding to its receptor, 
activates Caspase-2 and -8 directly and Caspase-3 indirectly via Caspase-8 [136-138]. 
It also prompts the cleavage of Bid to tBid, which translocates to the mitochondria to 
carry out its pro-apoptotic functions [137]. From earlier caspase activity profiles 
(Figure 6.1), Caspase-2, -3 and -8 activities were observed to be delayed and this 
implies that cgri-HSP27 may likely interact with TNF-α in cgri-HSP27 engineered 
cells cultured in fed-batch bioreactors.  
 
Figure 7.3 Network 3.                                                                                                                   
Network of signaling pathways generated from the differential transcriptome profile of cgri-
HSP27 engineered versus null vector engineered CHO-mAb fed-batch bioreactor cultures. 
Seed nodes are indicated by a blue circle. Canonical pathways fragments indicated by 




Network 4 (Figure 7.4) was described by GO processes involved in positive 
regulation of biological and cellular metabolic process, and intracellular receptor 
signaling pathway. However, only two canonical pathways fragments were involved 
in the network and they described the regulation of ESR1nuclear by ErbB1 in the 
extracellular matrix. This indicates that ESR1nuclear may be a key regulator involved in 
determining the signaling of biological and cellular process in cgri-HSP27 engineered 
CHO-mAb cells when cultured in fed-batch bioreactors. 
Notably, ErbB1 is a likely cgri-HSP27 interacting target curated from a high 
throughput screen (Table 7.1). It is part of the ErbB signaling pathway and its 
functions includes regulating cell proliferation, survival and cytoskeleton integrity.  
 
Figure 7.4 Network 4.                                                                                                                   
Network of signaling pathways generated from the differential transcriptome profile of cgri-
HSP27 engineered versus null vector engineered CHO-mAb fed-batch bioreactor cultures. 
Seed nodes are indicated by a blue circle. Canonical pathways fragments indicated by 
highlighted lines. Source: MetaCore™ (Thomas Reuters) 
 
Network 5 (Figure 7.5) was described by GO processes involved in positive 
regulation of cellular metabolic and nitrogen compound metabolic processes and 
positive regulation of response to stimulus. This network of pathways also involved 
the canonical pathways fragments of ESR1nuclear activity regulation by ErbB1 and the 
crosstalk between two transcription factors, Sox2 and NANOG. This pathway 
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supports the postulation that ESR1-nuclear as one of the central regulators of the 
transcriptome profiles. 
In the generated network 4 and 5, ErbB1 was shown to be activated upon 
stimulations by EGF, TGF-α and epiregulin, followed by activation of ESR1nuclear 
directly or indirectly via Akt. This suggests that improvement in maximum viable cell 
density in cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures may 
likely be due to ESR1 regulation of genes involved in cell proliferation via the ErbB1 
signaling pathway. Addtionally, looking at the ErbB1 signaling pathways, there were 
reported HSP27 interacting targets (Akt and SP1) and potentially HSP27 interacting 
targets (ErbB1 receptor and ESR1nuclear) along the pathways. The simultaneous 
interactions with HSP27 along the signaling pathways may enhance the activity of 
this signaling pathway and contribute to the higher cell growth in cgri-HSP27 
engineered CHO-mAb cells cultured in fed-batch bioreactors. 
These top five networks of pathways suggest that the differently regulated 
transcripts of cgri-HSP27 engineered CHO-mAb cells in fed-batch bioreactors are 
most likely connected to signaling pathways stimulated by extracellular ligands and 
their respective membrane receptors, affecting biological processes such as apoptosis, 
cell death and response to growth factors. Comparing to the previously isolated cgri-
HSP27 interacting targets (Akt, pro-Caspase 3 and Daxx), these pathway networks 






Figure 7.5 Network 5.                                                                                                                   
Network of signaling pathways generated from the differential transcriptome profile of cgri-
HSP27 engineered versus null vector engineered CHO-mAb fed-batch bioreactor cultures. 
Seed nodes are indicated by a blue circle. Canonical pathways fragments indicated by 
highlighted lines. Source: MetaCore™ (Thomas Reuters) 
 
7.2.3 Key Regulators of Transcriptome Profile 
Simultaneously, key regulators of the enriched biological gene functions and 
enriched signaling pathways identified in the first place were identified and compared 
against the list of probable cgri-HSP27 interacting targets  (Table 7.1). It is postulated 
that HSP27 is likely to interact with one of more of the key regulators of the 
transcriptome profiles cgri-HSP27 engineered CHO-mAb cells under fed-batch 
bioreactors conditions., regulate their gene processes and thus affecting the 
phenotypes. 
From the top five networks of signaling pathways discussed earlier (Figure 7.1-
7.5), ESR1nuclear appeared to be a key regulator of the transcriptome profiles of cgri-
HSP27 engineered CHO-mAbs cells cultured in fed-batch bioreactors. To find out 
what are the other possible key regulators of the transcriptome profiles, the list of 201 
differentially regulated transcripts previously obtained (Appendix 3) were inputted 
into MetaCore™ (Thomas Reuters) and ‘Transcription regulation function’ was used. 
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A  list of key regulators of the transcriptome profiles were generated, ranked by P-
value and interpreted by the GO processes involved (Table 7.2).  
Foremost on the list was CREB1, regulating 33% of the differentially regulated 
transcripts, followed by c-Myc, p53, SP1, GCR-a, Oct-3/4, ESR1 nuclear, Androgen 
receptor (AR) and NANOG which regulated 10-29% of the differentially regulated 
transcripts. The remaining key regulators involved 4-8% of the differentially 
regulated transcripts (Table 7.2). From the list, three key regulators (AR, SP1 and 
STAT3) were described to be direct interacting targets of HSP27 (Table 7.1) and the 
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HSP27 interactions with AR was reported to stabilize AR and facilitates its 
functions in prolonging cell growth and survival of prostate cancer cells [60, 67, 69, 
139]. SP1 has been reported to activate transcription of cell cycle inhibitors, p15 and 
p21 [140]. However, it was also reported to activate transcription of genes involved in 
promoting cell progression [141-143]. HSP27 interactions with SP1 was reported to 
enhance the activity of SP1 and contributed to protection of neurons [140]. 
Interestingly, upstream of SP1 signaling pathway, TGFB1l4 is identified as a possible 
cgri-HSP27 interacting target from a high throughput screen. It is part of the TGF-β 
signaling pathway and stimulation by growth and apoptosis factors induces 
transcriptional regulation activity of SP1 via Smad 2/4 to promote the growth arrest in 
the cells [142-144]. This suggests that cgri-HSP27 in CHO-mAb cells may interact 
with TGFB1l4 and SP1 to maintain cellular homeostasis of cell growth stimulated by 
TGF-β signaling. Hence, its effect on other cell proliferation, promoting signaling 
pathways is most likely more prevalent, so as to contribute to the higher viable cell 
density achieved by cgri-HSP27 engineered CHO-mAb cells cultured in a fed-batch 
bioreactor. HSP27 interaction of STAT3 was reported to stabilize STAT3 and 
enhance its activation of anti-apoptosis genes in many human pathological tissues and 
cells [67]. 
Based on the GO description, AR, SP1 and STAT3 regulates targets in the 
transcriptome profile of cgri-HSP27 engineered CHO-mAb fed-batch bioreactor 
cultures involved in cell cycle, development, proliferation and senescence (Table 7.2). 
These regulations affected by cgri-HSP27 may have contributed to the improved cell 
proliferation observed in cgri-HSP27 engineered CHO-mAb cells as compared to null 
vector engineered CHO-mAb cells cultured in fed-batch bioreactors.  
ESR1nuclear, a probable cgri-HSP27 interacting target identified in a high 
throughput screening experiment, was reported to regulate cell cycle genes that 
promote cellular proliferation and can be activated independent of its ligand, estrogen. 
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In the transcriptome profile analysis, it was present in the generated Network 4 and 5 
(Figure 7.4 and 7.5) where it was shown to be directly regulated by Akt and EGFR 
via Scr. In turn, ESR1nuclear regulated the transcripts differentially in cgri-HSP27 
engineered CHO-mAb cells as seen in Appendix 3. This suggests that ESR1nuclear may 
also be regulated by cgri-HSP27 interaction with other upstream targets than due to 
its direct interaction with cgri-HSP27. Notably, AR, SP1 and STAT3 were also 
shown to be regulated by ESR1nuclear in the generated networks of pathways. 
Similarily for NANOG, which was also identified in a high throughput screen 
experiment and was illustrated to be regulated by SP1 and STAT3. 
ATF2 was a probable cgri-HSP27 interacting target identified in a high 
throughput screen experiment and present in the list of key regulators (Table 7.2) that 
regulated the differently expressed transcripts. However, it was ranked at the bottom 
of the list because it involved only two differentially expressed transcripts and 
transcription regulation of these two transcripts by ATF2 have not been validated 
experimentally. This suggests that ATF2 may likely be a false positive cgri-HSP27 
interacting target evolved from the high throughput screen.  
NF-kβ is one of the key regulators identified (Table 7.2) to regulate the 
transcriptome profiles (Appendix 4) but not a target of HSP27 (Table 7.1). However, 
upstream of NF-kβ signaling cascade, several HSP27 interacting targets were present 
in the list of probable cgri-HSP27 interacting targets (Table 7.1). IKK-α, IKK-β and 
IKβ-α were validated experimentally to be true interacting targets of HSP27. Upon 
binding to HSP27, these three targets would activate the NF-Kβ signaling pathway 
[131,132]. IKK-α and IKK-β together with IKK-ɣ, which was identified in a high 
throughput screen, phosphorylate IKβ-α, leading it to be degraded by the proteosome 
and releasing NF-Kβ to be translocated to the nucleus to regulate its transcriptional 
activities of pro-survival and anti-apoptosis genes [145-147]. HSP27 has also been 
reported to bind to IKβ-α on its own, phosphorylating IKβ-α and leading it to the 
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proteosome for degradation [71]. All these interactions allowed for more freed NF-
Kβ to carry out its pro-survival and pro-proliferation regulation activities.  
Farther upstream, there are two potential cgri-HSP27 interaction targets. 
TRAF-6, an experimentally validated interacting target of HSP27 (Table 7.1), is also 
involved in the NF-Kβ signaling pathway. Its interaction with HSP27 caused it to be 
ubiquitinated for interaction with TAK1 and IKK-ɣ and resulted in an enhanced NF-
Kβ signaling pathway [67]. TAK1, an intermediate in the NF-Kβ signaling pathway, 
is a potential cgri-HSP27 interacting target identified in a high throughput screen 
(Table 7.1). TAK1 regulates the NF-Kβ signaling cascade by activating the IKK-
complex via phosphorylation [146, 147]. Similar to ErbB signaling pathways, HSP27 
may interact with multiple targets along the NF-Kβ signaling pathway to result in 
more freed NF-Kβ available to promote cell survival and cell growth. 
Noticeably, a handful of the key regulators in the list was known  to be 
regulated by Akt, pro-Caspase-3 and Daxx; validated HSP27 interacting targets 
identified in human and mouse cells and recently, in cgri-HSP27 engineered CHO-
mAb cells cultured in fed-batch bioreactors (Figure 6.2). It is suggested that Akt 
interaction with HSP27 leads to enhance activity of Akt and modulate its 
transcriptional activity [70, 85] which includes key regulators in the list: CREB1 
[148], SP1 [150], ESR1nuclear [150] and AR [69, 150] (Table 7.2). Daxx mediates 
activation of the JNK signaling pathway [151-153], which regulates several 
transcription factors leading to caspase-independent cell death. Daxx interaction with 
HSP27 inhibits activation of the JNK signaling and as such, affects the transcription 
regulation of the transcription factors downstream [86], which includes 12 of the key 
regulators in the list including c-Myc [154], p53 [155-157], SP1 [157] , Oct-3/4 [157] 
and AR [157, 158] (Table 7.2). Active Caspase-3 regulates the activity of several 
transcription factors via its proteolysis-cleavage functions [159-161]. pro-Caspase-3 
interactions of HSP27 inhibits the activation of Caspase-3, hence affecting the 
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cleavage of its substrates which includes CREB1 [161], SP1 [160]  and NANOG [159, 
162] from the list of key regulators (Table 7.2). 
Interestingly, some of the key regulators are known to -regulate other key 
regulators in the list and vice versa (e.g. ESR1nuclear and NF-ĸB regulates 
transcriptional activity of SP1, AR is regulated by both ESR1nuclear and SP1 and c-
Myc regulates p53, GCR-α, c-Jun and STAT3), and several of the differentially 
regulated transcripts are known to be regulated by more than one key regulator in the 
list (Table 7.2). This suggests crosstalk and transcription regulation collaboration 
between the transcription factors and resulted in the observation that not all of the 
differentially regulated transcripts were regulated and expressed in the expected 
direction. 
Overall, 14 potential cgri-HSP27 interacting targets in CHO-mAb cells that 
may contribute to improved cell growth and extended the culture duration were 
identified (Table 7.3). It is postulated that cgri-HSP27 can potentially modulate the 
apoptosis signaling pathway and cell cycle control simultaneously to enable better 
resistance to apoptosis and increase cell proliferation in cgri-HSP27 engineered 
CHO-mAb cells during fed-batch bioreactor cultures. The modulation by cgri-HSP27 
may have occurred before Day 3 of the fed-batch bioreactor cultures and continued 
till Day 5 or longer as the intensities of the differentially regulated transcripts 
remained relatively constant throughout. This suggests that constitutive expression of 
cgri-HSP27 enables cgri-HSP27 to interact with its targets and confer the associated 
cellular functions as opposed to stress-induced transient expression of cgri-HSP27. 






Table 7.3 Potential cgri-HSP27 interacting targets in CHO-mAb fed-batch bioreactor 
cultures identified based on transcriptome profiling study. 
 
 
7.3  Metabolic Profiling of cgri-HSP27 Engineered CHO-mAb Fed-batch 
Bioreactor Cultures 
Metabolomics is employed to study the metabolites involved in the cellular 
metabolism representing the phenotype observed. Cellular metabolism plays a role in 
regulating cell growth and apoptosis and metabolic pathways are often cross linked 
with cell cycle and apoptosis signaling pathways [163-165]. Since better cell 
proliferation and delayed onset of cell death were observed, it is postulated that cgri-
HSP27 may likely modulate the metabolic pathways, besides apoptosis signaling 
pathways; in cgri-HSP27 engineered CHO-mAb cells to achieve better culture 
performance in fed-batch bioreactors. However, the reverse may also be likely: the 
metabolite profiles observed was due to the enhanced cell proliferation and prolonged 
culture duration of cgri-HSP27 engineered versus null vector engineered CHO-mAb 
cells in fed-batch bioreactor cultures. There is, currently to our knowledge, no 
reported HSP27 interacting target that is involved specifically and directly in the 
cellular metabolism signaling pathway. 
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Therefore, the intracellular metabolite profiles were examined to investigate 
any potential metabolic pathways that may be affected in cgri-HSP27 engineered 
CHO-mAb cells or are affected by the enhanced proliferation and delayed dropped in 
culture viabilities during the fed-batch bioreactor cultures. The intracellular 
metabolite profiles were obtained from both cgri-HSP engineered and null vector 
engineered CHO-mAb fed-batch bioreactor cultures on Day 3, Day 4 and Day 5 
(Figure 5.5), together with the cell harvesting for transcriptome profiling analysis. On 
Day 3 and 4 of the fed-batch bioreactor cultures, both cell lines were at exponential 
growth phase where cell growth was optimal, viable cell densities at each day 
between the cell lines were similar, culture viabities were above 95% during both 
days, concentrations of extracellular metabolites were similar and nutrients were not 
limiting. Hence, the differences in metabolic profiles on Day 3 would be due to cgri-
HSP27 engineering. Cell growth, effects of extracellular nutrients and by-products, 
and possibility of dysfunctional mitochondria membrane induced by nutrients 
limitations, should not interfere with the intracellular metabolite profiles. 
Additionally, clonal variation will also not be captured as both cell lines had a similar 
growth profile up to Day 4, including Day 4. On Day 5 of the fed-batch bioreactor 
cultures, cgri-HSP27 engineered CHO-mAb cells continued to proliferate at 
exponential growth phase while null vector engineered CHO-mAb cells had entered 
the stationary growth phase while the culture viabilities remained above 95%. 
Nutrients deleption was not observed on Day 5. 
7.3.1 Intracellular Metabolite Profiles  
A total of 26 intracellular metabolites with putative identities had 
significantly differential intensity values between cgri-HSP27 engineered and null 
vector engineered CHO-mAb fed-batch bioreactor cultures by a ratio of more than or 
equal to ± 1.5 times on either of the 3 days with a P-value of less than 0.05 and were 
shortlisted for further analyses (Table 7.4) using MetaCore (Thomas Reuters). Out 
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of the 26 differential intracellular metabolites, 24 had identifications recognized by 
MetaCore (Thomas Reuters) metabolite library and thereafter, all further analyses 
were carried out based these 24 recognized metabolites (Table 7.4). 
 
Table 7.4 List of differential intracellular metabolites from cgri-HSP27 engineered 
versus null vector engineered CHO-mAb fed-batch bioreactor cultures.                                               
Metabolite not recognised by the database is indicated with an asterik. 
 
 
‘Analyse network algorithm function’ by MetaCore™ (Thomas Reuters) was 
used to identify networks of pathways that the 24 differential intracellular metabolites 
(Table 7.4) were most involved in. A total of 14 networks were generated (Appendix 
4), ranked accordingly to the number of classical pathways fragments present, P-
values and described by the GO processes the networks were involved in. The 
generated networks involved one to nine of the 24 differential intracellular 
metabolites inputted and nine of the generated networks have P-value less than 0.05. 
Five out of the nine generated networks did not involve any GO processes. It suggests 
that the differential intracellular metabolites present in cgri-HSP27 engineered versus 
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null vector engineered CHO-mAb fed-batch bioreactor cultures were not enriched in 
any specific metabolic pathways. 
Interestingly, Network 4 (Appendix 5) described by GO processes involved 
in response to oxidative stress, reactive oxygen species and homeostatic process 
contained mainly canonical pathways linking AMP cytoplasm. It contained two 
intracellular metabolites present in the input list, SOD1 and thioredoxin, in the 
network. HSP27 was reported to interact with SOD1 to prevent its aggregation and 
inactivation to regulate oxidative stress in the cells [166-169]. However, no other 
reactive oxidative stress involved metabolites were found to be present in differential 
intensities. Due to the low number of the differential intracellular metabolite present, 
this network of pathways may likely be a false positive. 
 
Conclusions 
14 potential cgri-HSP27 interacting targets involved in growth factor 
response, apoptosis signaling pathways and cell cycle control were identified (Table 
7.3) based on transcriptome profiling and compared against the exhaustive list of 
probable cgri-HSP27 interacting targets (Table 7.1). In concert with the observed 
phenotypic differences between cgri-HSP27 engineered and null vector engineered 
CHO-mAb fed-batch bioreactor cultures, and the validated cgri-HSP27 interacting 
targets, it is proposed that cgri-HSP27 can potentially modulate the apoptosis 
signaling pathway and regulated cell cycle control by interaction with multiple targets, 
resulting in enhanced cell growth and prolonged culture duration. This is illustrated in 
Figure 7.6. Future studies will be needed to establish and validate these potential 
interacting partners. 
Furthermore, looking at the cgri-HSP27 interacting network in CHO-mAb 
cells during fed-batch bioreactor cultures (Figure 7.6), the mitochondria-mediated 
apoptosis signaling pathway was the least affected. Cytochrome c was detected in the 
cell lysate of cgri-HSP27 engineered CHO-mAb cells during the exponential growth 
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phase of the fed-batch bioreactor cultures (Figure 6.2), indicating that the 
mitochondria membrane integrity may have been compromised during the 
exponential growth phase of fed-batch bioreactor cultures and may likely activate the 
onset of apoptosis. Besides Cytochrome c, other apoptosis inducing proteins, 
including AIF and SMAC/DIABLO are released from the mitochondria to induce 
caspase-dependent or independent cell death. Hence it is postulated that modulating 
the mitochondria-mediated apoptosis signaling pathway of cgri-HSP27 engineered 
CHO-mAb cell line may further delay the onset of apoptosis, resulting in extended 
culture duration and subsequently, even higher increased in recombinant mAb titers 
during fed-batch bioreactor cultures. Possible cell line engineering candidates would 
be Bcl-2 or Bcl-xL. Both of these anti-apoptotic proteins have been shown to 
maintain the mitochondria membrane integrity during stress to delay release of 
Cytochrome c and other apoptosis inducing proteins in CHO cells. Additionally, the 
mitochondrion is responsible for the cells main metabolic pathways, including TCA 
cycle, pentose phosphate pathway, glycolysis, fatty acid oxidation and urea cycle. By 
preventing the deterioration of the mitochondria membrane, apoptosis induced by 








Figure 7.6 Proposed schematic illustration of cgri-HSP27 protein-protein interactions and molecular roles in the apoptosis and growth factor 
response signaling pathways.  
Shaded box represents validated cgri-HSP27 interacting targets. Star represents cgri-HSP27 and the potential interacting target.
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CHAPTER 8 Conclusions & Recommendations 
 
8.1 Conclusions  
 Constitutive overexpression of cgri-HSP27 in CHO cells producing 
recombinant mAbs has resulted in higher maximum viable cell density and extended 
the culture duration when cultured in an industry-relevant culture mode, fed-batch 
bioreactor. These improvements contributed to a 160% increase in recombinant mAb 
titer. Furthermore, the subsequent characterization of the N-glycosylation quality of 
the recombinant mAb produced by cgri-HSP27 engineered CHO-mAb in fed-batch 
bioreactor cultures showed that they were not compromised. Together with the 
previous application in CHO cells producing recombinant human IFNɣ fed-batch 
bioreactor cultures, another class of recombinant biologics, the generic applicability 
of cgri-HSP27 overexpression strategy in producing two distinct classes of biologics 
in two different parental CHO host cell lines under fed-batch bioreactor systems has 
been successfully demonstrated.   
 One of the cellular functions of cgri-HSP27 that is likely to contribute to the 
higher viable cell density and delayed loss of culture viability during fed-batch 
bioreactor cultures was the regulation of apoptosis cell death. cgri-HSP27 interaction 
with Akt, pro-Caspase-3 and Daxx were validated in the CHO cells under fed-batch 
bioreactor cultures conditions and are most likely the avenue by which cgri-HSP27 
impart its anti-apoptosis cellular functions to the CHO cells. Concomitantly, activities 
of Caspase-2, -3, -8 and -9 were delayed. The regulation of apoptosis by cgri-HSP27 
were further supported by the global transcriptome profiling of cgri-HSP27 
engineered CHO-mAb cells during the exponential growth stage of the fed-batch 
bioreactor cultures, where the differentially regulated genes were enriched in 
signaling pathways regulating apoptosis. These observations provided a greater 
understanding of cgri-HSP27 in the CHO cells bioprocessing context and further 
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complement the current knowledge of HSP27 in other mammalian cell lines besides 
human and mouse cell lines and other stress conditions. 
Nevertheless, cgri-HSP27 can potentially interact with more of its interacting 
targets besides the three validated interacting targets to attribute to its anti-apoptosis 
functions and other cellular functions that may cross-modulate to contribute to the 
enhanced cell growth and extended the culture duration, resulting in the greatly 
increased recombinant mAb titer. Studies based on transcriptome profiling and 
metabolic profiling were carried out on the cgri-HSP27 CHO-mAb fed-batch 
bioreactor cultures and 14 potential cgri-HSP27 interacting targets (Figure 7.6) 
involved in the apoptosis and cell cycle signaling pathways were identified. These 
targets may likely contribute to the improved culture phenotype observed.  
 
8.2 Recommendations 
 The following recommendations are suggested for future research: 
 
8.2.1 Verification of Identified Potential cgri-HSP27 Interacting Targets in 
CHO-mAb Cells  
 Confirmation of the identified probable interacting targets of cgri-HSP27 in 
cgri-HSP27 engineered CHO-mAb fed-batch bioreactor cultures likely contributed to 
the improved recombinant mAb titer is recommended. It will further increase the 
understanding of cgri-HSP27 cellular functions in CHO-mAb cells under fed-batch 
bioreactor stress conditions and enable identification of pathways that are least 
affected in CHO-mAb cells during fed-batch bioreactor cultures as targets for further 
cell line engineering of cgri-HSP27 engineered CHO-mAb cells. 
 
8.2.2 Understanding the Difference in Culture Improvements of cgri-HSP27 
Engineered CHO-IFNɣ and cgri-HSP27 Engineered CHO-mAb cells   
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 In Chapter 5, it was observed that cgri-HSP27 engineered CHO-mAb cells 
gained higher viable cell density and extended the culture duration in fed-batch 
bioreactor cultures. However, in the previous study done on CHO cells producing 
human IFNɣ, only the extension of culture duration was observed when cultured 
under similar fed-batch bioreactor system and conditions [36].  
The apoptosis transcription profiling of CHO cells producing recombinant 
human IFNɣ fed-batch bioreactor cultures states that the effect of the recombinant 
IFNɣ on inducing apoptosis in CHO cells seems unlikely [33] hence other effects of 
IFNɣ on mammalian cells were looked into. IFN is known to have anti-proliferative 
and growth inhibition effects on cells via activation of the JAK/STAT1 signaling 
pathway, leading to the up-regulation of cyclin-dependent kinase (CDK) inhibitors, 
p21cip and p27kip, and causing cell cycle arrest at G1/S checkpoint [170]. Up-
regulation of p21cip and p27kip also suppresses the remodelling and rearrangement of 
the cytoskeleton, which is involved in cell division, cell proliferation and transduction 
of cellular signaling pathways [140]. Additionally, IFNɣ is reported to up-regulate 
Mad1, which counteracts the function of c-Myc, to inhibit cell proliferation [170]. On 
the other hand, there are no known reports, to our knowledge, on recombinant anti-
Rhesus D IgG mAb having anti-proliferative and anti-apoptosis effect on mammalian 
cells. Thus, it is postulated that the recombinant human IFNɣ produced in CHO cells 
may have affect proliferation by inhibiting cell cycle and preventing rearrangement of 
cellular actin cytoskeleton and ‘compete’ with cgri-HSP27 for interaction with 
proteins involved in cell cycle, which reduces the effects of cgri-HSP27 in improving 
cell growth that was not observed in cgri-HSP27 engineered CHO-IFN fed-batch 
bioreactor cultures. Whereas, cell proliferation enhancing cellular function of cgri-
HSP27 are most likely not affected in CHO-mAb cells, as observed by the higher 
viable cell density achieved by cgri-HSP27 engineered CHO-mAb fed-batch 
bioreactor cultures. Further studies will be needed to verify this hypothesis. 
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Understanding the difference may potentially be useful when applying the cgri-
HSP27 overexpression strategy to CHO cells lines producing other classes of 


































AIF  Apoptosis inducing factor 
Apaf-1   Apoptotic protease activating factor 1 
AR  Androgen receptor 
ASK  Apoptosis stimulating kinase 
ATF2   Activating transcription factor 2 
Bad   Bcl-2-associated death promoter 
Bax   Bcl-2-like protein 4 
Bcl2  B-cell lymphoma 2 
Bcl-xL  B-cell lymphoma-extra large 
Bid   BH3 interacting-domain death  
Bim   BCL2-Like 11  
Cgri  Cricetulus griseus  
CHO  Chinese Hamster Ovary 
Co-Ip  Co-Immunoprecipitation 
CREB1  cAMP responsive element binding protein 1 
c-Myc  V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
c-Jun   Jun Proto-Oncogene 
Daxx   Death-associated protein 6 
DAVID  Database for Annotation, Visualization and Integrated Discovery 
Dhfr-  Dihydrofolate reductase negative 
DO  Dissolved oxygen 
ECL  Enhanced chemiluminescent 
ErbB1   Epidermal growth factor receptor 
ESI  Electrospray ionization 
ESR1-nuclear Estrogen Receptor 1 
FADD   Fas-Associated protein with Death Domain 
FAIM   Fas apoptotic inhibitory molecule 
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Fas   TNF Receptor Superfamily, Member 6 
FDA  Food and Drug Administration 
GATA-1  Erythroid transcription factor 
GCR-  Glucocorticoid receptor  
GO  Gene ontology 
HDM2   E3 ubiquitin-protein ligase Mdm2 
Her2  Human epidermal growth factor receptor 2 
Hsap  Homo sapiens 
HRP  Horse-radish peroxide 
HSP27   Heat Shock Protein 27 
IFN  Interferon gamma 
IK-  NF-kappa-B inhibitor alpha 
IKK   Inhibitor of nuclear factor kappa-B kinase subunit alpha 
IKK    Inhibitor of nuclear factor kappa-B kinase subunit beta 
IKK   Inhibitor of nuclear factor kappa-B kinase subunit gamma 
IRES  Internal ribosome entry site 
IVCD  Integrated viable cell density 
JNK   c-Jun NH2-terminal kinases 
LDS  Lithium dodecyl sulfate 
MALDI-TOF Matrix-assisted laser desorption ionization-time of flight 
Mmus  Mus musculus  
mAb  Monoclonal antibody 
MS  Mass spectrometry 
NF-K   Nuclear factor kappa-B 
Oct 3/4  Octamer-binding transcription factor 3 alternative variant 
p15   CDKN2B cyclin-dependent kinase inhibitor 2B 
p21   Cyclin-dependent kinase inhibitor 1 
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p53   Tumor protein 53 
Pea-15   Phosphoprotein Enriched In Astrocytes, 15kDa 
PI3-K   Phosphatidylinositol-3-kinases 
PTEN   Phosphatase and tensin homolog 
Qp  Specific productivity 
Qammonium Specific ammonium production rate 
Qglucose Specific glucose consumption rate 
Qglutamine  Specific glutamine consumption rate 
Qlactate  Specific lactate production rate 
qRT-PCR Quantitative Real-Time Polymerase Chain Reaction 
RIPA  Radio-immunoprecipitation assay  
RT-PCR  Reverse transcription polymerase chain reaction. 
SOD1   Superoxide dismutase 
Sox2   SRY (sex determining region Y)-box 2 
SP1  Specificity Protein 1 
STAT2  Signal transducer and activator of transcription 2 
STAT3  Signal transducer and activator of transcription 3 
TAK1   Transforming growth factor beta-activated kinase 1 
TRAF-6  TNF receptor-associated factor 6 
TGF-  Transforming growth factor-beta 
TGF1I4  Transforming growth factor beta 1 induced transcript 4 
TNF-  Tumor necrosis factor-alpha 
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Growth profiles of HSP27 engineered versus null vector engineered versus untransfected 




(A) Viable cell density and (B) culture viability and (C) cumulative IVCD were monitored 
and calculated daily (n=1; error bars denote standard deviation of duplicate technical 





































Growth and recombinant mAb production profiles of HSP27 engineered versus null 




(A) Viable cell density and (B) culture viability and (C) mAb titer were monitored and 
calculated daily (n=1; error bars denote standard deviation of duplicate technical replicates 
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1  Introduction
In 1987, Activase, an anti-coagulant used for the treat-
ment of acute myocardial infarction, became the first
approved recombinant biologic produced from Chinese
hamster ovary (CHO) cells. Since then, CHO cells have
been used for production of many different classes of bio-
logics such as blood factors, cytokines, fusion proteins,
growth factors, hormones, monoclonal antibodies (mAbs)
and therapeutic enzymes. In recent years, recombinant
mAbs produced in CHO cells were among the top best-
selling biologics and approximately 40 newly US Food and
Drug Administration (FDA) approved recombinant mAbs
were made available in the market [1]. As the demands for
recombinant mAbs continue to grow, there is continual
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need for robust CHO production cell lines with maximized
product titers. Furthermore, with the emergence of inno-
vative biologics and biosimilars in the market [2], differ-
ent CHO production cell lines are most likely to be used as
production hosts of reference biologics are propriety
knowledge [3]. To meet these needs, this current study
presents the use of a cell line engineering strategy to
improve recombinant mAbs production in CHO cells.
An in-house apoptosis transcriptome profile of CHO
fed-batch bioreactor cultures established that the expres-
sion of heat shock protein (HSP) 27 was down-regulated
towards the late-exponential and stationary growth
phase. HSP27 is a small 27 kDa stress inducible HSP locat-
ed mainly in the cytosol and functions primarily as a
molecular chaperone where it aids in preventing aggre-
gation of proteins and participates in the refolding of mis-
folded proteins with the help of other molecular chaper-
ones [4]. Recent studies on human pathological tissues
and cell lines such as U937, THP-1 and MCF-1 reported
high expression of HSP27. In response to a variety of dif-
ferent apoptotic insults, the high expression level of
HSP27 was demonstrated to modulate the apoptosis sig-
naling pathways and resulted in increased resistance to
apoptotic cell death [5, 6]. The link between high HSP27
expression and the observed apoptosis-resistant pheno-
types was HSP27 interactions with targets along the
apoptosis signaling pathways: Akt [7], cytochrome c
released from dysfunctional mitochondria [8], inactive
form of caspase 3, pro-caspase 3 [9] and Daxx [10]. 
Henceforth, it was hypothesized that engineering
CHO production cell lines with overexpression of HSP27
can increase robustness of CHO fed-batch bioreactor
processes by delaying apoptotic cell death and result in
higher recombinant biologics yield. Earlier overexpres-
sion of HSP27 in CHO-DxB11 cells resulted in extension of
fed-batch bioreactor culture duration and increased
recombinant human interferon gamma (IFN-γ) yield [11].
This paper reports on the application of HSP27 overex-
pression strategy in CHO-DG44 cells producing a recom-
binant IgG mAb against Rhesus D antigen [12]. To date,
besides the reported delayed increase in caspase activi-
ties in CHO-IFN-γ fed-batch bioreactor cultures [11], no
other mechanistic studies on HSP27 anti-apoptotic roles
in CHO fed-batch bioreactor cultures have been reported.
Hence, an attempt to further expand this limited knowl-
edge by validating HSP27-interacting apoptosis targets
in CHO-DG44 cells producing recombinant mAb based
on human and mouse cell line studies is also reported.
2  Materials and methods
2.1  Cell culture
CHO-mAb 2.11 subclone M250-9, a CHO-DG44-derived
suspension cell line expressing a recombinant secreted
humanized IgG monoclonal antibody against Rhesus D
antigen [12] was used and referred to as CHO-mAb in 
this study. The cells were maintained in a protein-free
media mixture consisting of a 1:1 ratio of HyQ-PF-CHO
(HyClone-GE Healthcare, Sweden) and CD CHO (Life
Technologies, USA), supplemented with 6 mM glutamine
(Sigma-Aldrich, USA), 0.05% Pluronic F-68® (Life Tech-
nologies), 600 μg/mL Geneticin® (Life Technologies) and
250 nM methotrexate (Sigma-Aldrich). Cells were grown
in shake flasks maintained at 37oC, 8% CO2 atmosphere
on an orbital shaker maintained at 110 rpm with shaking
amplitude of 12.5 mm, and subcultured every three to four
days with exponentially growing cells at seeding viable
cell concentration of 3.0 × 105 cells/mL and starting cul-
ture volume of 20 mL. 
2.2  Generation of expression vectors
To generate the control null vector pIRES2, the truncated
internal ribosome entry site (IRES) fragment from mam-
malian expression vector, pIRES (Clontech Laboratories,
USA), was replaced with that from mammalian expres-
sion vector, pIRES-DsRedExpress (Clontech Laborato-
ries), using restriction enzymes, EcoR I and Xba I (Sup-
porting information, Fig.  S1A). The neomycin selection
marker was then replaced with hygromycin selection
marker from vector pcDNA 3.1-hyg (Life Technologies)
using restriction enzymes, Stu I and Bst BI. To generate
vector pIRES2-27 for overexpression of HSP27, the coding
region of CHO-K1 HSP27 from pIRES-27 vector [11] was
digested using restriction enzymes, Nhe I and Xho I, and
inserted into multiple cloning site A of pIRES2 vector
(Supporting information, Fig.  S1B). To ensure efficient
translation, a Kozak sequence, GCCGCC, was placed
upstream of the HSP27 start codon. 
2.3  Generation of stable HSP27-overexpressing
CHO cells
CHO-mAb cells were stably transfected with pIRES2 and
pIRES2-27 expression vectors to obtain stable p2.Blank
and p2.27 CHO-mAb cells respectively. Briefly, transfec-
tion was performed using Lipofectamine® 2000 reagent
(Life Technologies), as per manufacturer’s instructions, in
six-well culture plates under static condition and expand-
ed into shake flasks, upon confluence, at conditions
described in Section 2.2. Pools of stable transfectants
were obtained after 14 days of culturing under 300 μg/mL
hygromycin (Clontech Laboratories) selection pressure
and expanded thereafter under 100 μg/mL hygromycin
reduced selection pressure for banking, initial assess-
ment in batch shake flasks and single cell cloning. For
batch shake flasks assessment, the exponentially grow-
ing cells were seeded at viable cell concentration of
3.0  ×  105 cells/mL with a starting culture volume of
130 mL. Viable cell concentration, culture viability, recom-
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binant mAb titer and extracellular metabolite concentra-
tions were monitored off-line daily till culture viability
dropped below 50%. Concurrently, single cell clones were
obtained from the respective stable transfected cell pools
for evaluation in fed-batch bioreactors by seeding one cell
per well in 96-well plates using limiting dilution. Wells
containing more than one cell were excluded and half of
the media in each of the remaining wells were replaced
twice weekly. Surviving clones, upon reaching conflu-
ence, were expanded into shake flasks for banking and
selected clones evaluated in fed-batch bioreactors. 
2.4  Fed-batch bioreactor set-up 
and feeding strategy
Fed-batch bioreactor systems of 1.5-L working volume
were set up and performed as previously described [11].
Two separate feeds were used; a glucose-free, protein-
free feed formulated based on a fortified 10X DMEM/F12
(Sigma-Aldrich) supplemented with 10  g/L of soybean
protein hydrolysate (Kerry, USA) and a 180  g/L glucose
feed (Sigma-Aldrich). Feed-forward control strategy was
employed to achieve discrete control of glutamine and
glucose concentrations at set points of 0.04  g/L and
0.5 g/L respectively. Briefly, based on pre-determined glu-
tamine and glucose specific consumption rates during
exponential growth phase, projected amount of glutamine
and glucose that will be consumed by the cells until the
next forecasted sampling time was fed at pre-set intervals
of 90 min. 
2.5  Analysis of cell growth, extracellular metabolite
concentrations and recombinant mAb titer
Viable cell concentration was determined by manual cell
counting using an Improved Neubauer haemocytometer
(Weber, England) and culture viability was estimated
based on the trypan blue exclusion method. Integrated
viable cell density (IVCD) was calculated using the for-
mula: IVCD = 0.5(t2 – t1) (x1 + x2), where t is the culture
time (h) and x is the viable cell concentration (cells/mL).
Concentrations of extracellular metabolites (glucose, glu-
tamine, lactate and ammonium) were determined by
analysing spent media offline using the YSI 7100 bio-
chemical analyser (Yellow Spring Instruments, USA).
Recombinant mAb titers were determined using an
IMMAGE 800 immunochemistry system (Beckman Coul-
ter, USA) based on nephelometry method, according to
manufacturer’s instructions.
2.6  Detection of caspase 2, 3, 8 and 9 activities
2.0 × 106 cells were collected at every 24 h intervals from
the fed-batch bioreactor cultures until cultures viabilities
dropped below 80%. Caspase 2, 3, 8 and 9 activities were
detected as previously described [11]. 
2.7  Quantitative real-time polymerase chain
reaction (qRT-PCR) 
1.0 × 107 cells were collected on day 3 of the batch shake
flask cultures and total RNA was extracted using Trizol™
reagent (Life Technologies) as per manufacturer’s instruc-
tions. Total RNA extracted was quantified using
GeneQuant™ Pro RNA/DNA Calculator (GE Healthcare),
followed by reverse transcription using 1 μg of total RNA
and the Improm-II™ Reverse Transcription System
(Promega, USA) as per manufacturer’s instructions. The
resulting first strand cDNA was used in equal amount for
qRT-PCR carried out using ABI PRISM 7000 Sequence
Detection System (Life Technologies) with SYBR Green
PCR Master Mix (Life Technologies). Gene expression lev-
els of HSP27 and pIRES2-27 expression vector were eval-
uated. Duplicate runs were conducted per sample and
normalized against β-actin (U20114). Fold change in gene
expression was calculated using the delta-delta threshold
cycle method as described in [13]. Primers used are listed
in Supporting information, Table S1. 
2.8  Semi-quantitative reverse-transcriptase PCR
(RT-PCR) 
1.0 × 107 cells were collected on day 3 of the batch shake
flask cultures and total RNA was extracted using
RNeasy™ mini kit (Qiagen, Netherlands) as per manufac-
turer’s instructions. Total RNA extracted was quantified
using NanoDrop™ 2000 UV-VIS spectrophotometer
(Thermo Scientific, USA), followed by RT-PCR with 1 μg
of total RNA using OneStep™ RT-PCR kit (Qiagen) as per
manufacturer’s instruction. Gene expression levels of
HSP27 and pIRES2-27 expression vector were evaluated
and normalized against β-actin. The RT-PCR exponential
phase was determined at 26 cycles and the amplified 
RT-PCR products were subjected to electrophoresis for
visualization on a 1.5% agarose gel containing 0.05 μg/mL
of ethidium bromide, followed by UV analysis using the
InGenius3 system (Syngene, UK). Primers used are listed
in Supporting information, Table S1.
2.9  Western blots 
1.0 × 107 cells were collected, washed once with ice-cold
1× phosphate buffered saline solution (Life Technologies)
and lysed in radio-immunoprecipitation assay (RIPA)
buffer (Pierce-Thermo Scientific, USA) supplemented
with 1× Complete™ protease inhibitor cocktail (Roche,
Switzerland) for 40 min on ice with intermittent vortexing.
The complex mixture was centrifuged at 14 000 rpm for
20 min at 4oC to obtain total cellular proteins in suspen-
sion and quantified using BCA Protein Assay kit as per
manufacturer’s instructions (Pierce-Thermo Scientific).
Equal amount of total cell lysate was treated with 1× lithi-
um dodecyl sulphate (LDS) sample buffer (Life Technolo-
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gies), denatured for 5 min at 95oC, separated on 10% Bis-
Tris gel (Life Technologies) and transferred onto iBlot™
nitrocellulose membranes (Life Technologies). The mem-
brane was then probed for HSP27 and β-actin using rab-
bit anti-HSP27 (#06-517, Upstate-Merck Millipore, Ger-
many) and mouse anti-β actin (ab8226, Abcam, England)
antibodies respectively. The primary antibodies were
detected using horse radish peroxide (HRP)-conjugated
anti-rabbit (ab6721, Abcam) and HRP-conjugated anti-
mouse HRP (ab6728, Abcam) respectively, visualized
using enhanced chemiluminescent (ECL) substrate (GE
Healthcare) for HRP and captured on ImageQuant LAS
500 imager system (GE Healthcare). The antibodies were
verified and shown to work for CHO cellular proteins pri-
or to use.
2.10  Co-immunoprecipitation (Co-IP) 
1.0 × 107 cells were collected, washed twice with ice-cold
1× phosphate buffered saline solution (Life Technologies)
and lysed by mechanical pipetting in lysis buffer contain-
ing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet
P40, 0.5% sodium deoxycholate, 1× Complete™ protease
inhibitor cocktail and 1× PhosSTOP™ phosphatase
inhibitor cocktail (Roche). The mixture was then cen-
trifuged at 13 000 rpm for 10 min at 4oC to collect the total
cellular proteins containing the protein-protein interac-
tion complexes in suspension and quantified using the
BCA Protein Assay kit as per manufacturer’s instructions
(Pierce-Thermo Scientific). Protein samples were pre-
cleared by incubating with 100 μL of Protein G agarose
beads suspension (Roche), for 3 h at 4oC with constant
mixing. Pre-cleared protein samples were collected after
centrifugation at 13 000  rpm for 20  s before incubating
overnight with mouse anti-HSP27 (sc13132, Santa Cruz,
USA) or anti-mouse (sc2025, Santa Cruz) antibodies
respectively in separate tubes at 4oC with constant mix-
ing. 100 μL of Protein G agarose beads suspension was
then added followed by further incubation for 3 h at 4oC
with constant mixing. The bead complexes were washed
sequentially twice with lysis buffer, followed by twice
with buffer containing 50 mM Tris-HCl pH 7.5, 500 mM
NaCl, 0.1% Nonidet P40 and 0.05% sodium deoxycholate
and once with buffer containing 10 mM Tris-HCl pH 7.5,
0.1% Nonidet P40 and 0.05% sodium deoxycholate. Pro-
tein complexes retained on beads were eluted by incu-
bating with 1× LDS sample buffer for 5 min at room tem-
perature, followed by incubating at 95oC for 5 min. Eluted
proteins were separated from the Protein G agarose beads
by centrifuging at 13 000 rpm for 20 s. The eluted proteins
and total cellular proteins were separated on 4–12% Bis-
Tris gel and transferred onto iBlot™ nitrocellulose mem-
branes. The membranes were then probed for Akt,
cytochrome c, Daxx, HSP27 and pro-caspase 3 using rab-
bit anti-Akt (#9272, Cell Signalling Technology, USA), rab-
bit anti-cytochrome c (#4280, Cell Signalling Technology),
rabbit anti-Daxx (#07-471, Upstate-Merck Millipore), rab-
bit anti-HSP27 (#06-517, Upstate-Merck Millipore) and
rabbit anti-pro-caspase 3 (#9662, Cell Signalling Technol-
ogy) antibodies respectively. The antibodies were diluted
in blocking buffer (1× Tris Buffered Saline, 0.1% Tween20
and 3% BSA) except rabbit anti-cytochrome c was dilut-
ed in Signal Enhancer HIKARI Solution A (Nacalai
Tesque, USA). The primary antibodies were detected
using HRP conjugated anti-rabbit (ab6721, Abcam) dilut-
ed in blocking buffer or Signal Enhancer HIKARI Solution
B (Nacalai Tesque) for detection of rabbit anti-cytochrome
c, visualized using ECL substrate (GE Healthcare) for HRP
and captured on ImageQuant LAS 500 imager system.
The antibodies were verified and shown to work for CHO
cellular proteins prior to use.
2.11  N-glycan profiling of purified recombinant
monoclonal antibody
The recombinant mAb present in the fed-batch bioreac-
tor cultures spent media were purified using a Tricorn
5/150 Protein A column packed with MabSelect SuRe (GE
Healthcare). The N-glycan distribution of the purified
recombinant mAb was analysed using matrix-assisted
laser desorption ionization-time of flight mass spectrom-
etry (MALDI-TOF MS) before categorization as described
previously [14]. 
3  Results 
3.1  Generation of stable HSP27-overexpressing
CHO-mAb cell pools and evaluation in batch
shake flask culture
CHO-mAb cells were maintained in culture for 12.5 weeks
before being transfected either with control null vector
pIRES2 or HSP27-overexpressing vector pIRES2-27 for 
the generation of p2.Blank cells and p2.27 CHO-mAb 
cells respectively. Stably transfected p2.Blank and p2.27
CHO-mAb cell pools were obtained after two weeks of
selection in hygromycin-supplemented culture media
and expanded for another two and a half weeks before
banking and initial assessment in batch shake flasks. 
To verify that HSP27 was overexpressed in the p2.27
CHO-mAb cell pool, qRT-PCR and Western blot analyses
were performed on day 3 of the batch shake flask cultures.
Higher HSP27 gene and protein expression level was
detected in p2.27 CHO-mAb cell pool compared to
p2.Blank CHO-mAb cell pool, confirming that p2.27 
CHO-mAb cell pool was overexpressing HSP27 (Support-
ing information, Fig. S2). 
As an initial assessment of whether HSP27 overex-
pression can improve CHO-mAb batch shake flask cul-
ture performance, stably transfected CHO-mAb cell pools
were evaluated under hygromycin selection pressure
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(Fig.  1). This assessment on the stably transfected cell
pools also served to eliminate possible artefacts from clon-
al selection. To assess the effect of transfection and
hygromycin selection on the transfected cell pools, the
growth and production curves from the untransfected
CHO-mAb cells cultivated without hygromycin selection
was also determined. 
Comparing the p2.Blank CHO-mAb cell pool with the
untransfected CHO-mAb cells, it was observed that while
these cells had similar growth profiles (Fig. 1A and B), the
recombinant mAb titer of the p2.Blank CHO-mAb cell
pool was 30% lower than that of the untransfected CHO-
mAb cells (Fig. 1D), demonstrating that the transfection
process and the presence of hygromycin in the culture
medium have negatively affected the recombinant mAb
production in the transfected cell pool. This may be due
to the non-specific inhibitory effect of hygromycin on the
p2.Blank CHO-mAb cells, and post-transfection chromo-
somal rearrangements in stably transfected cell pools that
may have occurred during the stable transfection process,
especially since CHO cells are prone to spontaneous
mutations when under selection pressure or stressful con-
ditions [15, 16]. Notably, the effect of stable selection can
also be observed from the differences in extracellular
metabolite profiles of the untransfected and transfected
cell pools (Supporting information, Fig. S3).
On the other hand, the p2.27 CHO-mAb cell pool
achieved 76 and 110% higher maximum viable cell con-
centration compared to p2.Blank CHO-mAb cell pool and
untransfected CHO-mAb cells respectively (Fig. 1A) and
sustained at high culture viability of above 80% for an
additional one day (Fig. 1B). These growth improvements
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Figure 1. Characterization of stably transfected CHO-mAb cell pools and untransfected CHO-mAb cells in batch shake flasks. Stably transfected HSP27-
overexpressing CHO-mAb cell pool (p2.27; black triangles) and stably transfected null vector-overexpressing CHO-mAb cell pool (p2.Blank; grey circles)
were cultivated in hygromycin-containing selection media. The untransfected CHO-mAb cells (unfilled squares) were cultivated in hygromycin-free non-
selecting media. Exponentially growing cells were seeded at viable cell concentration of 3.0 × 105 cells/mL with a starting culture volume of 130 mL. 
(A) Viable cell concentration, (B) culture viability, (C) cumulative IVCD were monitored off-line daily till culture viability dropped below 50%. (D) Recombi-
nant mAb titers were quantified on day 9 of the batch shake flask cultures. N=1 and the error bars represents the SD from the mean of technical triplicates.
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lead to 70 and 84% higher maximum cumulative IVCD of
10.0  ×  108 cells-h/mL compared to p2.Blank CHO-mAb
cell pool and untransfected CHO-mAb cells respectively
(Fig. 1C). It is postulated that the inhibition of apoptosis
by HSP27 may be a likely mechanism for the observed
growth improvements in p2.27 CHO-mAb cell pool batch
shake flask cultures: while p2.Blank CHO-mAb cell pool
and untransfected CHO-mAb cells entered death phase
due to culture stress after day 5, overexpression of HSP27
(Supporting information, Fig. S2) may have prevented the
same from happening to the p2.27 CHO-mAb cell pool to
allow further proliferation of these cells. With the improve-
ment in cumulative IVCD, the p2.27 CHO-mAb cell pool
achieved a 38% higher recombinant mAb titer (Fig. 1D)
that that of p2.Blank CHO-mAb cell pool although the
recombinant mAb specific productivity of p2.27 CHO-
mAb cell pool was also negatively affected by the trans-
fection process and the presence of hygromycin in the
culture medium. 
3.2  Fed-batch bioreactor culture performance of
HSP27-overexpressing CHO-mAb cell clones
Next, effects of HSP27 overexpression on cell growth 
and recombinant mAb production characteristics of
CHO-mAb fed-batch bioreactor cultures were evaluated
(Fig. 2). As the stably transfected cell pools are hetero-
geneous in population, single cell clones are preferred for
better consistency in fed-batch bioreactor cultures.
 Limiting dilution was thus carried out and three p2.27
CHO-mAb clones (p2.27-1, p2.27-2 and p2.27-3) were
selected out of 23 clones based on HSP27 expression,
cell growth and recombinant mAb production profiles in
batch shake flasks (Supporting information, Fig.  S4).
Three p2.Blank CHO-mAb clones (p2.Blank-1, p2.Blank-
2 and p2.Blank-3) were selected out of 15 clones as con-
trols in later fed-batch bioreactors evaluation. The
selected p2.Blank CHO-mAb clones had lower HSP27
expression level compared to p2.27 CHO-mAb clones
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Figure 2. Characterization of selected p2.27 and p2.Blank CHO-mAb
clones in fed-batch bioreactors. Stably transfected HSP27-overexpressing
CHO-mAb clones (p2.27; triangles) and stably transfected null vector-
overexpressing CHO-mAb clones (p2.Blank; circles) were cultivated in
hygromycin-containing selection media. Exponentially growing cells were
seeded at viable cell concentration of 3.0 × 105 cells/mL with a starting
culture volume of 1.5 L. (A) Viable cell concentration, (B) culture viability, 
(C) cumulative IVCD and (D) recombinant mAb titer were monitored off-
line daily till culture viability dropped below 50%. N=1 and the error bars
represent the SD from the mean of technical triplicates. (E) HSP27 expres-
sion levels at late exponential and stationary growth phase were analyzed
using Western blots. The same blot was probed for β-actin as loading con-
trol. Western blot shown here is of p2.27-3 and p2.Blank-3, representative
of the other p2.27 and p2.Blank CHO-mAb clones.
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(Supporting information, Fig,  S4). Notably, p2.Blank-2
had similar maximum cumulative IVCD and recombi-
nant mAb titer compared to the three selected p2.27
CHO-mAb clones in batch shake flasks (Supporting
information, Fig. S4).
Compared to fed-batch bioreactor cultures of p2.Blank
CHO-mAb clones, p2.27 CHO-mAb clones achieved 
2.2-fold higher maximum viable cell concentration of 
2.0 ± 0.2  ×  107 cells/mL (Fig.  2A) and sustained for an
additional average of two days at culture viabilities above
80% (Fig. 2B). These growth improvements led to a 2.5-
fold higher maximum cumulative IVCD of 2.0 ± 0.5 × 109
cells-h/mL (Fig. 2C) and 2.3-fold higher recombinant mAb
titer of 1146 ± 451 mg/L (Fig. 2D) compared to p2.Blank 
CHO-mAb clones fed-batch bioreactor cultures. All the
clones in fed-batch bioreactor cultures had similar aver-
age specific recombinant mAb productivities. Figure 2E
shows that HSP27 remained highly expressed in the 
late-exponential and stationary growth phase of p2.27 
CHO-mAb clones cultured in fed-batch bioreactors as
compared to p2.Blank CHO-mAb clones cultured in fed-
batch bioreactors. This demonstrates that overexpression
of HSP27 greatly increases recombinant mAb titer by
improving cell growth and extending culture duration at
above 80% viability of CHO-mAb fed-batch bioreactor
cultures. The growth improvements observed in fed-
batch bioreactor cultures was not a consequence of the
feeding strategy as all cultures were not deprived of glu-
cose and glutamine during culture (data not shown). 
Additionally, the effect of HSP27 overexpression strat-
egy on the quality of the recombinant mAbs produced 
by HSP27-overexpressing CHO-mAb cells cultured in 
fed-batch bioreactors were evaluated. p2.27-3 and
p2.Blank-1, cultured in triplicated fed-batch bioreactors
as described in Section 2.4, were used in this study (Sup-
porting information, Fig. S5). There was no significant dif-
ference between the N-glycan distribution profiles of the
recombinant mAbs produced in both p2.27-3 and
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Figure 3. Caspase activity profiles of stably transfected p2.27 and p2.Blank CHO-mAb clones fed-batch bioreactor cultures. Stably transfected HSP27-over-
expressing CHO-mAb clones (p2.27; triangles) and stably transfected null vector-overexpressing CHO-mAb clones (p2.Blank; circles) were cultivated in
hygromycin-containing selection media before cultured in fed-batch bioreactors (Fig. 2). (A) Caspase 2, (B) caspase 8, (C) caspase 9 and (D) caspase 3
activities were monitored off-line daily in 24 h intervals until culture viabilities dropped below 80%. N=1 and the error bars represent the SD from the mean
of technical triplicates. 
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p2.Blank-1 CHO-mAb fed-batch bioreactor cultures (Stu-
dent t-test with p-Value < 0.05) despite p2.27-3 having
4.6-fold higher recombinant mAb titer than that of
p2.Blank-1 (Supporting information, Fig. S6). This demon-
strates that overexpression of HSP27 in CHO-mAb cells
did not result in changes in N-glycan profiles or introduce
abnormal glycan structures.
3.3  Caspase 2, 8, 3 and 9 activities of HSP27-
overexpressing CHO-mAb cell clones 
in fed-batch bioreactor cultures 
Current knowledge of HSP27 molecular roles in improving
CHO fed-batch bioreactor cultures is limited to delayed
increase of caspase 2, 3, 8 and 9 activities reported previ-
ously [11]. To verify whether HSP27 overexpression result-
ed in the same phenotype in CHO-mAb clones in fed-
batch bioreactor cultures, activity profiles of the above-
mentioned caspases were evaluated (Fig. 3). 
Increases in caspase 2, 8 and 9 activities were delayed
by an average of one day in p2.27 CHO-mAb clones cul-
tured in fed-batch bioreactors as compared to p2.Blank
CHO-mAb clones cultured in fed-batch bioreactors
(Fig. 3A–C). Notably, caspase 8 activity of p2.Blank-1 was
observed to be lower than that of other two p2.Blank and
p2.27 CHO-mAb clones cultured in fed-batch bioreactors
(Fig.  3B). This depicts clonal variability and inherent
mutability of transfected CHO cells. Executioner caspase
3 activities were also delayed by an average of two days
in p2.27 CHO-mAb clones cultured in fed-batch bioreac-
tors as compared to p2.Blank CHO-mAb clones cultured
in fed-batch bioreactors (Fig.  3D). These delays in cas-
pase activities corroborated with the delayed loss of cul-
ture viabilities in p2.27 CHO-mAb clones as compared to
p2.Blank CHO-mAb clones cultured in fed-batch bioreac-
tors (Fig. 2B). This suggests that one of HSP27 anti-apop-
totic roles in CHO-mAb fed-batch bioreactor cultures is
modulating apoptosis by delaying increase in caspase 2,
3, 8 and 9 activities. 
3.4  Interacting targets of HSP27 
in CHO-mAb fed-batch bioreactor cultures
Studies done on human and mouse pathological cell lines
reported that HSP27 interactions with Akt, cytochrome C,
pro-caspase 3 and Daxx from the apoptosis signalling
pathways resulted in increased resistance to apoptotic
cell death [5]. As delays in caspase 2, 3, 8 and 9 activities
were observed in p2.27 CHO-mAb clones cultured in fed-
batch bioreactors compared to p2.Blank CHO-mAb
clones cultured in fed-batch bioreactors (Fig. 3), it is pos-
tulated that HSP27 in CHO-mAb fed-batch bioreactor cul-
tures interacts with similar apoptosis targets reported in
human and mouse cells studies. Henceforth, the above-
mentioned reported HSP27 interacting targets were
examined in this study (Fig. 4). p2.27-3 cultured in tripli-
cated fed-batch bioreactors (Supporting information,
Fig. S5) was used. 
HSP27 was pulled down with anti-HSP27 antibody,
but not with anti-mouse antibody, which served as a neg-
ative control for isotype and species specificity, demon-
strating that the Co-IP method can pull down HSP27
specifically (Fig.  4). Akt, Daxx and pro-caspase 3 were
also pulled down using anti-HSP27 antibody, but not with
anti-mouse antibody (Fig. 4). HSP27-Akt interaction may
enhance the activity of Akt and increase regulation of pro-
survival and pro-proliferation signals and activities in
CHO-mAb cells [17]. Akt has also been reported to inhib-
it activity of caspase 8 indirectly via a death-effector
domain [18] and caspase 9 directly [19]. This corroborat-
ed with the delayed increased in caspase 8 and 9 activi-
ties of p2.27 CHO-mAb clones as compared to p2.Blank
CHO-mAb clones, when cultured in fed-batch bioreactors
(Fig. 3B–C). HSP27-Daxx interaction may inhibit caspase-
independent cell death by preventing interaction of Ask1
with Fas-receptor, resulting in delayed loss of culture via-
bilities observed in p2.27 CHO-mAb clones cultured in
fed-batch bioreactors as compared to p2.Blank clones cul-
tured in fed-batch bioreactors (Fig. 2). The interaction of
HSP27 with pro-caspase 3 may have prevented its matu-
ration into active caspase 3, resulting in the delayed
increased in caspase 3 activity (Fig. 3D). caspase 3 active
proteolytic functions have been shown to activate pro-
caspase 2 to active caspase 2 [20]. This corroborated with
the delayed activation of caspase 2 in p2.27 CHO-mAb
clones compared to p2.Blank CHO-mAb clones, when cul-
tured in fed-batch bioreactors (Fig. 3A).
On the other hand, cytochrome c, was not pulled down
using both anti-HSP27 and mouse IgG, although the pro-
tein was detectable in the cellular protein lysates of 
p2.27-3 cells (Fig. 4). This was despite the long exposure
time of 2 min 30 s for the Co-IP complex blot versus 10 s
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Figure 4. Western blots of total cellular lysates and eluted Co-IP complex
of HSP27 interacting targets in p2.27-3 CHO-mAb clone fed-batch biore-
actor cultures. Total cellular lysates were co-immunoprecipitated with
anti-HSP27 and anti-mouse antibodies separately. Anti-mouse antibody
serves as a negative control for isotype and species specificity. Both total
cellular lysates and eluted Co-IP complex were immunoblotted with anti-
Akt, anti-cytochrome c, anti-pro-caspase 3, anti-Daxx and anti-HSP27 anti-
bodies. Figure shown here is representative of biological triplicates.
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for the cellular protein lysates blot. While HSP27 has been
shown to interact with cytochrome c in human cells [8],
CHO HSP27 [11] and CHO cytochrome c (XP_003498601)
protein sequences differ from those of human (NP_001531
and NP_061820 respectively) by 14% (data not shown).
These variations may have resulted in different HSP27-
cytochrome c interaction in human and CHO cells. 
Hence, we demonstrated that HSP27 protein is able to
interact with Akt, pro-caspase 3 and Daxx, but not
cytochrome c, in CHO-mAb cells and these interactions
may have contributed to better p2.27 CHO-mAb fed-
batch bioreactor cultures performance as shown in Fig. 2. 
4  Discussion 
Differential HSP27 transcript expression during the late-
exponential and stationary growth phase of CHO fed-
batch bioreactor cultures has led to the hypothesis that
overexpression of HSP27 in CHO cells can improve CHO
fed-batch bioreactor culture performance. Consequent
overexpression of HSP27 in a CHO-DxB11 cell line pro-
longed fed-batch bioreactor culture duration and
increased recombinant human IFN-γ yield [11]. In this
study, we wanted to apply the HSP27 overexpression
strategy in fed-batch bioreactor cultures of a different
CHO cell line (CHO-DG44), producing a different recom-
binant protein (recombinant mAb, a class of rapidly
expanding recombinant biologics). Moreover, with the
emerging introduction of innovative biologics and bio -
similars in the market, there are opportunities to use new
CHO production cell line engineered with increased cul-
ture robustness. Hence, it would be of importance to eval-
uate the effects of HSP27 overexpression in improving
recombinant mAb production in CHO fed-batch bioreac-
tor cultures. 
Preliminary evaluation of HSP27 overexpression in
improving CHO-mAb batch shake flask cultures was car-
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Figure 5. Proposed schematic illustration of HSP27 anti-apoptotic functions in HSP27-overexpressing CHO-mAb cells. HSP27 interactions with Akt, Daxx
and pro-caspase 3 enhance survival and proliferation, inhibit caspase-independent cell death and inhibit caspase 3-induced apoptosis respectively. How -
ever, HSP27 does not interact with cytochrome c as reported in human cell lines studies. Overexpression of HSP27 also delays hike in caspase 2, 3, 8 and 
9 activities.
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ried out using stably transfected cell pools (Fig. 1). It was
established that HSP27 overexpression can increase peak
cell density and delay loss of culture viability but not
improve recombinant mAb production in CHO-mAb
batch shake flask cultures (Fig. 1). This was further veri-
fied during the selection of stably transfected clones
under batch shake flask conditions. Stably overexpress-
ing HSP27 p2.27 clones had slightly higher cumulative
IVCD but similar recombinant mAb titer to p2.Blank
clones stably transfected with the null vector (Supporting
information, Fig.  S4). Subsequently, the selected p2.27
and p2.Blank clones were evaluated in fed-batch bioreac-
tors. The p2.27 CHO-mAb clones cultured in fed-batch
bioreactors achieved higher maximum cumulative IVCD
that greatly increased recombinant mAb titers (Fig.  2)
without significantly altering the N-glycan distribution
profile of purified recombinant mAb as compared to
p2.Blank CHO-mAb clones in fed-batch bioreactor cul-
tures (Supporting information, Fig. S6). 
In addition, we wanted to identify anti-apoptotic func-
tions of HSP27 that contributed to the improvements in
p2.27 CHO-mAb fed-batch bioreactor cultures perform-
ance as compared to p2.Blank CHO-mAb fed-batch biore-
actor cultures (Fig.  2). Figure  5 shows the proposed
schematic illustration of HSP27 anti-apoptosis functions
identified and validated in HSP27-overexpressing 
CHO-mAb cells: modulation of caspase activities (Fig. 3)
and HSP27 interactions with Akt, pro-caspase 3 and Daxx
along the apoptosis signaling pathways (Fig. 4). 
Comparing the effect of HSP27 overexpression in
CHO-mAb and in CHO cells producing recombinant
human IFN-γ, both engineered cells showed improve-
ment in IVCD and delayed hikes in caspase activities in
fed-batch bioreactor cultures. However, while the peak
viable cell density was improved in the HSP27-overex-
pressing CHO-mAb fed-batch bioreactor cultures, IVCD
improvement in HSP27-overexpressing CHO-IFN-γ fed-
batch bioreactor cultures was only due to extension of cul-
ture duration without improvement in peak viable cell
density [11]. It would be interesting to elucidate whether
the difference in parental host cell lines or recombinant
proteins produced had any effects on the molecular func-
tions of HSP27 that resulted in the different CHO fed-
batch bioreactor culture phenotype. Furthermore, even
though HSP27 overexpression has been demonstrated to
delay loss of culture viability via its anti-apoptotic func-
tions, culture viability of p2.27 CHO-mAb clones in fed-
batch bioreactor cultures continued to drop after day 8
(Fig. 2). This indicates that there may be other signaling
pathways leading to apoptosis that are not affected by
overexpression of HSP27 and these would make interest-
ing cell line engineering targets for further improving
robustness of HSP27-overexpressing CHO-mAb fed-batch
bioreactor cultures to achieve even higher recombinant
mAb titers.
In conclusion, together with the earlier study [11], we
have successfully demonstrated the applicability of
HSP27 overexpression strategy in improving titers of two
classes of recombinant biologics (recombinant cytokine
and recombinant mAb) produced by two CHO production
host cell lines (CHO-DxB11 and CHO-DG44 respectively)
under fed-batch bioreactor culture mode. We have also
validated the anti-apoptotic functions of HSP27 that con-
tributed to better p2.27 CHO-mAb fed-batch bioreactor
culture performances. 
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Comment 1: The literature review provided the background of the thesis subject area, the original 
sources should be provided nevertheless. E.g. in the first paragraph of Section 2.1.1, no reference 
was cited. This gave the impression that the basis of the thesis was an imaginative one, rather than a 
well-documented phenomenon. Likewise, no reference was cited in the first half of Section 2.1.2. 
Student’s response 1: References citations are now added in both Section 2.1.1 (page 18) and 
Section 2.1.2 (19) of the revised thesis. 
 
Comment 2: In the description of centrifugation in page 44 (line 4), and page 47 (line 15, 22 and 26), 
centrifugation force (x g) should be provided, rather than the centrifugation speed (rpm). For a 
centrifugation speed of different rotor diameters give different centrifugation forces. 
Student’s response 2: For more precise description of centrifugal conditions in the methods used, 
centrifugation force in g was also described as recommended. The changes are now reflected in page 
38, 40-42 and 45 of the revised thesis.  
 
Comment 3: Page 52 and 53 were curiously repetitive. The statement that “HSP27 overexpression 
strategy was used to increase mAb production” was first stated at the end of paragraph one in page 
52, repeated at the end of paragraph 2 in page 52, and again repeated in the 2nd paragraph of page 
53. 
Student’s response 3: The repetition of the statement in the introduction section of Chapter 4 has 
been amended. At the end of paragraph one in page 52, the statement “HSP27 overexpression 
strategy can be extended to a CHO production cell line producing recombinant mAb, cultured in fed-
batch bioreactors’ was necessary to clarify the one of the main objectives of the thesis. The 
subsequent paragraphs were re-thought to prevent unnecessary repetition of the objective statement.  
The second statement “HSP27 overexpression can also extend culture viability and improve 
recombinant mAb titer in batch shake flask cultures was conducted” was necessary as it was a 
separate objective looking at the effects of HSP27 overexpression on batch shake flask cultures.  
These amendments are now reflected in the first paragraphs of page 50 and 51. 
 
Comment 4: In the legend for Figure 4.2, there is a typo-error. The (D) should be (C) (line 5). 
Student’s response 4: The description for Figure 4.2 legend has been amended to reflect the typo 
error. The amendment is now reflected in Figure 4.3 on page 55 of the revised thesis.  
 
Comment 5: It was concluded at the end of page 57 that “HSP27 overexpression is not an effective 
strategy for improving recombinant mAb titre in the shake flask batch culture of stably transfected cell 
pools, although it can improve cell growth and delay loss of culture viability”. A paragraph should be 
added to explain why were these transfected cells further studied, despite of a negative result? If the 
batch culture was not a compatible system, why was it concluded as a preliminary screening and 
reported here? 
Student’s response 5: Prior to the evaluation of HSP27 engineered CHO-mAb clones cultured in fed-
batch bioreactors, the process involved culturing of stably transfected cell pools and single cell clones 
in shake flasks under batch conditions. As HSP27 overexpression has not been shown to improve 
batch shake flask cultures (a different culture system from fed-batch bioreactors), hence the growth 
and mAb production characteristics of stably transfected cell pools cultured in batch shake flasks 
were conducted and reported in Chapter 4 of this thesis. Additionally, stable transfected cell pools are 
frequently employed for the rapid production of sufficient recombinant proteins as pre-clinical 
materials used in drug candidate screening as well as later stages of pharmacology, formulation and 
stability studies. Batch shake flask culture systems are often preferred for convenience and process 
simplicity. Hence it would be of interest to look at the effects of HSP27 overexpression in batch shake 
flask cultures. 
The stably transfected single cell clones in fed-batch bioreactors were further studied because HSP27 
transcript and protein expression levels were initially observed to be down-regulated and reduced 
towards the end of CHO fed-batch bioreactor cultures, leading to the hypothesis that HSP27 
overexpression can improve CHO fed-batch bioreactor cultures. Subsequent overexpression of 
HSP27 in CHO cells producing recombinant interferon-gamma showed improvement in fed-batch 
bioreactors. Therefore, one of the end goals and aims of this thesis was to evaluate the effects of 
HSP27 overexpression in improving fed-batch bioreactors of CHO cells producing recombinant mAbs.  
These explanations are now added in page 51 and 66-67 of the revised thesis. 
 
Comment 6: Likewise in page 68, an explanation should be provided on the decision that 
“nevertheless, further evaluation fed-batch bioreactor culture system…should still proceed”, without 
the support of preliminary data. If the explanation is “due to the variation in viable cell seeding density 
in the different experiments” (last sentence of page 67 and first sentence of page 68), that reflected 
poor experimental design and control of the project, and renders the studies scientifically irrelevant. 
Student’s response 6: The one-time point analysis was carried out as a quick screening for selecting 
single cell clones to be cultured in fed-batch bioreactor; hence variability in viable cell seeding density 
may be expected. Both stably HSP27 transfected cell pools and cell clones cultures in batch shake 
flasks did not show improvement in recombinant mAb titers despite the improvements in maximum 
cumulative integrated viable cell densities and overexpression of HSP27, as compared to the null-
vector transfected CHO-mAb cells. This was due to the non-improvement in specific productivity of 
the cells. Hence it is a phenomenon observed in both batch shake flask cultures and it could be due 
to the different stress and culture conditions. Fed-batch bioreactor systems are different by batch 
shake flasks systems in terms of culture environment control, nutrients availability and depletion, and 
stress experienced by the cells. Hence, further evaluation in fed-batch bioreactor culture systems 
needed to be carried out. Additionally, as explained in previous comments, preliminary observation of 
HSP27 protein reduction and subsequent improvement in fed-batch bioreactor culture of HSP27 
overexpression CHO cells producing recombinant interferon-gamma gave indications on the effect of 
HSP27 overexpression in CHO cells producing recombinant mAb fed-batch bioreactor cultures. 
These clarifications are now added in page 64-67 of the revised thesis. 
 
Comment 7: Page 75, a statement should be included at the end of the page to explain why higher 
mAb production was not observed in the batch culture despite heightened expression of HSP27. Was 
it the nutrient supply? 
Student’s response: Although the selected HSP27 engineered CHO-mAb clones had higher 
expression of HSP27 compared to the null-vector engineered CHO-mAb clone, under batch shake 
flasks system, the mAb titers were similar. This was also observed in the stable transfected cell pools 
batch shake flask cultures study, demonstrating that overexpression of HSP27 does not improve 
batch shake flask cultures of CHO-mAb cells. However, in the fed-batch bioreactors, HSP27 
engineered CHO-mAb clones had a much higher maximum recombinant mAb titer compared to null-
vector engineered CHO-mAb clone. This demonstrates that HSP27 overexpression greatly improves 
the recombinant mAb titer of CHO-mAb fed-batch bioreactor culture. This could be due to the different 
stress and culture conditions. Fed-batch bioreactor systems are different from batch shake flask 
systems in terms of culture environment control, nutrients availability and depletion, and stress 
experienced by the cells. 
These clarifications are now added in page 74 of the revised thesis. 
Examiner 2 
Comment 1: HSP27 was selected from microarray study. I wonder if the student has checked and 
confirmed the protein levels of HSP27 during different phases of cell culture. 
Student’s response 1: HSP27 protein levels during different phases of fed-batch bioreactor cultures 
has been checked and confirmed to be reduced towards the exponential and stationary death phases. 
This trends corroborated with the HSP27 transcript profile. This data is now shown in Figure 4.2 on 
page 53 of the revised thesis. 
 
Comment 2: Figure 2.1. More information needs to be provided for this figure. For example, different 
colors were found in describing the expression levels at different culture stages.  Why are there 
different colors? Do those indicate the expression levels at different culture stages? If so, please 
specify. 
Student’s response 2: The different colors represent the fold-change of the transcript based on the 
color bar chart legend in the figure, and that the three boxes represent sequential transcriptome 
profiles over 3 different growth phases: exponential, stationary and death. These descriptions are now 
added to the legend for Figure 2.1 on page 21 of the revised thesis. 
 
Comment 3: In Figure 4.3, no changes in mAb titers between the untransfected CHO mAb and p2.27 
CHO mAb cells. Thus, the impact of HSP27 overexpression on protein production is questionable. In 
Chapter 5, the titer of p2.27 CHO mAb cells is much higher than that of p2.Blank CHO mAb cells in 
fed-batch bioreactor culture. I wonder if the student has compared the titer of p2.27 CHO mAb cells to 
that of the untransfected CHO mAb cells. Is there any improvement for mAb production? It would be 
appropriate if the student investigate the production of the untransfected CHO mAb cells in fed-batch 
bioreactor culture as well. 
Student’s response 3: The production profile of the untransfected CHO-mAb fed-batch bioreactor 
cultures was investigated and observed to be similar to that of p2.Blank CHO-mAb fed-batch 
bioreactor cultures. When comparing the mAb production of p2.27 CHO-mAb fed-batch bioreactor 
cultures to that of the untransfected CHO-mAb fed-batch bioreactor cultures, 220% improvement in 
mAb titer was observed for the p2.27 CHO-mAb fed-batch bioreactor cultures. This shows that 
overexpression of HSP27 can improve mAb production in CHO-mAb fed-batch bioreactor cultures. 
This data is now shown in Appendix 2 on page 146 of the revised thesis.   
 
Comment 4: In Chapter 6.2, the student identified few HSP27 binding proteins by Co-Ip (Fig. 6.2) and 
proposed a signaling model induced by HSP27 overexpression (Fig. 6.3). Unfortunately, this model is 
purely speculative. Data from Co-IP can only provide the support for protein-protein interaction, but 
not the functional importance of such interactions. For example, HSP27 binds to Akt and the student 
speculates that binding with HSP27 may activate Akt. If so, the student should show the effects of 
HSP27 overexpression of Akt phosphorylation. However, such data is missing. Another example of 
over-interpretation: the student proposed that the HSP27-pro-caspase 3 interaction may prevent the 
activation of caspase 3. If so, where is the data for the effects of HSP27 overexpression on the 
proteolytic cleavage of caspase 3? Again, the result is missing. Same criticism applies to Daxx as well. 
Additional experiments are required to support the model proposed in Fig. 6.3. 
Student’s response 4: The HSP27 binding proteins targeted in the Co-Ip experiments (Akt, 
cytochrome c, Daxx and pro-caspase 3) were previously identified to have affected the apoptosis of 
both human and mouse cells. These binding proteins and the effect of binding to HSP27 have been 
extensively studied and validated in both human and mouse cell line studies. Hence the aim of the 
Co-Ip experiment in the thesis was to observe if these binding translate to HSP27 in CHO-mAb cells, 
under fed-batch bioreactor culture conditions and to provide insights into the improvements of HSP27 
engineered CHO-mAb fed-batch bioreactor cultures. These clarifications have been added to Chapter 
6, Introduction section, of the revised thesis (page 85) to better describe the objective of the study and 
why functions of the above-mentioned interactions were not looked at. 
 Comment 5: All the analyses described in Chapter 7 are based on the microarray study, 201 genes 
are identified. Has the student confirmed the mRNA levels of these 201 genes by RT-PCR? In 
addition, does an increase in mRNA levels guarantee an elevated protein levels? Probably not. 
Therefore, without confirming the changes in protein levels of these 201 genes, all these analyses 
may not be able to conclude anything. 
Student’s response 5: I agree that for any microarray study, confirmation of the mRNA levels via RT-
PCR should be carried out. However, the purpose of this microarray experiment was not to look for 
specific gene targets. The purpose was to validate and to provide support for the previously identified 
binding targets mentioned in Chapter 6 (Akt, Daxx and pro-Caspase 3). Additionally, the microarray 
experiment is used for providing insights into other potential molecular roles of HSP27 in CHO fed-
batch bioreactor cultures by using validated HSP27 interacting targets reported in both human and 
mouse studies as reference. Based on this method, 14 potential HS27 interacting targets in CHO-
mAb fed-batch bioreactor cultures were identified. The microarray study serves as a platform for 
future hypothesis driven research. These were described in page 95 and 101-102 of the revised 
thesis. 
An increase in mRNA levels does not guarantee an elevated protein levels as protein levels are 
affected by both rate of synthesis and degradation. For this particular microarray profiling study 
performed in the thesis, we were looking at regulation of transcript affected by HSP27 engineering. It 
is based on the assumption that upon HSP27 interaction with its targets, transcript levels downstream 
will be affected due to cellular regulation during HSP27-target interaction. Hence we were looking at 
the regulation of transcripts affected by HSP27 engineering in CHO-mAb cells during fed-batch 
bioreactor cultures. These were described in page 95 of the revised thesis.  
 
Comment 6: The list of 201 differentially expressed transcripts generates a list of 30 networks (page 
101). How do we know which network is the most crucial one? What is the evidence to support such 
conclusion? I think it is extremely hard to draw any conclusions from these speculative analyses. 
Student’s response 6: The networks were created by connecting the transcription factors present in 
the list of 201 differentially expressed transcripts to its relevant receptor using the shortest pathway. 
Multiple pathways may exist for each transcription factors-receptor and a network of pathways will be 
generated where they are ranked based on the number of classical signaling pathway fragments 
present.  
Based from the input list of 201 differentially expressed transcripts, a total of 30 networks were 
generated. We would not be able to know which one of the networks generated is the most crucial as 
the mammalian cells have complex biological pathways and networks. Alternatively, these networks 
were used to provide further support for the involvement of previously isolated cgri-HSP27 interacting 
targets and its cellular functions in CHO-mAb cells under fed-batch bioreactor conditions. Previously 
isolation of HSP27 interacting targets identified Akt, pro-Caspase, Daxx as potential interacting 
targets, and were involved in the apoptosis signaling pathways. From the generated networks, 
apoptosis and programmed cell death biological processes were the most enriched, providing further 
support that these targets were likely interacting with HSP27 in CHO-mAb fed-batch bioreactor 
cultures. Additionally, these networks were used to provide insights into potential interaction targets of 
cgri-HSP27 in CHO-mAb fed-batch bioreactor cultures. 






 Examiner 3  
Comment 1: Page 20-21, section 2.1.1. Please align format.  
Student’s response 1: Section 2.1.1 has been aligned and the change is reflected on page 18-19 of 
the revised thesis. 
 
Comment 2: Page 23, Fig. 2.1. Please explain the dotted square.  
Student’s response 2: The dotted square represents genes that were not represented in the 
microarray used in the apoptosis transcriptome profile of CHO fed-batch bioreactor cultures. This 
description is now added to the legend for Figure 2.1 on page 21 of the revised thesis. 
 
Comment 3: Page 55, unpublished data. It is better to show the data.  
Student’s response 3: The unpublished data was for the previously reported HSP27 engineered, null 
vector engineered and non-engineered CHO cells producing recombinant interferon batch shake flask 
cultures. It further supports that HSP27 overexpression can improve CHO batch shake flask cultures. 
The data is now shown in Appendix 1 on page 145 of the revised thesis. 
 
Comment 4: Page 63, line 86 from the bottom. ‘Furthermore, regulatory authorities…cell clone [97,99]. 
Please refer prompt regulatory issue or comment.     
Student’s response 4: Regulatory authorities, namely European Medicine Agency (EMA), World 
Health Organization (WHO) and Food and Drug Authority (FDA) have similar guidelines on the use of 
single cell clone for the production of recombinant biologics from mammalian cells. For the 
development, production, characterization, specifications, quality and safety of biotherapeutics protein 
products prepared by recombinant DNA technology, the cell used for production should be a stable 
and continuous monoclonal cell line. Additionally, master and working cell banks used for production 
have to originate from the same single cell clone. Relevant regulatory guidelines commenting on this 
are now cited and added in the reference section on page 132 of the revised thesis. 
 
Comment 5: Page 65, both triangle and closed circle are cell viability? Please indicate clearly. 
Student’s response 5: Both open triangle and closed circle represent the cell viability of the clones 
cultured in batch shake flasks. The open triangles represent the cell viability of p2.Blank CHO-mAb 
clones and the closed circles represent the cell viability of p2.27 CHO-mAb clones. These 
descriptions are now added to the legend for Figure 4.9 on page 64 of the revised thesis. 
 
Comment 6: Page 132-133, ‘Biotechnology and bioengineering’ should be Biotechnol Bioeng. Page 
134, ‘Embo j’ should be ‘EMBO J’. 
Student’s response 5: The appropriate abbreviations for the relevant journals have been amended 
accordingly and are now reflected in the reference section on page 132 of the revised thesis. 
 
